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Abstract 
Endothelial colony forming cells (ECFCs) are circulating cells able to differentiate 
into mature endothelial cells and replenish the endothelial lining at the sites of vascular 
damage. Their utilization for cell therapies aiming to restore healthy endothelial lining of 
blood vessels and stimulate neovascularization of ischemic tissues has been the object 
of intense investigation. The overall aim of this project was to investigate and develop 
novel approaches for the promotion of vasculogenesis and endothelisation of vascular 
grafts by ECFCs. 
First, protease-activated receptors (PARs) were investigated as potential targets to 
stimulate in ECFC-driven vasculogenesis and promote therapeutic revascularization. 
Our data showed that PAR-1 and PAR-2 are both expressed in ECFCs and functionally 
coupled to the ERK1/2 pathway. Specific stimulation of PAR-1, but not PAR-2, 
significantly inhibits in vitro tube formation by ECFCs, and this effect is due to the 
down-regulation of VEGFR-2. Although the role of PAR-2 remains elusive, this study 
sheds new light on the regulation of the vasculogenic activity of ECFCs and suggests a 
potential link between adult vasculogenesis and the coagulation cascade.  
Secondly, we investigated the use of human platelet lysate gel (hPLG) as an 
animal product-free and patient-specific tool to isolate, amplify, differentiate and deliver 
endothelial progenitor cells. This extracellular matrix (ECM) was able to support the 
proliferation of ECFCs in 2D cultures and the formation of a complete microvascular 
network in vitro in 3D cultures. Interestingly, the culture of ECFCs on hPLG led to the 
upregulation of several angiogenic genes, such as VEGFR-2 and PDGFR-β, and also 
induced the robust sprouting of existing vessels in an ex vivo model. This discovery 
has the potential to accelerate the development of regenerative medicine applications 
based on implantation of microvascular networks expanded ex vivo or the generation 
of fully vascularised organs. 
Finally, the biomimetic and pro-angiogenic properties of human platelet lysate 
(hPL) were utilised to facilitate adhesion and proliferation of ECFCs on polymeric 
materials. hPL was shown to promote endothelisation of biomaterials, which can be 
utilised for tissue engineering purposes. Novel electrospun polymeric tubular scaffolds 
were developed and their surface properties enhanced using plasma treatment. These 
scaffolds exhibit increased adsorption of proteins from hPL, which acted as an 
interfacial layer to promote the adhesion and proliferation of ECFCs on their surface. 
Such findings demonstrate that the pro-angiogenic and pro-vasculogenic properties of 
 	 VII 
platelet-derived factors can be transferred to scaffolds to stimulate endothelial growth 
on synthetic scaffolds for tissue engineering without the use of recombinant or animal 
products. 
In conclusion, we propose the use of ECFCs with platelet-derived products as an 
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1.1. Tissue engineering and regenerative medicine 
The tissue engineering field has exponentially grown over the last decade and has 
progressively moved from being exclusively a lab-bench discipline to an emerging part 
of today’s medical care. It has largely evolved from the pre-existent field of biomaterials 
and consists in the de novo engineering of tissues and organs by combining scaffolds, 
cells and biological molecules, often drawing cues from the most up-to-date knowledge 
in developmental biology (Berthiaume, Maguire and Yarmush, 2011). Although, this 
field is focused mainly on the replacing damaged or lost tissues, it is often somewhat 
misnamed by the term “regenerative medicine”, which has a broader meaning. The 
latter encompasses research on self-healing – where the emphasis is rather placed on 
inducing the healing of a target tissue by potentiating the body’s own ability to 
regenerate, through the delivery of biologically active agents, such as nucleic acids or 
proteins (Koria, 2012). In addition, tissue engineering has revolutionized the study of 
human diseases and drug toxicity by supporting the development of three-dimensional 
in vitro models that can mimic far more realistically tissue- and organ-level structures 
and functions that are at the root of disease (Benam et al., 2015).  
While our complex immune system performs remarkably well at keeping us safe 
from disease, its inherent ability to protect us from any foreign agent is also the main 
reason why the replacement of body tissues and organs is so challenging (Starzl et al., 
1993). Although, the surgical techniques for transplanting organs have improved 
tremendously, it is simply not possible to cope with the overwhelming demand for 
tissues and organs by retrieving them from volunteering donors (Orlando, Soker and 
Stratta, 2013). Moreover, even in cases where a suitable donor is found and an organ 
is successfully transplanted, the therapeutic efficacy is only partial and temporary. The 
most important limitation is that the immune response against the implanted organ 
requires permanent immunosuppression and ensues a lifelong struggle against 
immune rejection (Katabathina et al., 2016). Thus, tissue engineering aims at 
overcoming these hurdles by creating new tissues or organs from the cells of the same 
patient who receives the treatment. This would eliminate the necessity of either finding 
a compatible donor or using immunosuppressant drugs. 
There are four important factors that need to be considered in order to successfully 
engineer a tissue in vitro: an appropriate cell population, a scaffold that can support the 
cells, the right biomolecules, such as growth factors, and physical and mechanical 
stimulus to influence the proper development of the construct into the target tissue 
(Hansmann et al., 2013) (Figure 1.1). Engineering such tissue surrogates at a scale 
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that is clinically relevant brings about a major challenge: the diffusion of oxygen, 
nutrients and waste products. In the human body, most cells are found within 100-
200 μm from the nearest capillary, which allows for that exchange to happen, and in 
the lab this can be simulated - or at least compensated for - through the use of 
perfusion bioreactors (Fiedler et al., 2014). Without its own vascular network, any 
areas of a construct that are beyond the referred diffusional limit will not be sufficiently 
oxygenated resulting in cell death and, most likely, overall scaffold failure soon after 
implantation (Fiedler et al., 2014). Therefore, the engineering of artificial blood vessels 
and capillary networks is not only a major area of interest within the field, but it is also 
one from which the future success of the whole tissue engineering endeavour depends 
upon (Laschke and Menger, 2016). 
This introduction will address the potential cell sources and scaffold types, with 







Figure 1.1. Key stages in the tissue engineering cycle. Cells are harvested from a patient, 
and expanded ex vivo. These are then seeded on an appropriate scaffold and cultured with 
biochemical and mechanical stimuli. The engineered tissue or organ is then implanted back into 
the patient to substitute or repair the diseased organ.  
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1.2. Cell sources for vascular tissue engineering 
Each tissue engineering strategy faces its own specific challenges and 
considerations with regards to the choice of cells, but a number of these are common 
to all, independently of the target tissue. Firstly, it must be feasible to either directly 
obtain the required number of cells, or devise a method of inducing the proliferation of 
the starting population to expand these to the necessary numbers, either in vitro or in 
situ (Kumar and Starly, 2015). Next, these cells should be as easy to isolate as 
possible. In this context, applications based on cells originating from peripheral blood 
or from relatively non-vital superficial tissues (e.g. skin or adipose tissue) are more 
likely to be translated to the clinic than those created with cells that require more 
complicated surgical interventions (e.g. bone marrow or vascular tissue). Cells also 
need to possess the correct phenotype or be able to permanently differentiate into it, in 
order to perform the desired cellular functions, such as ECM deposition, cytokine 
release, etc. Other requirements may include the ability of these cells to integrate in a 
seamless manner with the native cells and tissue, as well as to connect with the 
existent neural and/or vascular networks. Lastly, cells should be amenable to the 
chosen delivery method. For example, endothelial cells must be delivered using a 
material that is permissive to their adhesion via surface integrins as their survival is 
known to be intimately linked to this process (Chavakis and Dimmeler, 2002). 
Depending on the nature of the approach and its specifications, a number of different 
sources of cells can be used for the engineering of vascular tissues. Most patients with 
vascular disorders are elders, thus mature vascular cells from these patients are not 
suitable for tissue engineering. As an example, smooth muscle cells (SMCs) isolated 
from the walls of blood vessels have been shown to suffer from aging-associated 
cellular changes, such as decreased proliferation and collagen synthesis (McKee et al., 
2003). Therefore, alternative cell sources with a more proliferative and healthy profile 
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1.2.1. Embryonic stem cells (ESCs) 
Embryonic stem cells are derived from the inner cell mass of the pre-implantation 
blastocyst and are capable of differentiation into all mature cell types. In addition to 
their pluripotency, ESCs can also replicate indefinitely while in their undifferentiated 
state, mainly due to their high telomerase activity. Originally, ES cell lines were derived 
by co-culture on growth arrested mouse embryonic fibroblasts (Skottman and Hovatta, 
2006), but more recently they have also been derived under Good Manufacturing 
Practices (GMP) conditions using human fibroblasts or amnion epithelial cells and 
avoiding also the use of animal products in the culture medium (Tannenbaum et al., 
2012; Lai et al., 2015), which reduces the risk of animal-borne disease transmission 
and improves their clinical applicability. 
Several groups have managed to differentiate human ECSs into ECs, with various 
degrees of success, and demonstrate their ability to form capillary networks in vivo 
using murine ischaemic hindlimb models (Levenberg et al., 2002) (Wang et al., 2007). 
The differentiation of ESCs has also been guided towards a smooth muscle cell (SMC) 
phenotype (Huang et al., 2006; Xie et al., 2007; Cheung et al., 2012), which could be 
valuable for the in vitro generation of arterial vessels.  
Although ESCs constitute a suitable cell source for in vitro disease and drug 
toxicity modelling and also provide useful insight into the de novo formation of blood 
vessels (i.e. vasculogenesis) (Nakagami et al., 2006), their clinical use is severally 
hampered by ethical issues that arise from the necessary destruction of human 
embryos (Vats, Tolley, Bishop and Polak, 2005). In addition, another major hurdle has 
been the potential for teratoma formation as a result of administering patients with 
pluripotent cells. However, in recent reports of long-term patient following, no adverse 
effects of this nature were shown, despite the immunosuppressant regimen that these 
were on (Schwartz et al., 2015). Crucially, just like with transplanted organs, ESCs 
need to be matched to individual patients to avoid immune rejection, thus their future 
application in the engineering of organs and tissues is dependent on the creation of 
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1.2.2. Mesenchymal stem cells (MSCs) 
Among adult stem cells, mesenchymal stem cells (MSCs) exhibit unique 
characteristics, which make them of great interest for regenerative purposes (Mo et al., 
2016). MSCs appear to reside in niches in a variety of tissues and can differentiate into 
numerous lineages to repair damaged tissues, including connective tissue, bone, 
cartilage or fat (Kern et al., 2006). These undifferentiated cells were isolated originally 
from the bone marrow, but have been since detected and isolated in many other adult 
tissues such as muscle (Young et al., 2001), dental pulp (Perry et al., 2008), lung 
(Martin et al., 2008; Majka et al., 2005), saphenous vein (Covas et al., 2005), liver or 
adipose tissue (Heidari et al., 2013), thus providing less invasive sources of MSCs for 
therapy. As with ESCs, these cells have greater in vitro expansion capacity, but are 
also known for actively secreting trophic factors that promote tissue regeneration and 
regulate the immune system (Squillaro, Peluso and Galderisi, 2016; Castro-Manrreza 
and Montesinos, 2015). 
MSCs from bone marrow have been extensively investigated in vascular tissue 
engineering (Li, Sengupta and Chien, 2014), especially to study the interplay between 
ECM, growth factors and mechanical forces in the differentiation these cells into SMCs 
during their seeding in vascular grafts (Kurpinski et al., 2010; Gong and Niklason, 
2008). Equally, MSCs from adipose tissue (often called AD-SCs) and muscle have 
been differentiated into contractile SMCs (Rodríguez et al., 2006; Nieponice et al., 
2008), proliferating on both decellularised veins (Harris et al., 2011) and artificial 
scaffolds which had satisfactory mechanical strength (Heydarkhan-Hagvall et al., 2008; 
Zambon et al., 2014; Nieponice et al., 2008).  
Nevertheless, MSCs appear to be unable to differentiate into ECs in vitro or in situ, 
as necessary for the lumenisation of grafts or the formation of microvascular networks. 
Researchers have implanted vascular grafts loaded with GFP-labelled BM-MSCs and 
shown that, despite the beneficial effect of MSCs on the formation of an endothelial 
lining, this layer had its origin in the host tissue and not from the implanted stem cells 
(Mirza et al., 2008). Accordingly, BM-MSCs injected into immunodeficient mice cannot 
form capillary networks on their own but are able to assist in the stabilisation of 
networks formed by endothelial progenitor cells (EPCs) through the secretion of a 
plethora of a pro-angiogenic factors (Melero-Martin et al., 2008; Lin et al., 2012). This 
lack of differentiation ability towards an endothelial phenotype may be due to the 
epigenetic methylation of CD31 and VE-cadherin promoters, as observed in AD-SCs 
(Boquest et al., 2007).  
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A hypothesis that has been gaining increasing support suggests that most tissue 
resident MSCs originate within the perivascular space and not directly from the bone 
marrow (Corselli et al., 2013), being often labelled as pericyte/adventitial progenitor 
cells (Spencer et al., 2015; Katare et al., 2011). As blood vessels are ubiquitously 
present throughout the body, these MSCs can be rapidly recruited to areas in need of 
repair in their vicinity (da Silva Meirelles, Caplan and Nardi, 2008). 
 
1.2.3. Induced pluripotent stem cells (iPSCs) 
In the last decade, the discovery of a method for reprogramming mature cells into 
pluripotent stem cells by Shinya Yamanaka’s lab (Takahashi and Yamanaka, 2006) 
has provided a new cell source for tissue engineering that bypasses the immunogenic 
and ethical issues of other stem cell types. This reprogramming is based on the 
introduction of four specific genes encoding transcription factors (also known as 
Yamanaka factors) and prompts adult cells to regress into a stem cell-like state, with 
comparable self-renewal ability and differentiation potential as ESCs. Similar to the 
latter, iPSCs can be differentiated into ECs (Li et al., 2011), SMCs (Bajpai et al., 2012; 
Wang et al., 2012) and pericytes (Orlova et al., 2014). Zanotelli et al. have shown that 
ECs obtained this way can self-assemble into capillary networks when cultured in 
peptide-functionalized poly(ethylene glycol) (PEG) hydrogels in a manner that is 
representative of the physiological vascular morphogenesis (Zanotelli et al., 2016). 
Additionally, Wang et al. has shown that human iPSC-derived SMCs can be 
successfully cultured onto macroporous poly(L-lactide) (PLLA) scaffolds and maintain 
their phenotype after subcutaneous implantation for at least 2 weeks (Wang et al., 
2014a). 
In recent years, a new line of research has emerged which is focused on the direct 
conversion of adult cells into other cell types, including ECs (Margariti et al., 2012; 
Ginsberg et al., 2012) and SMCs (Karamariti et al., 2013), while avoiding an 
intermediate pluripotency stage (Kelaini, Cochrane and Margariti, 2014). This shorter 
process can be achieved through transdifferentiation, in which lineage-specific factors 
are ectopically expressed, or through direct reprogramming, that includes an initial 
partial reprogramming towards the pluripotent state. ECs generated using this partial-
iPS technology improved neovascularization and blood flow recovery when injected in 
a hindlimb ischaemia model, and could re-establish the endothelial lining of 
decelularized vessels in vitro, maintaining their patency (Margariti et al., 2012). In 
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addition, co-seeding of these vascular grafts with SMCs obtained from partial-iPSCs 
(PiPSCs) led to improved survival following implantation in mice, when compared with 
cell-free grafts (Karamariti et al., 2013). 
Besides the potential of the iPS technology in providing autologous cell sources for 
regenerative purposes, it is also ideally suited for disease modeling, as the cells 
generated with these techniques maintain the genetic mutations that were already 
present in the starting cell population (Kim, 2014). 
 
1.2.4. Endothelial Progenitor Cells (EPCs) 
Early endothelial progenitor cells (eEPCs) 
The first putative kind of circulating progenitor was proposed by Asahara and 
colleagues in 1997 and was derived by culturing the adherent CD34+ mononuclear cell 
(MNC) fraction from peripheral blood on to fibronectin coated plates (Asahara et al., 
1997). After 3-7 days, they differentiate and express a number of endothelial/progenitor 
cell surface markers such as CD133, CD34 and vascular endothelial growth factor 
receptor (VEGFR-2), and were thus labelled as early endothelial progenitor cells 
(eEPCs). Although these cells were shown to enhance angiogenesis in a mouse model 
of hindlimb ischaemia (Asahara et al., 1997; Kalka et al., 2000), their capacity to 
differentiate into ECs was questioned in subsequent studies implying an 
haematopoietic origin and showing that these cells did not exhibit a cobblestone 
morphology typical of endothelial cells or formed vascular networks (Case et al., 2007; 
Yoder et al., 2007; Rohde et al., 2006). Accordingly, a later study by Medina et al. has 
determined that eEPCs share a greater extent of their proteome with monocytes than 
with mature ECs, based on transcriptional and protein profiling of different endothelial 
progenitors (Medina et al., 2010b). Moreover, in the same study, caveolae and 
adherens junctions typical of ECs could not be detected in these cells. It is now fairly 
agreed in the field that these short-lived eEPCs contribute to neovascularization by 
secreting angiogenic growth factors and cytokines, such as VEGF or interleukin 8, 
rather than forming themselves new blood vessels (Hur et al., 2004) 
Therefore, it appears to be more correct to consider these cells as pro-angiogenic 
monocytes rather than true endothelial progenitors and, for this reason, they should be 
used with caution in therapeutic angiogenesis (van der Pouw Kraan, van der Laan, 
Piek and Horrevoets, 2012; Medina et al., 2010b). 
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Endothelial colony forming cells (ECFCs) 
Differently to eEPCs, the so-called endothelial colony forming cells (ECFCs) are 
regarded as a true type of endothelial progenitor and show a lack of expression of 
hematopoietic markers (Ingram et al., 2004). These cells are also derived from the 
MNC fraction of blood but are instead obtained as large colonies of adherent 
endothelial CD45- cells with cobblestone morphology, after 2-3 weeks of culture on 
dishes coated with matrix proteins (e.g. collagen) (Yoder, 2009). For this reason, these 
cells are also referred as late EPCs or outgrowth endothelial cells (OECs) in some 
research groups, which often generates some confusion in the field (Fadini, Losordo 
and Dimmeler, 2012). This isolation method, which is detailed in Chapter 2.1, was first 
described by Ingram et al. and is believed to induce the differentiation of a rare 
population of CD34+/CD133-/CD146+ progenitors into ECs, as these cells can be 
obtained from both the total MNC fraction as well as from the referred MNC subsets 
from peripheral blood (PB) and cord blood (CB) (Timmermans et al., 2007; Mund et al., 
2012). Although the expression of CD34+ at their surface points to the bone marrow as 
their probable source, it is not known with certainty if these progenitors are released 
directly from this tissue into the bloodstream or if they originate from the wall of bigger 
vessels, with conflicting reports suggesting both origins (Tura et al., 2013; Lin, 
Weisdorf, Solovey and Hebbel, 2000). ECFCs are characterized by the expression of 
EC markers, such as CD31, VEGFR-2, CD146 and von Willebrand factor (vWF) and 
absence of leukocyte markers expression (i.e. CD14 or CD45) (Ingram et al., 2004). 
Functionally, ECFCs are known for taking up acetylated low-density lipoprotein (Ac-
LDL) and being able to form tubes in vitro on Matrigel as well as capillary networks in 
vivo (Critser and Yoder, 2010; Critser, Kreger, Voytik-Harbin and Yoder, 2010; Mead, 
Prater, Yoder and Ingram, 2008). Additionally, these cells exhibit a highly proliferative 
profile and considerable self-renewal capacity, but unlike stem cells, their fate is 
already committed, thus do not present any risk of teratoma formation (Hirschi, Ingram 
and Yoder, 2008).  
As with iPSCs, ECFCs can be isolated from any person, hence they are ideally 
suited for autologous therapies aimed at treating ischaemic diseases or for the 
generation of vascular grafts (Medina et al., 2010a), as well as tool for studying 
vascular diseases (Medina et al., 2012). However, these applications have also been 
hampered due their low frequency in blood, with less than 1 colony obtained per 20 mL 
of blood (Ingram et al., 2004). Fortunately, due to the relatively non-invasive nature of 
blood cell collection, this procedure can be repeated several times to improve the 
Chapter 1: Introduction 
_______________________________________________________________________________________________ 
	 10 
likelihood of successfully isolating these cells. Some researchers have alternatively 
attempted to increase the number of circulating EPCs prior to blood drawing by 
promoting their release into the bloodstream with a variety of compounds, such as with 
the CXCR4 antagonist AMD3100 (Yin et al., 2007; Sun et al., 2016; Chao et al., 2016). 
Of interest to the prospective utilization of these cells for human therapeutic purposes, 
an animal product-free ECFC isolation and culture method was developed by replacing 
the foetal bovine serum in the endothelial growth medium (EGM) with pooled human 
platelet lysate (hPL), getting one step closer to the GMP requirements for clinical use 
(Reinisch et al., 2009). 
In summary, blood constitutes a source of both EPCs and pro-angiogenic 
hematopoietic cells, which can be exploited to synergistically promote vascular repair 
and overall healing of damaged tissues (Yoon et al., 2005). 
 
1.3. Scaffold-based approaches for vascular tissue engineering 
The engineering of vascular tissues is subdivided into two main development 
areas: microvascular networks and vascular grafts. The first involves the creation of 
capillary networks with the aim of improving blood perfusion and reducing ischaemia in 
damaged tissues (Rouwkema and Khademhosseini, 2016). Some examples are 
myocardial infarction, where the promotion of local blood supply is necessary to match 
the considerable oxygen demand of the infarcted myocardium and guarantee its 
survival (Ardehali and Ports, 1990), and chronic wounds, where insufficient blood 
vessel network has been shown to hinder full tissue repair (Gordillo and Sen, 2003). 
The second comprises the development of replacements for greater calibre vessels to 
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1.3.1. Microvascular network formation 
In order to promote the formation of capillary-like tubes through self-organization of 
ECs, a scaffold material should meet a set of requirements: 
- Allow the encapsulation either in vitro or in situ of the target cells. 
- Provide a 3D architecture for cell growth. 
- Be biocompatible (i.e. not eliciting an inflammatory response). 
- Allow the diffusion of oxygen and nutrients. 
- Possess similar mechanical properties to the targeted tissue. 
- Allow the quick adhesion of cells. 
- Be biodegradable either naturally or by the direct action of the cells. 
- Allow the establishment of a growth factor gradient. 
Hydrogels present several advantages that make them the ideal material type to 
fulfil these demands. The gelation process through which these hydrophilic networks 
are formed allows them to be moulded in vitro into any desired shape, while permitting 
the homogenous dispersion of cells throughout it, or be injected without damaging the 
targeted and surrounding tissues during delivery (Johnson and Christman, 2013). Due 
their high water content and permeability, the diffusion of oxygen, nutrients as well as 
secreted molecules is greatly facilitated, which is essential for cell survival. The 
mechanical profile of these materials also resembles that of most vascularized soft 
tissues, thus are able to flex in concert with deformations of host tissue (Zhu and 
Marchant, 2011). Their application is not restricted to soft tissues though, as their 
mouldable nature allows them to be combined with harder materials into bi-phasic 
scaffolds in order to meet the required stiffness parameters, as for example in the case 
of engineered bone implants (Daculsi et al., 2010). Hydrogels can be derived from 
synthetic polymers, such as polyethylene glycol, (PEG) and poly(lactic-co-glycolic acid) 
(PLGA), or from both natural materials, including silk fibroin, alginate, Matrigel, 
chitosan, collagen or fibrin, and have been extensively reviewed by others (Johnson 
and Christman, 2013; El-Sherbiny and Yacoub, 2013; Rufaihah and Seliktar, 2016).  
Depending on the specific type of origin, natural hydrogels have a number of 
advantages, including a natural ability to bind biomolecules (e.g. growth factors), low 
cost, improved cell adhesion due to inclusion of integrin-binding sequences or 
susceptibility to cell-mediated proteolytic degradation (Munarin, Petrini, Bozzini and 
Tanzi, 2012). However, there are also drawbacks linked to the use of these natural 
materials, which include issues with purification and batch replicability, immunogenicity 
or pathogen transmission.  
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For example, collagen is one of the most popular hydrogels used for tissue 
engineering, as it is one of the main constituents of the native ECM. However, it is 
usually sourced from animal tissue, which carries a risk of disease transmission and 
may elicit an immune response due to being recognized as a non-human protein, 
which hinder the approval for clinical use. On the other hand, fibrin has proven to be a 
material which can overcome most of these issues and has been object of increasing 
interest (Ceccarelli and Putnam, 2014). For example, in a study by Birla and 
coworkers, fibrin hydrogels supported the formation of a densely vascularized cardiac 
tissue by seeded neonatal cardiomyocytes 3 weeks post-implantation in rats (Birla, 
Borschel, Dennis and Brown, 2005). This human-derived polymer acts as a provisional 
matrix during wound healing and tissue remodeling and is endowed with an excellent 
safety record regarding pathogen transmission, which grants it a superior degree of 
biocompatibility and great potential of approval for medical use (Dunn and Goa, 1999). 
Unfortunately, the cost arising from its purification from human blood and its poor 
mechanical properties have limited its widespread therapeutic application. 
Synthetic hydrogels are advantageous compared to collagen- or fibrin-based 
hydrogels due to the greater control over material characteristics (including mechanical 
properties), reduced batch-to-batch variability and absence of disease transmission 
risk (Zhu and Marchant, 2011). Their superior tunability also allows the design of 
hydrogels that can react to environmental conditions, changing properties depending 
on the factors such as temperature or pH (Klouda et al., 2011). Nevertheless, these 
polymers need to be modified in order to promote cell adhesion or degradation, 
through coupling of integrin-binding domains (e.g. RGD peptides) and sequences 
cleavable by matrix metaloproteases (MMPs) respectively. In addition, while ECM 
proteins can naturally bind to most angiogenic GFs, synthetic polymers can only 
efficiently achieve that following chemical modification (Reed and Wu, 2014). As a 
consequence, the final cost of synthetic hydrogels for tissue engineering is usually 
considerably higher than that of natural ones. Finally, any new synthetic polymer needs 
to go through a rigorous process of safety assessment, as many synthetic polymers 
are potentially cytotoxic (Tian et al., 2012). 
Therefore, synthetic and natural materials can be combined, exploiting the unique 
properties of each type to obtain a hydrogel with superior overall properties compared 
to its individual constituents. Such synergistic effect has been recently shown by mixing 
fibrin and PEG hydrogels in the delivery stem cell-derived ECs in an animal model 
(Benavides et al., 2015). The fibrin component allowed the formation of a vascular 
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network and infiltration of supporting pericytes, while PEG increased the stability and 
longevity of the injectable scaffolds. In a similar manner, Deng et al. showed that the 
crosslinking of collagen hydrogels with chitosan improves their mechanical properties 
and increases the in vivo vascular growth into this matrices (Deng et al., 2010). 
 
1.3.2. Artificial vascular grafts 
Synthetic grafts for large-caliber arterial replacement (internal diameter > 6 mm) 
have already proven rather successful in the clinical setting and are usually produced 
out of non-degradable poly(ethylene terephthalate) (Dacron®), expanded 
poly(tetrafluoroethylene) (Teflon®) or polyurethane (Chlupác, Filová and Bacáková, 
2009; Spadaccio et al., 2013). The lower shear stress near the walls of bigger vessels 
(e.g. aorta), limits thrombogenicity and leads to satisfactory results with these grafts in 
terms of patency and durability, despite incomplete endothelisation. However, in the 
case of small-diameter artery (e.g. coronary arteries) grafts made of the same 
materials, the shear stress is higher resulting in thrombus formation and intimal 
hyperplasia at the anastomotic site (Binns et al., 1989; Bennion et al., 1985). Coating 
of these Teflon-based grafts with heparin has also been attempted with a partial 
improvement in patency rates (Dorrucci et al., 2008). Nonetheless, this surface 
treatment is likely to provide short-lasting benefits for the period immediately following 
implantation. Because of the limitation of artificial blood vessel implants, most of the 
vascular interventions are performed using autologous grafts, such as the saphenous 
vein. In spite of being the current gold standard, the performance of these veins is still 
not at a satisfactory level, mainly due to the mechanical mismatch. Veins have thinner 
walls than arteries and are not prepared for the higher arterial pressure. This leads to 
aneurism formation, followed by thickening of the vessel wall (intimal hyperplasia) and 
accelerated atherosclerosis (Owens et al., 2009; Sur, Sugimoto and Agrawal, 2014). 
Additionally, one third of the patients with peripheral artery disease do not have 
suitable veins that can be used as autografts and the harvesting of these veins may 
also result in donor site morbidity (Li, Sengupta and Chien, 2014), thus there is a great 
demand for an artificial alternative. 
There have been two main strategies for engineering vascular grafts: in vitro and in 
situ. The first aims at generating functional constructs in the laboratory by using cells, 
scaffolds and bioreactors (Isenberg, Williams and Tranquillo, 2006). In this case a 
biodegradable synthetic or naturally derived scaffold is seeded with ECs, SMCs, MSCs 
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or a combination of these. Before being implanted, constructs are cultured in a pulsatile 
flow bioreactor to mimic the physiological conditions and stimulate cells to remodel the 
scaffold into the different layers of the blood vessel.  Due to its long in vitro culture 
period, this approach is not suitable for urgent interventions. Nevertheless, a great 
number of vascular interventions can be planned with sufficient time to fabricate such 
kind of graft. The other approach is to engineer a cell-free graft that can selectively 
recruit cells from the host and allow the remodelling to happen in situ. Because no in 
vitro incubation is necessary, these grafts can be made available immediately to 
surgeons as well as at a lower cost. In recent example of this type of approach, an 
electrospun vascular graft was modified with recombinant mussel adhesive protein 
fused to RGD peptides to promote cellular recruitment in situ (Kang et al., 2015). This 
led to enhanced re-endothelisation by mobilized ECs/EPCs and lower graft failure in an 
in vivo rabbit model.  
Independently of the approach followed, lab-engineered grafts are designed with a 
set of specifications in mind, with the final goal of mimicking the native tissue. The most 
important mechanical requirements are a burst pressure ≥1,700 mmHg (similar to that 
of saphenous vein) and to be able to resist the cyclic strain of the hemodynamic 
environment for 30 days in vitro without dilating (Seifu, Purnama, Mequanint and 
Mantovani, 2013). It is crucial that the elasticity of the graft is as close as possible to 
that of the native vessel, as any compliance mismatch leads to turbulence in the blood 
flow near anastomoses, which in turn increases platelet activation and thrombus 
formation (Mitchell and Niklason, 2003). Strategies aimed at reducing the 
thrombogenicity of the surface are often based on the chemical modification the 
surface with clotting inhibitors or through seeding/capture of ECs/EPCs (de Mel, 
Cousins and Seifalian, 2012). In order to be properly integrated over time, the 
implanted scaffold should also allow the ingrowth of cells from the host, while 
modulating their cell fate and differentiation to form new tissue. This could be controlled 
by the microscopic properties, such as porosity, topography, surface chemistry and 
bioactivity (Fioretta et al., 2012) and applies not only to vascular specific cell types but 
also to immune cells that mediate the inflammatory response to the implant. For 
example, it has been shown, that the polarization of macrophages towards the tissue 
remodelling (M2) phenotype on vascular grafts can be promoted by increasing the fibre 
thickness and porosity of the scaffolds, leading to enhanced ECM deposition by the 
invading cells (Wang et al., 2014b). The newly synthetized ECM gradually takes over 
the mechanical integrity of the graft, whilst the scaffold materials are degraded. 
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Therefore, the scaffold’s degradation rate is another essential parameter to be 
considered and should be in tune with ECM deposition (Bouten et al., 2011). In this 
context, synthetic biodegradable polymers are the first choice for vascular grafts as, 
compared to natural materials, they provide a much greater control over the 
degradation rate and other parameters such as porosity, elasticity or microscopic 
structure (Kim and Mooney, 1998). Degradable polyesters, including poly(glycolic acid) 
(PGA), PLA, poly(caprolactone) (PCL) and their co-polymers, are the most frequently 
used in this approach. These polymers are known for being degraded at considerably 
distinct speeds, thus are often combined in the same scaffold to achieve the ideal 
degradation rate for the different graft layers. An interesting example is the work by Lim 
et al., in which a vascular graft was fabricated using poly(lactide-co-epsilon-
caprolactone) (PLCL) and further reinforced with PGA fibers (Lim et al., 2008). 
Following seeding of vascular cells differentiated from autologous BM stem cells, grafts 
were implanted into the abdominal aorta of dogs and remained patent for the whole 
duration of the study (8 weeks). In summary, scaffolds for vascular grafts should be 
designed so that they act as an anti-thrombotic interface with the blood, providing a 
provisional template for the regeneration of the new arterial vessel, while preventing 
inflammatory processes that can lead to thrombosis and intimal hyperplasia, especially 
at the graft anastomoses. 
 
Methods of scaffold fabrication 
Tubular scaffolds for vascular tissue engineering can be produced from synthetic 
polymers via several methods. The most common ones are electrospinning, solvent 
casting and particulate leaching, gas foaming, freeze drying and 3D printing, with 
respective pros and cons, as extensively reviewed by (Fioretta et al., 2012). Among 
these, electrospinning is probably the most promising and widely used for this purpose, 
as it allows the fabrication of fibrous scaffolds with interconnected pores and tuneable 
fibre architecture that resemble the native ECM. This method produces fibres by 
applying a high-voltage to a liquid droplet in order to draw charged threads of polymer 
solutions, which are collected onto a grounded conductive target (Figure1.2).  
 




The most commonly used setup for producing tubular scaffolds includes a rotating 
mandrel as fibre collector, allowing polymeric fibres to be arranged in a cylindrical 
construct (Ercolani, Del Gaudio and Bianco, 2013). The operating conditions, e.g. 
voltage, flow rate, needle-to-target distance, mandrel speed rotation, can be controlled 
to tailor the fibre diameter, organization, microstructural and mechanical properties. 
Therefore, the layers of the scaffold can be produced with different porosities to induce 
the differential migration and differentiation of specific cell populations, this way 
accurately replicating the microstructure of a normal arterial wall (Bonani et al., 2011). 
Exploiting this concept, Soletti et al. developed an electrospun small-diameter scaffold 
made of a single polymer with a highly porous inner layer, to allow cell ingrowth, and 
an external densely packed fibrous layer, to mechanically reinforce it (Soletti et al., 
2010). Two or more different polymers can also be electrospun in sequence to produce 
bilayered grafts that can mimic the biomechanical characteristics of the different vessel 
wall layers (Montini-Ballarin et al., 2016).   
 
 
Figure 1.2. Diagram of the electrospinning process. The application of voltage to a liquid 
droplet stretches it, forming a Taylor cone. Due to electrostatic repulsion the jet is then 
elongated in a whipping process, during which the solvent evaporates. Solid fibres are finally 
deposited on the grounded collector (Diagram by Joanna Gatford at The New Zealand Institute 
for Plant and Food Research Ltd, distributed under a CC BY 3.0 License, Wikimedia 
Commons). 
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Scaffold surface modification  
In order to mimic native cell-ECM interactions and increase adhesion and/or 
proliferation of cells, the surface scaffolds can be modified and functionalized with 
bioactive molecules (Marklein and Burdick, 2010).  
Methods of modifying the surface chemistry of electrospun fibres include includes 
plasma treatment, wet chemical methods or surface graft polymerization (Yoo, Kim and 
Park, 2009). Wet chemical modification consist in the random chemical scission of 
ester bonds on the polymer backbones, giving origin to carboxylic and hydroxyl groups 
(Ercolani, Del Gaudio and Bianco, 2013), while surface graft polymerization is 
performed with plasma and UV-irradiation to deposit a layer of polymeric chains on 
scaffolds made of another polymer (Xu, Wan and Huang, 2009). Plasma treatment is 
employed to introduce various functional groups on a scaffold surface, modifying the 
surface energy and hydrophilicity to improve biocompatibility and immobilization of 
molecules, such as ECM peptides or GFs (Duque Sánchez et al., 2016). 
Bioactive molecules can be incorporated into scaffolds either via covalent binding 
or physical adsorption. The first requires the surface to be modified (e.g. wet chemical 
method) to add a linker molecule, prior to incubation with the desired moiety (Gabriel et 
al., 2016). Although this method allows molecules to be bound permanently and with 
relative specificity, the binding efficiency is generally low due to the several reaction 
steps that are needed. Conversely, physical adsorption is based on non-covalent 
interactions (e.g. Van der Walls or hydrogen bonds) between proteins and biomaterial 
surfaces, and does not require the use of additional linkers (Wei et al., 2014). These 
methods can be used for example to load scaffolds with GFs, which direct cell 
differentiation or growth over their release period (Perets et al., 2003), or to coat their 
surface with antibodies that can capture the cells of interest from circulation (e.g. ECs) 
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1.4. Platelets in angiogenesis and regenerative medicine 
Complete tissue repair occurs as a series of four overlapping phases - 
haemostasis, inflammation, proliferation and remodelling – and is highly dependent on 
the restoration of the vascular system (Martin and Nunan, 2015). An important event 
leading to tissue repair is revascularisation, which occurs via angiogenesis (i.e. 
branching of existing blood vessels) or vasculogenesis (i.e. de novo formation of 
endothelial networks by mobilized EPCs) (Balaji, King, Crombleholme and Keswani, 
2013). Both events rely on the efficient stimulation of endothelial cell proliferation, 
migration and differentiation, in a process that is greatly influenced by platelets (Rhee 
et al., 2004). Following trauma, activated platelets are accumulated and retained at the 
injury site and initiate the formation of a fibrin-based plug that stops the haemorrhage 
(Golebiewska and Poole, 2015). Platelets are anucleate cells produced by 
megakaryocytes in the bone marrow in a process called proplatelet formation, during 
which genomic DNA is lost (Italiano, Lecine, Shivdasani and Hartwig, 1999). Therefore, 
although platelets remain partially capable of synthetizing proteins via translation of 
remnant cytoplasmic mRNA in response to specific conditions and stimuli (Sim, Poncz, 
Gadue and French, 2016), the majority of the proteome of platelets is received from the 
megakaryocyte at the moment of proplatelet formation. This may account for the 
limited lifespan of platelets in circulation (i.e. 7-10 days) (Lebois and Josefsson, 2016).  
The majority of platelet regulatory proteins and growth factors are stored in the alpha 
granules and released upon stimulation (Nurden, 2011; Peterson et al., 2010). PDGF, 
VEGF, FGF-2 and EGF are some of the main growth factors released and are known 
as potent stimulators of angiogenesis and other reparative processes (Burnouf, Strunk, 
Koh and Schallmoser, 2016). In addition, fibrous proteins such as fibrinogen, 
fibronectin and vitronectin that potentiate the effect of the GFs are also contained in the 
platelet clot and are regarded as ideal for the preparation of tissue engineering 
scaffolds (Wang, Gallant and Ni, 2016). Therefore, the local application of platelet-
derived materials have been proposed as a way of delivering GFs and ECM proteins to 
enhance wound healing and organ regeneration, as recently reviewed in depth by 
other researchers (Piccin et al., 2016; Martínez, Smith and Palma Alvarado, 2015; 
Burnouf et al., 2013). 
Platelet-based materials are initially prepared as platelet-rich plasma (PRP), 
collected by single-donor autologous donation or by pooling of allogeneic donations 
(Greppi et al., 2011). The most common method for PRP application consists in the 
gelation via stimulation of the coagulation cascade with thrombin and/or CaCl2 to 
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convert fibrinogen into fibrin (Piccin et al., 2016). Because this gel has little tensile 
strength, it is sometimes combined with stiffer materials or further enriched with human 
fibrinogen, depending on the target application. As expected, various studies 
performed in animal models have reported a stimulatory effect on angiogenesis by 
platelet products. An example of that is the work by Roy and colleagues, where PRP 
gel was shown to significantly increase wound vascularization in an ischaemic pig 
model (Roy et al., 2011). Since then, several reports have further evidenced the 
beneficial effect of using platelet gels for chronic and acute wound healing (Serra et al., 
2013; Shan et al., 2013) and a recent systematic review has concluded in favour of the 
use of these materials for various clinical applications, such as adipose and bone 
tissue graft implantations (Sommeling et al., 2013). In addition, these platelet-derived 
materials appear to possess antimicrobial and anti-inflammatory properties, which 
further increases their therapeutic potential (Edelblute, Donate, Hargrave and Heller, 
2015; Andía and Maffulli, 2013). 
A modification of the use of PRP is the introduction of cell lysis, which releases the 
full platelet content into the plasma (Schallmoser and Strunk, 2012). Membrane 
fragments can then be removed, creating an entirely acellular product with even less 
immunogenic risk. Although this material has not been yet properly investigated for in 
vivo vascularization, it has provided a much-needed alternative to foetal bovine serum 
(FBS) for the expansion of MSCs and ECFCs (Schallmoser et al., 2007; Reinisch et al., 
2009). Platelet lysates (PL) were shown to support the expansion of MSCs form 
various sources, including bone marrow, fat or cord blood, while maintaining their full 
differentiation potential. Lysed PRP can find important translational applications and 
represent a valid alternative to animal products, which would reduce the risk of 
viral/prion disease transmission and find easier approval for clinical use (Doucet et al., 
2005).  												
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1.5. Polymeric materials for vascular engineering  
The ECM is composed of a number of structural proteins and polysaccharides that 
can provide three-dimensional support to cells. While naturally derived polymers, such 
as collagen or gelatin, are inherently superior as scaffolds with regard to adhesion and 
proliferation of cells, they possess weak mechanical properties when processed by 
electrospinning. In addition, concerns over the risk of immunogenic responses and 
disease transmission, have propelled the development of synthetic polymers for tissue 
engineering. Biodegradable synthetic polymers offer key advantages such as the 
control over their mechanical and degradation profiles to tailor for specific applications. 
These materials can be processed into scaffolds by variety methods and can also be 
chemically modified to modulate their bioactivity (Kai, Liow and Loh, 2014). 
 
1.5.1. Polycaprolactone (PCL) 
PCL (figure 1.3) is an hydrophobic biodegradable polyester, with a glass-transition 
temperature of -60 ºC and melting point around 59–64 C, due to the crystalline nature 
of PCL, which allows its manipulation at relatively low temperatures (Woodruff and 
Hutmacher, 2010). It has been approved by the Food and Drug Administration (FDA) 
for biomedical applications, such as drug delivery or sutures, and is particularly suited 
for long-term applications due to its degradation time (~2 years). PCL has low tensile 
strength, but a very high elongation at break (700%) (Woodruff and Hutmacher, 2010; 
Ercolani, Del Gaudio and Bianco, 2013). 
Several groups have used this polymer (pure or blended with other polymers) to 
fabricate vascular scaffolds by electrospinning, as previously reviewed (Ercolani, Del 
Gaudio and Bianco, 2013). Such vascular grafts were characterized by mechanical 
properties (i.e. burst pressure and compliance) comparable with those of native 
vessels (McClure et al., 2009). In addition, small-diameter electrospun PCL grafts 
exhibited superior endothelialization in rat arterial model when compared to PTFE 
vascular grafts (Pektok et al., 2008). 			
Figure 1.3. Chemical structure of PCL.  
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1.5.2. Poly(lactic-co-glycolic acid) (PLGA) 
PLGA is a biodegradable polymer made from two monomers, lactic acid and 
glycolic acid (Figure 1.4). Since both of these occur naturally, PLGA has a minimal 
toxicity and as been approved by the FDA for human use. It has attracted considerable 
interest in tissue engineering owing to its biocompatibility, as well as due to the 
relatively tuneable degradation rate and mechanical properties (Astete and Sabliov, 
2006). These vary according to the molar ratio of the individual monomers the co-
polymer chain, as the hydrophilicity and speed of degradation increases with 
increasing glycolic acid content (BaoLin and Ma, 2014).  
This polymer has also been extensively investigated for the development of tubular 
scaffolds, showing great improvements compared to poly(glycolic acid) (PGA) scaffolds 
(Ercolani, Del Gaudio and Bianco, 2013). One group investigated the engineering of 
small-diameter tubular scaffolds with pre-seeded ECs and SMCs an tested these as 
arterial substitutes in adult dogs (Kim et al., 2008). These seeded grafts could induce 
the formation of neointima and maintain patency for 3 weeks, while cell-free grafts 
became occluded within 1 week. 									
								
Figure 1.4. Chemical structure of PLGA. The structure of this linear copolymer varies with 
the ratio of its constituent monomers. X (lactic acid) and Y (glycolic acid) indicate the number 
of times each unit repeats. 
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1.5. Aims & Objectives 
The aim of this project was to investigate and develop novel approaches for the 
promotion of vasculogenesis and endothelisation of vascular grafts by ECFCs. For this 
purpose, three different lines of research were pursued. The first will dissect the role of 
protease-activated receptors (PARs) in ECFC-driven vasculogenesis as potential 
therapeutic targets in tissue engineering. The second explores the utilization of human 
platelet lysate gel (hPLG) as an angiogenic support for the ex vivo expansion of 
ECFCs and formation of microvascular networks. Finally, the last research chapter is 
focused on the development of polymer-based tubular scaffolds with increased 
endothelial adhesion and proliferation as potential tool to generate artificial vascular 
grafts. 
Consequently, the main objectives of this work were:  
• Establish the isolation of ECFCs and phenotypically characterize them. 
• Investigate the expression of PARs in ECFCs and assess the effect of 
stimulation of these receptors on cell proliferation and vasculogenic response. 
• Characterize hPLG as a human substrate for culture of ECFCs. 
• Evaluate the ability of hPLG to induce the formation of capillary networks 
following encapsulation in this three-dimensional matrix. 
• Develop a new method of fabrication of tubular scaffolds by electrospinning with 
improved surface properties. 
• Assess the adhesion, proliferation and morphology of ECFCs on the vascular 
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2.1. Isolation and culture of peripheral blood Endothelial Colony Forming Cells 
(ECFCs) 
50 mL of blood were collected by venepuncture from the median cubital vein of 
healthy, drug-free volunteers after obtaining their written consent. The donor consent 
procedure and venepuncture protocol were approved by the Ethics Committee of the 
University of Bath. ECFCs were obtained from the peripheral blood mononuclear cell 
(PBMNC) fraction of whole human blood, which was separated by density gradient 
centrifugation, as previously described (Ingram et al., 2004). Heparinized blood 
(2.5 U/mL) was diluted with an equal volume of Ca2+/Mg2+-free Phosphate-buffered 
saline (PBS; Gibco, Thermo Fisher Scientific, Paisley, UK) and carefully overlaid onto a 
layer of Ficoll-Paque PLUS (GE Healthcare, Uppsala, Sweden), with a density of 
1.077 g/mL at 20 ºC, in conical tubes which were centrifuged at 400 x g (with low 
deceleration) for 30 min at room temperature. The intermediate layer, corresponding to 
the PBMNC fraction (i.e. buffy coat), was collected, resuspended in serum-free 
medium (EBM-2, cat. no. CC-3156, Lonza, Walkersville, US), centrifuged for 5 min at 
500 x g, washed in EBM-2 and, finally, centrifuged at 250 x g to remove any remaining 
Ficoll-Paque and excess plasma. Tissue culture plastic was coated with collagen I from 
rat tail (50 μg/mL in 0.02 N acetic acid; Corning, Bedford, MA, US) at a final 
concentration of 5 μg/cm2 of growth surface. Plates were then incubated at room 
temperature for 1 h, after which the collagen solution was carefully aspirated and the 
surfaces washed with PBS. Cells were seeded at a density of 2 x 105 cells/cm2 on the 
collagen-coated plastic in complete medium (EGM-2, Lonza), which contained 10% v/v 
FBS and the supplier’s growth factor supplement (i.e. human basic Fibroblast Growth 
Factor, Vascular Endothelial Growth Factor, human Epidermal Growth Factor and long 
R3 Insulin-like Growth Factor 1; cat. no. CC-4176, Lonza) and incubated at 37 ºC 
under a humidified atmosphere with 5% CO2. Cell culture medium was replaced every 
2 days to maintain adequate nutrient levels and remove non-adherent cells. Plates 
were regularly inspected for 3 weeks for colony appearance. Colonies with a distinct 
endothelial morphology (i.e. tightly packed cobblestone shaped cells) could be found 
between days 14 and 21 amongst non-proliferating spindle shaped cells (Figure 2.1). 
Colonies were selectively detached using TrypLE Express (Gibco) and separately 
expanded. For subsequent passaging, every semi-confluent flask or well was washed 
with pre-warmed PBS and cells detached with TrypLE through incubation at 37 ºC for 
5 min or until fully detached. The cell suspension pelleted by centrifugation at 220 x g 
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for 3 min in the presence of EGM-2 medium and cells were then seeded in new culture 
vessels at a sub-culture ratio of 1:3. 
For cryopreservation, early passage cells were detached and pelleted in the same 
manner as for regular passaging, but were instead resuspended in cold EGM-2 
containing 20% v/v FBS and 10% v/v DMSO. After transferring into cryovials, cells 
were gradually cooled at 1 ºC/min to -80 ºC in a freezing container (i.e. Mr Frosty) and 

















Figure 2.1. Method of isolation of ECFCs. Summary of method for isolating ECFCs from 
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2.2. Preparation of human platelet lysate (hPL) 
Units of leukocyte-depleted platelet-rich plasma (PRP), prepared by cytapheresis, 
were kindly provided by the Blood Bank at the Royal United Hospitals (RUH) Bath NHS 
Foundation Trust. The bags were anonymised and released for research purposes 
under the ethical approval of the South West - Central Bristol Research Ethics 
Committee (REC) after their expiry (5 days after harvesting). Preparation and handling 
were performed in accordance with the guidelines approved by the Ethics Committee 
of the University of Bath. The platelet count for each unit was >2.40 x 1011 in an 
average volume of 200 mL plasma (supplemented with citrate to prevent platelet 
activation and coagulation). Platelets from 5 or more donors were pooled and lysed by 
ultrasonication using a Model 150VT Ultrasonic Homogenizer (BioLogics, Manassas, 
VA, US). A stepped titanium micro tip was used and sonication was performed at 40% 
amplitude (power) output and 75% pulse for 4 minutes per sample of 25 mL of PRP. 
Aliquots were then centrifuged at 4,000 x g (15 min, 4 ºC) to remove platelet fragments 
and sequentially filtered through 0.45 μm and 0.2 μm pore filters (Millipore, Watford, 
UK) to obtain human platelet lysate (hPL; Figure 2.2).  
 
Figure 2.2. Production of platelet lysate. Overview of the procedure for the production of 
human platelet lysate (hPL) and human platelet lysate gel (hPLG). 
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2.3. Preparation of collagen, fibrin and platelet lysate gels 
Preparation of rat tail collagen I gels 
For the formation of collagen gels, rat-tail collagen I (Corning) was diluted to a final 
concentration of 1.5 mg/mL in acetic acid (0.02 N) and polymerized by neutralizing the 
pH using 1 M NaOH followed by incubation at 37 ºC for 10 min, as previously 
described (Koh, Stratman, Sacharidou and Davis, 2008).  
 
Preparation of human fibrin gels 
Fibrinogen from human plasma (Sigma-Aldrich) was dissolved in EBM-2 (Lonza) at 
2 mg/mL and filter-sterilized through a 0.2 μm pore filter (Millipore). Human thrombin 
(Sigma-Aldrich) was then added at a concentration of 0.5 U/mL and the mixture 
incubated at 37 ºC for 10 min, causing the polymerization of fibrinogen into fibrin.  
 
Preparation of human platelet lysate gels (hPLG) 
As hPLG consists mainly of a fibrin network with additional ECM proteins, for its 
polymerization the same concentration of thrombin was used as for pure fibrin gels. 
Therefore, hPL was diluted in basal medium (20% v/v) (EBM-2, Lonza) and human 
thrombin (Sigma-Aldrich) was added to a final concentration of 0.5 U/mL, after which it 
was incubated at 37 ºC. Formation of hPLG (i.e. gelation) was observed within 5 
minutes of thrombin addition.		
2.4. Fabrication of scaffolds via electrospinning 
Poly(D,L-lactic-co-glycolic acid) (PLGA; ester terminated, lactide:glycolide 75:25, 
molecular weight 76-115 kDa, Resomer® RG 756S, Boehringer Ingelheim) and 
polycaprolactone (PCL; number average molecular weight 80 kDa, Sigma-Aldrich) 
were dissolved at a concentration of 20% w/v in 9:1 2,2,2-trifluoroethanol (TFE) / 
hexafluoroisopropanol (HFIP) by stirring for 24 h at 20 ºC. Three different polymer 
blends were used: PLGA 25:75 PCL, PLGA 50:50 PCL and PLGA 75:25 PCL. The 
polymer solution was transferred to a 5 mL glass syringe (Hamilton) and electrospun at 
15 kV (73030P high voltage power supply; Genvolt) through a 20G stainless steel 
needle at room temperature. A constant flow rate (Table 2.1) was maintained using a 
syringe infusion pump (Cole Parmer, London, UK) and a total of 1 mL was electrospun 
per scaffold. Fibres were collected in an ethanol bath (6 cm deep) with a round copper 
earthed collector (10 cm diameter) at its bottom, and wound around a Teflon cylinder 
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(1 cm diameter, 5 cm length) rotating at 200 rpm powered by a DC motor (part no. 
919D501, Como Drills, Deal, UK). Prior to being removed from the tubular mold, each 
scaffold was washed three times in dH2O over a 2-hour period to elute any absorbed 
ethanol/solvent, and dried overnight. The electrospinning procedure is summarized in 
Figure 2.3. 
 
Table 2.1. Electrospinning parameters 
Polymer blend Voltage (kV) Flow rate (mL/h) 
PLGA 25:75 PCL 15 2.90 
PLGA 50:50 PCL 15 2.25 
PLGA 75:25 PCL 15 1.60 
 
 
Figure 2.3. Electrospinning method. Overview of electrospinning apparatus for the 
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2.5. Nitrogen gas plasma treatment 
Scaffold samples made of the different polymer blends of PLGA/PCL were 
exposed to nitrogen (N2) plasma in a ZEPTO low-pressure capacitively coupled radio-
frequency glow discharge plasma reactor (Diener Electronic, Ebhausen, Germany) at 
13.56 MHz. Plasma treatment was performed for 30 s, 60 s or 120 s, at 50% power 
setting (i.e. 25 W) with an inlet N2 pressure of 1 bar. 
 
2.6. Preparation and cell seeding on electrospun scaffold samples 
For the evaluation of ECFC adhesion, proliferation, viability and morphology onto 
differently treated PLGA/PCL scaffolds, circular samples were cut using a 7 mm punch. 
Scaffolds were plasma-treated or left untreated, and sterilized by UV irradiation 
(30 min) followed by incubation in PBS containing 1% Gentamicin/Amphotericin B 
(Lonza) and 3% Penicillin/Streptomycin (Gibco) for 2 h. After sterilization, scaffolds 
were rinsed in sterile PBS and incubated with either FBS or hPL (diluted 1:1 in PBS 
containing 0.1% Gentamicin/Amphotericin B) for 1 h at room temperature. 
Subsequently, scaffold discs were rinsed three times in PBS, to remove any unbound 
constituents of FBS or hPL, and centrally placed onto 48-well culture plates. To prevent 
cell adhesion to the bottom of the plates, these were coated with 200 μL of sterile ultra-
pure agarose (2% w/v in EBM-2; Invitrogen). ECFCs were then seeded at 
7,000 cells/disc by dispensing a 20 μL droplet of cell suspension onto the centre of the 
scaffolds. Samples were incubated for 1 h at 37 ºC under a 5% CO2 atmosphere after 
which time a further 250 μL of EGM-2 medium (10% FBS) was added to each well 
before samples were returned to the incubator for the desired time course. 	
2.7. Immunoblotting 
For the phenotypic characterization of ECFCs, cells were lysed in 
radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris, 150 mM NaCl, 0.1% w/v 
SDS, 0.5% v/v deoxycholic acid, 1% v/v Triton X-100) in the presence of protease 
inhibitors (cOmplete ULTRA, Roche, Burgess Hill, UK) and phosphatase inhibitors 
(PhosSTOP, Roche). Protein samples from ECFCs and PBMNCs were quantified 
through a colorimetric Micro BCA assay (Thermo Fisher Scientific) to enable loading of 
equal amounts per lane. Gel loading buffer (50 mM Tris-HCl, 2% w/v SDS, 20 mM 
DTT, 0.002% w/v bromophenol blue) was added to each sample at ratio of 1:5 v/v, and 
boiled for 5 minutes. Samples (10 μg) were then electrophoresed through sodium 
dodecyl sulfate polyacrylamide gels (SDS-PAGE) using 8%-12% w/v gels (depending 
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on target protein size) in electrophoresis Tris-glycine buffer (25 mM Tris, 192 mM 
glycine, 0.1% w/v SDS, pH 8.3), then transferred to PVDF membranes in wet transfer 
buffer (25 mM Tris, 192 mM glycine, 20% v/v methanol). Blots were blocked in either 
5% w/v non-fat milk or 5% w/v bovine serum albumin (BSA) in TBST (50 mM Tris, 150 
mM NaCl, 0.05% v/v Tween 20, pH 7.6) and probed with antibodies raised against the 
target protein (Table 2.2), diluted in TBST containing 5% w/v non-fat milk or BSA, 
overnight at 4 ºC. The primary antibody solution was then removed and blots were 
washed several times in TBST.  
 
Table 2.2. List of primary antibodies used for immunoblotting 
Antibody Species Manufacturer Catalogue number 
β-Actin Mouse Sigma-Aldrich A5316 
CD31 Mouse Cell Signaling 89C2 
ERK1/2 Rabbit Santa Cruz sc-94 
Phospho-ERK1/2 Rabbit Cell Signaling 9101S 
PAR-1 (N19) Goat Santa Cruz sc-8203 
PAR-2 (SAM11) Mouse Santa Cruz sc-13504 
VE-cadherin Goat Santa Cruz sc-6458 
VEGFR-2 Rabbit Cell Signaling 55B11 
vWF Rabbit Dako A0082 
 
 
For enhanced chemiluminescence (ECL) based detection, blots were blocked for 
30 min in TBST-milk, and then incubated in a species-appropriate horseradish 
peroxidase conjugated secondary antibody solution (1:2,000; Table 2.3) for 60 min. 
After washing in TBST, protein bands were detected by ECL and developed into 
photographic film (Fujifilm, Bedford, UK).  
For fluorescence-based detection, blots were blocked for 30 min in PBS-based 
Odyssey Blocking Buffer (LI-COR), and then incubated in a species-appropriate 
fluorescently conjugated secondary antibody (1:20,000; Table 2.3) for 60 min. After 
washing three times in TBST and once in PBS, membranes were scanned with a LI-
COR Odyssey CLx infrared imaging system. Densitometric analyses were performed 
using Image Studio Lite v5.0.21 (LI-COR). 
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Table 2.3. List of secondary antibodies used for immunoblotting 
Antibody Species Manufacturer Catalogue number 
Mouse IgG-HRP Sheep GE Healthcare NXA931 
Goat IgG-HRP Donkey Santa Cruz sc-2020 
Rabbit IgG IRDye 800CW Goat LI-COR 926-32211 
Goat IgG IRDye 800CW Donkey LI-COR 926-32214 
Rabbit IgG IRDye 680RD Goat LI-COR 926-68071 
Mouse IgG IRDye 680RD Goat LI-COR 926-68070 
 
2.8. Fluorescence staining 
2.8.1. Immunofluorescence 
Staining of cells grown on coverslips 
Cells grown on coverslips were fixed and permeabilized in ice-cold 100% v/v 
methanol for 10 min. Following fixation, cells were washed in PBS and blocked with 1% 
w/v BSA/PBS for 30 min. Subsequently, samples were incubated overnight at 4 ºC with 
primary antibody (Table 2.4) diluted in blocking buffer (1:100). After three washing 
steps, samples were incubated for 1 h at room temperature with an appropriate 
fluorescently-conjugated secondary antibody (Table 2.5), diluted in blocking buffer 
(1:200) and with 1 μg/mL 4',6-diamidino-2-phenylindole (DAPI, Sigma-Aldrich) in PBS 
for 20 min to label cell nuclei, followed by three additional washes in PBS. Incubation 
with secondary antibodies and DAPI at the same concentration with no prior incubation 
with primary antibodies was used as a negative control. Samples were mounted on 
microscope slides with Vectashield HardSet Mounting Medium (Vector Laboratories, 
Peterborough, UK). Epifluorescence images were obtained using a Leica DMI4000B 
microscope (Leica, Wetzlar, Germany) with a 10x objective, while confocal images 
were acquired on a LSM 510 META microscope (Zeiss, Cambridge, UK) using a 63x 
oil-immersion objective. Images were analysed using ImageJ software (National 
Institutes of Health, Bethesda, MD; https://rsb.info.nih.gov/ij/). 
 
Staining of cells grown on ECM-based substrates 
ECFCs were grown to confluence on either collagen I-coated plates or hPLG and 
fixed in 4% v/v paraformaldehyde (PFA)/PBS for 15 min at room temperature. 
Following fixation, cells were washed three times in PBS and permeabilized in 0.1% v/v 
Triton X-100/PBS for 15 min. Following, blocking with 1% w/v BSA/PBS for 30 min, 
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samples were incubated overnight at 4 ºC with primary antibody (Table 2.4) diluted in 
blocking buffer (1:100). After washing with PBS, slides were incubated for 1 h at room 
temperature with fluorescently conjugated secondary antibody (1:200; Table 2.5) in 
blocking buffer and with 1 μg/mL Hoechst 33342 (Thermo Fisher Scientific) in PBS for 
20 min to label nuclei. Epifluorescence images were obtained using a Leica DMI4000B 
microscope with a 10x objective. 
 
Staining of cells grown on fibrous scaffolds 
Cells were grown on synthetic fibrous scaffolds for 5 days and then fixed in 4% v/v 
PFA/PBS for 15 min at room temperature. Following fixation, samples were washed 
three times with PBS and cells permeabilized in 0.1% v/v Triton X-100/PBS for 15 min. 
Cellular F-actin and nuclei were labelled by incubating the samples for 20 minutes with 
5 units/mL of TRITC-conjugated phalloidin (Molecular Probes, Thermo Fisher 
Scientific) and 1 μg/mL DAPI in 1% BSA/PBS, respectively. Samples were mounted on 
microscope slides with Vectashield HardSet Mounting Medium and z-stacked images 
were acquired with LSM 510 META confocal microscope (Zeiss) with a 20x objective. 
Images were analysed using ImageJ software. 
 
Table 2.4. List of primary antibodies used for immunofluorescence 
Antibody Species Manufacturer Catalogue number 
CD31 Mouse Cell Signaling 89C2 
PAR-1 (N-19) Goat Cell Signaling sc-8203 
PAR-2 (SAM11) Mouse Santa Cruz sc-13504 
VE-cadherin Goat Santa Cruz sc-6458 
vWF Rabbit Dako A0082 
 
 
Table 2.5. List of secondary antibodies used for immunofluorescence 
Antibody Species Manufacturer Catalogue number 
Mouse IgG, Alexa Fluor 488 Rabbit Invitrogen A11059 
Goat IgG, Alexa Fluor 546 Donkey Invitrogen A11056 
Mouse, FITC Goat Invitrogen F-2761 
Rabbit, FITC Goat Invitrogen F-2765 
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2.8.2. Lectin staining of cultured cells 
ECFCs were grown to ~70% confluence on coverslips and fixed in 4% v/v PFA in 
TBS-based lectin buffer (50 mM Tris, 149 mM NaCl, 2.1 mM MgCl2, 1 mM CaCl2, pH 
7.6) for 15 min, following a previously described protocol (Brooks and Hall, 2012). 
Samples were then washed three times in lectin buffer, followed by permeabilization in 
0.1% v/v Triton X-100 for 15 min, and then blocked with 1% w/v BSA for 30 min (all 
solutions were prepared in lectin buffer). Cells were then incubated with FITC-labelled 
Ulex europaeus agglutinin (UEA) at a final concentration of 10 μg/mL and with DAPI 
(1 μg/mL) for 1 h. Coverslips were mounted in Vectashield HardSet Mounting Medium 
and epifluorescence images were obtained using a Leica DMI4000B microscope with a 
10x objective. 
 
2.8.3. Acetylated LDL (Ac-LDL) uptake  
Uptake of Acetylated Low Density Lipoprotein (Ac-LDL) by ECFCs was tested 
using a commercially available kit (cat. no. 022K, Cell Applications, San Diego, US). 
ECFCs were grown on coverslips to near confluency and 1,1’-dioctadecyl–3,3,3’,3’-
tetramethyl-indocarbocyanine perchlorate-labelled acetylated low-density lipoprotein 
(DiI-Ac-LDL) was then  added at a concentration of 10 μg/mL in medium. Cells were 
incubated at 37 ºC, 5% CO2 for 4 h. Culture medium was then removed and samples 
were washed three times with wash buffer (proprietary composition) and nuclei stained 
with 1 μg/mL DAPI, followed by an additional wash. Cells were mounted in Vectashield 
HardSet Mounting Medium and epifluorescence images were obtained using a Leica 
DMI4000B microscope  with a 10x objective using a standard rhodamine 
excitation/emission filter (552 nm excitation and 570 nm emission).   
 
2.8.4. Live/dead assay 
The identification of live and dead cells on scaffolds was performed using 
Viability/Cytotoxicity Assay Kit (Biotium, Hayward, CA, US). This assay uses calcein 
AM to label viable cells green and ethidium homodimer III (EthD-III) to label dead cells 
red. Scaffolds were prepared and seeded with 7,000 ECFCs/sample as described in 
2.62 μM calcein AM and 4 μM EthD-III in reduced serum medium (2% v/v FBS) for 
45 min at 37 ºC. Nuclei of all cells were stained using Hoechst 33342 (1 μg/mL) at the 
same time. At the end of the incubation period, the staining solution was removed and 
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fresh medium was added for subsequent imaging. Epifluorescence images were 
obtained using a Leica DMI4000B microscope at 10x magnification. 
 
2.9. RNA analysis 
2.9.1. RNA isolation 
RNA was extracted using two different techniques in order to obtain the best yield 
and purity: 
1) For the evaluation of PARs expression, and detection of genes regulated 
through PAR-activation, total RNA was prepared with TRI Reagent (Ambion, 
Thermo Fisher Scientific) from ECFCs, human lung fibroblasts, glomerular 
endothelial cells, human myofibroblasts, and HK2 human renal proximal 
tubule epithelial cells (kindly donated by Cristina Beltrami and Dr Donald 
Fraser, Cardiff University). Cells were seeded at a density of 3 x 104 
cells/well in 24-well plates and, after 24 h, were lysed in 500 μL of TRI 
Reagent solution then incubated at room temperature for 5 min to allow for 
nucleoprotein complexes to completely dissociate. The homogenate was 
then separated into aqueous and organic phases by adding 120 μL of 
chloroform and centrifuging at 12,000 x g for 15 min at 4 ºC. RNA was then 
precipitated from the aqueous phase by adding 250 μL of isopropanol and 
repeating the centrifugation step after 10 min of incubation at room 
temperature. The samples were then washed 3 times with 75% v/v ethanol 
and centrifuged for 5 min at 12,000 x g. RNA was then eluted in 15 μL of 
nuclease-free water. 
2) To assess the effect on gene expression induced by hPLG, ECFCs were 
isolated from 3 different donors and cultured in triplicate on collagen I-coated 
plates or hPLG for 24 h followed by RNA extraction. Total RNA was 
extracted with TRIzol (Ambion) and further purified with the RNeasy Micro Kit 
(Qiagen, Venlo, Netherlands). ECFCs were lysed with 1 mL of TRIzol, then 
vortexed and kept at room temperature for 5 min. A volume of 200 μL of 
chloroform was added to the homogenate before centrifugation at 12,000 x g 
for 15 min at 4 ºC. The aqueous phase containing the RNA was collected 
and mixed with 1.5 volumes of 70% v/v ethanol. Each sample was then 
transferred to an RNeasy spin column and spun for 30 s at 12,000 x g. After 
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washing each spin column with a series of buffers supplied by the 
manufacturer, RNA was eluted by addition of 50 μL nuclease-free water. 
Purity and concentration of RNA samples were assessed with the NanoDrop ND-
1000 Spectrophotometer (Thermo Scientific). 1 μL of each sample was measured at 
260 nm and 280 nm. Peak absorbance wavelengths for RNA and protein are 260 nm 
and 280 nm, respectively. The nucleic acid concentration is calculated using the Beer-
Lambert law. The 260/280 ratio is used to assess the purity of RNA in terms of protein 
contamination and a ratio of 2.0 is usually indicative of “pure” RNA. 
 
2.9.2. Reverse Transcription-Quantitative Polymerase Chain Reaction (RT-qPCR) 
cDNA synthesis 
Total RNA was converted into cDNA using one of the following protocols: 
1) For the assessment of the expression of PARs and related target genes, 
cDNA was generated using High Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems, Thermo Fisher Scientific). Reverse transcription (RT) 
master mix for one reaction was composed of 2 μL of 10X RT Buffer, 0.8 μL 
of 25X dNTP Mix (100 mM), 2 μL of 10X RT Random Primers, 1 μL of 
MultiScribe™ and 1 μL of RNAse Inhibitor. The 10 μL of 2X RT master mix 
was added to 10 μL of nuclease-free water containing 1 μg total RNA. The 
RT no template control contained only 10 μL of nuclease-free water. The 
following thermal cycler profile was used: 10 min at 25 °C, 120 min at 37 °C, 
5 min at 85 °C, followed by cooling to 4 °C.  
2) For samples relating to the study of hPLG’s effect on ECFCs, cDNA was 
generated from 250 ng of total RNA using QuantiTect Reverse Transcription 
kit (Qiagen). Any possible contaminations from genomic DNA was removed 
by adding 2 μL of gDNA Wipeout buffer (supplied with the kit) and incubating 
for 2 min at 42 ºC. Each sample was then placed immediately on ice and 
mixed with the RT master mix containing 1 μL of reverse transcriptase, 4 μL 
of 5X Quantiscript RT buffer and 1 μL of RT primer mix (total reaction 
volume of 20 μL). The RT no template control contained only 12 μL of 
nuclease-free water. Samples were incubated for 30 min at 42 ºC followed 
by 3 min at 95 ºC to inactivate the reverse transcriptase.  
The cDNA was stored at 4 ºC for a maximum of 1 week or at -20 ºC for up to 1 
year. 
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Quantitative PCR (qPCR) 
The qPCR master mix (final volume 20 μL) was prepared by combining 10 μL of 
Power SYBR® Green PCR Master Mix (Applied Biosystems), 300 nM of gene specific 
primers and cDNA. The amplification of a single PCR product for the genes of interest 
was confirmed by melting curve analysis. The nucleotide sequences of the primer pairs 
can be found in the table 2.6 The thermal cycling parameters used were: 10 min at 
95 °C followed by 40 cycles at 95 °C for 15 s and 60 °C for 1 min. qPCR was carried 
out on a ViiA™7 or a QuantStudio™ 6 Flex Real-Time PCR System (Applied 
Biosystems). Gene-specific mRNA levels were estimated by the 2-ΔΔCt method and 
normalized against GAPDH levels to obtain relative changes in gene expression, as 
previously described (Livak and Schmittgen, 2001).  
The primers were designed using Primer-BLAST (NCBI, Bethesda, US) against 
mRNA sequences taken from the NCBI database. In order to avoid amplification of 
genomic DNA, when possible, primers were designed to span exon-exon junctions. 
PCR product length was ideally around 100-150 bp and the annealing temperature 
around 60 °C. 
 
 
Table 2.6. List of primers used for qPCR 
Gene Primer Reverse Primer Forward 
GAPDH 5’-TGACGAACATGGGGGCATCA 5’-AGCCGCATCTTCTTTTGCGT 
Angiogenin 5’-CTGGGCGTTTTGTTGTTGGTC 5’-GGTTTGGCATCATAGTGCTGG 
CD31 5’-TCGGAAGGATAAAACGCGGTC 5’-CCAAGGTGGGATCGTGAGG 
CXCR4 5’-CCCACAATGCCAGTTAAGAAGA 5’-ACTACACCGAGGAAATGGGCT 
eNOS 5’-TGATGGCGAAGCGAGTGAAG 5’-ACTCATCCATACACAGGACCC 
FGFR-1 5’-AATGAGTACGGCAGCATCAAC 5’-ACCTCGATGTGCTTTAGCCAC 
IL-8 5’-AACCCTCTGCACCCAGTTTTC 5’-ACTGAGAGTGATTGAGAGTGGAC 
PAR-1 5’-GTAATGCGCAATCAGGAGGACG 5’-GTATCCCATGCAGTCCCTCTCC 
PAR-2 5’-TGAAGATGGTCTGCTTCACG 5’-TCTGCATCTGTCCTCACTGG 
PDGFR-β 5’-AGACACGGGAGAATACTTTTGC 5’-AGTTCCTCGGCATCATTAGGG 
SDF-1 5’-ATTCTCAACACTCCAAACTGTGC 5’-ACTTTAGCTTCGGGTCAATGC 
VE-cadherin 5’-TCTCCAGGTTTTCGCCAGTG 5’-AAGCGTGAGTCGCAAGAATG 
VEGFA 5’-AGGGTCTCGATTGGATGGCA 5’-AGGGCAGAATCATCACGAAGT 
VEGFR-2 5’-CCAGTGTCATTTCCGATCACTTT 5’-GGCCCAATAATCAGAGTGGCA 
vWF 5’-GCCCTGGTTGCCATTGTAATTC 5’-AGCCTTGTGAAACTGAAGCAT 
Chapter 2: Materials & Methods 
_______________________________________________________________________________________________ 
	 37 
2.10. Quantification of growth factor (GF) concentrations in hPL and hPLG-
conditioned medium 
The concentrations of VEGF-A, EGF, PDGF-BB and FGF-2 in three separate 
batches of 20% v/v hPLG preparations, and GF release from hPLG into basal medium 
were determined by enzyme-linked immunosorbent assay (ELISA) using the Human 
Growth Factor II ELISA Strip Kit (Signosis, Santa Clara, US) according to the 
manufacturer’s instructions. 100 μL of sample were used per well and absorbance was 
measured spectrophotometrically at 450 nm. The concentrations of the growth factors 
in each sample are directly proportional to its colour intensity and were calculated 
using a standard curve obtained with the supplied GF protein standards. 
 For the time course GF release experiment, hPLG was prepared as previously 
described in 12-well plates, and 1 mL of medium was added immediately after 
polymerization. Samples of conditioned medium in the absence of cells were collected 
after 1, 3 and 5 days incubation at 37 ºC, and kept at -80 ºC. As above, 100 μL of 
sample were used per well and absorbance was measured spectrophotometrically at 
450 nm to quantify the GF concentrations in each sample, with the use of a standard 
curve. 
 
2.11. Cell proliferation 
2.11.1. Nuclei quantification assay 
ECFCs were seeded at a density of 12,000 cells/well in 24-well plates on collagen 
I-coated wells or hPLG, and cultured in complete medium (EGM-2, Lonza) with 10% 
v/v FBS with or without pharmacological treatments. Cells were fixed after 24 h in 4% 
v/v PFA/PBS and nuclei stained with Hoechst 33342 as above. Fluorescent images 
were acquired using a Leica DMI4000B microscope (5x objective) and nuclei were 
manually counted using ImageJ software to quantify cell numbers. 
 
2.11.2. Resazurin-based cell viability assay 
Viability of cells seeded onto scaffolds was measured using a resazurin-based 
assay as an indicator of cell proliferation (Sittampalam et al., 2004). Scaffolds were 
prepared and seeded with 7,000 ECFCs/sample as described in section 2.6. 
PrestoBlue Cell Viability reagent (Molecular Probes, Thermo Fisher Scientific) was 
diluted 1:10 v/v in cell culture medium and added to cells at 200 μL per well, followed 
by incubation at 37 ºC for 3 h. At this point, medium was collected and transferred into 
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a 96-well plate and fluorescence intensity was read with excitation at 560/10 nm and 
emission at 590/10 nm using a CLARIOstar microplate reader (BMG Labtech, 
Aylesbury, UK). The fluorescence values of the no-cell control wells was averaged and 
subtracted from the fluorescence value of each experimental well. After each reading, 
fresh medium was added to the cells and plates were returned to the incubator. The 
assay was performed at 1, 3 and 5 days post-seeding on the same samples and was 
repeated a total of four independent times with three replicates per condition. 
 
2.11.3. Double stranded DNA (dsDNA) quantification assay 
The amount of dsDNA in each scaffold after 5 days of culture was quantified using 
the Quant-iT™ PicoGreen assay kit as an indicator of cell proliferation (Ng, Leong and 
Hutmacher, 2005). Scaffolds were prepared and seeded with 7,000 ECFCs/sample as 
described in section 2.6. A working solution was prepared by diluting the PicoGreen 
dsDNA reagent (1:200) in TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 7.5). Scaffolds 
were transferred to microtubes and 150 μL of lysis buffer (10 mM Tris pH 8, 1 mM 
EDTA, 0.1 % v/v Triton X-100) was added to each tube. Samples were vortexed for 10 
seconds every five minutes for 30 min on ice and homogenized using a 21-gauge 
needle to ensure the efficient disruption of all cellular content. 100 μL of cell lysate 
samples (previously diluted 1:10 in TE buffer) were mixed with 100 μL of PicoGreen 
working reagent and incubated in microplate wells for 5 min at room temperature in the 
dark. Following incubation, fluorescence was measured with excitation at 483/15 nm 
and emission at 530/30 nm using a CLARIOstar microplate reader (BMG Labtech) with 
a dichroic filter at 502.8 nm. The fluorescence values of the blank control wells were 
averaged and subtracted from the fluorescence value of each experimental well. The 
assay was repeated a total of four times with three replicates per condition. 
 
2.12. Angiogenesis/vasculogenesis assays 
2.12.1. In vitro network formation assay   
The procedure followed a protocol previously described (Arnaoutova and 
Kleinman, 2010) and is outlined in figure 2.4. Growth Factor Reduced (GFR)-
Matrigel™ (BD Biosciences, Oxford, UK) was used to provide an extracellular matrix 
for cell culture by adding 65 μL of Matrigel into each well of a 96-well microplate and 
incubating at 37 ºC for 30 min to achieve gelation. ECFCs were detached using 
Accutase (Life Technologies) and plated at 7,500 cells/well in 100 μL of basal medium 
containing 2% v/v FBS and respective pharmacological treatments. Cells were cultured 
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at 37 ºC, 5% CO2 for 4 hours. Phase contrast pictures were taken on an EVOS FL Cell 
Imaging System (Life Technologies, Thermo Fisher Scientific) with an UPlan FL N 
4X/0.13 objective. Images were processed with ImageJ.  
The vasculogenic coefficient was calculated by measuring the number of tubes, 
total tube length and number of nodes normalized to control using ImageJ with 
Angiogenesis Analyzer plugin (Gilles Carpentier, Faculté des Sciences et Technologie, 
Université Paris Est, Creteil Val de Marne, France). 
 
 
2.12.2. In vitro 3D vasculogenesis assay 
Encapsulation of ECFCs was performed in three different gel matrices: collagen I, 
fibrin and hPLG, which were prepared as described in section 2.3. Cells were mixed 
with the three gel precursors at a density of 2 x 105 cells/mL and 70 μL of each cell 
suspension was added per well of a 96-well plate. Gelation was completed by 
incubation at 37 ºC for 10 min. Cells were then cultured for 3 days in serum-free basal 
medium for hPLG, and with complete medium (containing 10% v/v FBS plus 
recombinant GFs specified in the cell culture method – i.e. hFGF2, VEGF, hEGF and 
R3-IGF1) for cells in collagen and fibrin gels. For assessment of endothelial growth, 
constructs were fixed in 4% v/v PFA in TBS-based lectin buffer (see section 2.8.2) for 
20 min, permeabilized in 0.1% v/v Triton X-100 for 15 min and blocked with 1% w/v 
Figure 2.4. Summary of in vitro network formation assay on basement membrane matrix 
(Matrigel). Cells were seeded on GFR-Matrigel and cultured for 4 h before being imaged. 
Higher network formation was characterized by increased connections between cells (i.e. 
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BSA for 30 min. Samples were then double stained with FITC-conjugated Ulex 
europaeus agglutinin (UEA) (10 μg/mL, overnight, 4 ºC) and Hoechst 33342 (1 μg/mL, 
30 min, room temperature). For live cell imaging of lumenized networks in hPLG, gels 
with encapsulated ECFCs were formed inside plastic cloning rings (of equivalent 
diameter to a well of 96-well plate) which were placed on top of a thin glass bottom 
35 mm imaging dish (µ-Dish, Ibidi, Martinsried, Germany) and cells were cultured in 
basal medium for 3 days. Cells were then incubated with Calcein AM (10 μM, 1 h) and 
Hoechst 33342 (1 μg/mL, 15 min) to stain their cytoplasms and nuclei, respectively. 
After replacing the medium, epifluorescence images were obtained using an EVOS FL 
microscope (Life Technologies) with 4x and 10x objectives whereas confocal live 
microscopy was performed with a LSM 510 META confocal microscope (Zeiss) with 
10x and 20x objectives under 37 ºC, 5% CO2 atmosphere. Image analysis and 
quantification of length of the capillary network in the different conditions were 
performed using ImageJ. 
 
2.12.3. Aortic ring/ECFC co-culture assays 
The aortic ring angiogenic assay was performed as previously described by 
Nicosia et al. (Nicosia and Ottinetti, 1990) with some modifications. 4 to 6-week-old 
Wistar rats, euthanatized by cervical dislocation, were obtained from Emma Robson 
and Prof. Roland Jones. Procedures were approved by the University’s Animal Welfare 
and Ethical Review Body Committee and performed in conformity with the U.K. 
Animals (Scientific Procedures) Act 1986, the European Communities Council Directive 
1986 (86/609/EEC) and were further subject to conformity with the University of Bath 
ethical review document. Each animal was surface-sterilized with 70% v/v ethanol and 
laid, back down, on a dissecting board in a laminar flow tissue culture hood to ensure 
sterility. With the use of a dissection microscope, aortas were harvested and the 
surrounding fibro-adipose tissues were removed. After rinsing with EBM-2 culture 
medium, aortas were sectioned into 1 mm ring segments. Rings were serum-starved 
for 24 h in EBM-2 supplemented with gentamicin (30 μg/mL) and amphotericin 
(15 ng/mL) at 37 ºC and 5% CO2. These were then embedded in collagen I, fibrin or 
hPLG and cultured for 3 days in EBM-2 (with 2% v/v FBS, except for hPLG). Phase 
contrast images were acquired with an EVOS FL microscope (Thermo Fisher 
Scientific), and sprouting (area and length) was quantified manually using ImageJ 
software.  
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For the co-culture assay, 2 x 105 ECFCs/mL were encapsulated in hPLG 
surrounding the aortic rings and cultured as above. After 3 days, constructs were fixed 
in 4% v/v PFA in TBS-based lectin buffer (see section 2.8.2) for 20 min, permeabilized 
in 0.1% v/v Triton X-100 for 15 min and blocked with 1% w/v BSA for 30 min. 
Differential staining of human and rat endothelial cells was performed by incubating 
constructs overnight with FITC-UEA (10 μg/mL) and TRITC-conjugated Isolectin GS-
IB4 (10 μg/mL), respectively, in addition to Hoechst 33342 (1 μg/mL) for staining of 
nuclei from both species. Epifluorescence images were obtained using an EVOS FL 
microscope with 4x and 10x objectives. 
 
2.13. Electron Microscopy 
2.13.1. Scanning electron microscopy (SEM) 
Encapsulated ECFCs (see section 2.12.2) or cell-free fibrin and hPLG samples 
were fixed with 2.5% v/v glutaraldehyde (GDA) in serum-free medium overnight at 
4 ºC, followed by post-fixation with 1% v/v osmium tetroxide containing 1% w/v 
potassium ferrocyanide for 1 h. The samples were washed three times in PBS for 
15 min, stained in 1% aqueous uranyl acetate solution for 1 h in the dark and 
dehydrated in the following acetone series: 50%, 70%, 90%, 95% v/v for 10 min each, 
and then in 100% acetone for 20 min. Subsequently, samples were dried by 
evaporation with hexamethyldisilazane and adhered to aluminium stubs using carbon 
tape.  
Samples of ECFC-seeded PLGA/PCL scaffolds were fixed in 4% v/v PFA/PBS at 
4 ºC overnight. These were further fixed in 2.5% v/v GDA in 0.1 M sodium cacodylate 
buffer (pH 7.3) for 2 h at room temperature. Samples were then rinsed three times in 
sodium cacodylate buffer and post-fixed with 1% v/v osmium tetroxide containing 1% 
w/v potassium ferrocyanide for 1 h at room temperature. After washing in distilled water 
three times over 15 min, samples were snap-frozen and freeze-dried. For the 
preparation of cell-free polymer fibre scaffolds, samples were adhered to aluminium 
stubs using carbon tape, and immediately degassed in vacuum overnight.  
All samples were coated with gold using a Sputter Coater S150B system 
(Edwards, Crawley, UK). Images were captured with a JSM-6480LV Scanning Electron 
Microscope (JEOL, Tokyo, Japan). 
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2.13.2. Transmission electron microscopy (TEM) 
ECFCs, encapsulated in hPLG (see section 2.12.2), were cultured for 3 days, after 
which they were fixed with 2.5% v/v GDA in serum-free medium overnight at 4 ºC, 
followed by post-fixation with 1% osmium tetroxide containing 1% potassium 
ferrocyanide for 1 h. The samples were then washed three times in 0.1 M sodium 
cacodylate buffer for 15 min, stained in 1% aqueous uranyl acetate solution for 1 h in 
the dark and dehydrated in an acetone series: 50%, 70%, 90%, 95% for 10 min each at 
4 ºC and then in 100% acetone for 20 min at room temperature. Samples were then 
infiltrated with Spurr’s Epoxy Resin by immersion in 1:1 v/v resin/dry acetone for 2 h 
and then overnight in 100% resin. The samples were then embedded in 100% resin 
and polymerized at 70 ºC for 8 h. Electron micrographs of 100 nm sections were taken 
using a JEM-1200EX II transmission electron microscope (JEOL). 
 
2.14. Fibre diameter measurement 
The average fibre diameter of electrospun PLGA/PCL scaffolds was determined by 
measuring 100 randomly selected individual fibres per scaffold type using ImageJ 
software. SEM images, at 1,500x magnification for PLGA 25:75 PCL scaffolds and at 
3,000x for the other blends, were analysed using ImageJ. Data were plotted as a 
frequency distribution histogram with a bin width of 0.2 μm for PLGA 25:75 PCL 
scaffolds and of 0.1 μm for the other blends to which a gaussian non-linear regression 
was then fitted using Prism 5 (GraphPad Software, La Jolla, US). 
 
2.15. Contact angle analysis 
Untreated and plasma-treated (see section 2.19) PCL/PLGA electrospun scaffolds 
were cut into rectangles of 0.5 x 1 cm and held flat on glass slides using masking tape. 
A 10 μL droplet of distilled water was automatically dispensed from a Hamilton glass 
syringe onto each specimen using an OCA 15Pro (DataPhysics Instruments, 
Filderstadt, Germany) contact angle analysis system. A video was captured for 60 s at 
3 frames/s for each drop using the built-in USB camera coupled to a 6x zoom lens 
directly opposite a light source. Right and left water contact angles of individual frames 
were determined using the SCA software (DataPhysics) by applying tangents at the 
intersections of the drop outline and the baseline. Three replicates were performed for 
each of the triplicate scaffolds.  
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2.16. Surface analysis 
2.16.1. Fourier transform infrared spectroscopy (FTIR) 
Platelet lysate (hPL), native and plasma-treated (see section 2.5) PLGA/PCL 
scaffolds and hPL-treated scaffolds were assessed with regards to their surface 
chemistry by Fourier transform infrared spectroscopy (FTIR). Samples of hPL-
incubated scaffolds were rinsed three times in PBS and then freeze-dried prior to 
analysis. Spectra were obtained using a FTIR spectrometer (PerkinElmer Frontier) with 
an Attenuated Total Reflectance (ATR) accessory. For each sample, 10 scans were 
performed over a wavelength range of 4,000-600 cm-1 at a resolution of 2 cm-1, and 
spectra then normalized using advanced ATR correction. 
 
2.16.2. X-ray photoelectron spectroscopy (XPS) 
The surface functionalization of the electrospun scaffolds following nitrogen gas 
plasma treatment was studied by X-ray photoelectron spectroscopy. Spectra were 
obtained at the XPS Surface Analysis Facility (Cardiff Catalysis Institute) at Cardiff 
University. Untreated and freshly plasma-treated samples (see section 2.5) were 
analysed in a K-Alpha+ XPS instrument (Thermo Scientific), using monochromatic Al 
Kα X-rays over a 400 μm area. For all samples, a pass energy of 150 eV and a step 
size of 1 eV were employed for survey spectra, while a pass energy of 40 eV and a 
step size of 0.1 eV were used for high resolution spectra of the elements of interest 
(carbon, oxygen and nitrogen).  One sample was analysed per condition, and in each, 
three spots were investigated. Quantification was performed using CasaXPS v2.3.17 
(Casa Software) using Scofield elemental sensitivity factors and an energy 
dependence of -0.6. 
 
2.17. Quantification of protein adsorption by electrospun scaffolds 
Samples cut from the three different PLGA/PCL blend scaffolds using a 7 mm 
diameter punch and plasma-treated for 30 s, 60 s or 120 s (as described in section 
2.5), or left untreated. These discs were then placed in 48-well plates and incubated 
with 1:1 hPL/PBS for 1 h at room temperature. Scaffold samples were then rinsed 
three times in PBS to remove any unbound protein, followed by protein extraction using 
150 μL of RIPA buffer with added protease inhibitors (cOmplete ULTRA, Roche) for 2 h 
at 4 ºC. The amount of protein from hPL adsorbed onto scaffolds was quantified 
through a colorimetric Micro BCA assay (Thermo Fisher Scientific). 
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2.18. Statistical analysis 
Data are expressed throughout as mean values ± standard error of the mean 
(SEM). Statistical analysis was performed using Prism 6 (GraphPad Software). 
Statistical significance was analysed by one-way ANOVA with Bonferroni post-test 
(when comparing experimental conditions versus a control) or Tukey’s (when 
comparing all conditions in between them) for experiments with three or more 
conditions and Student’s T-test for experiments with two conditions. For grouped 
experiments, data was analysed by two-way ANOVA with Tukey’s post-test. Normality 
and equality of group variances were tested by Shapiro-Wilk and Brown-Forsythe tests 
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Protease-activated receptors (PARs) are a group of G protein-coupled receptors 
that are essential to coagulation and are involved in the regulation of vascular tone, 
permeability and secretory activity in mature endothelial cells (Hamilton, Nguyen and 
Cocks, 1998; Roy et al., 1998; Ballerio et al., 2007). PARs are irreversibly activated by 
cleavage of their extracellular domain by extracellular proteases, which include 
thrombin (Vu, Hung, Wheaton and Coughlin, 1991), trypsin (Nystedt, Emilsson, 
Wahlestedt and Sundelin, 1994), tryptase (Molino et al., 1997) and coagulation factors 
VIIa and Xa (Camerer et al., 2002). The cleavage by proteases unmasks a 'peptide 
agonist' domain of the extracellular domain of the receptors. When unmasked, the 
‘peptide agonist’ domain interacts in an intramolecular manner with the extracellular 
portion of the receptor, inducing receptor activation and its coupling with intracellular 
signalling pathways (Figure 3.1a) (Coughlin, 2005). Therefore, short synthetic peptide 
sequences corresponding to the tethered ligand motif of the proteolytically generated 
new N-terminal region can be used to selectively activate these receptors (Figure 
3.1b), mimicking the effect of the activating enzymes (e.g. thrombin and trypsin) without 
cleaving other proteins which are also substrates (Hollenberg, Saifeddine, Al-Ani and 
Kawabata, 1997). 
A number of studies have corroborated the role of PAR-1 and PAR-2 in the 
promotion or regulation of angiogenesis, in both reparative and pathological states. A 
significant increase in the expression of thrombin has been observed in the retinas of 
patients with proliferative diabetic retinopathy, which is characterized by excessive 
neovascularization, and an increase in the levels of cleaved PAR-1 in rat retinas 
following induction of diabetes (Abu El-Asrar et al., 2016). Evidence points to platelets 
as the main intermediaries in this phenomenon, with several authors reporting a 
significant release of vascular endothelial growth factor (VEGF) and stromal cell–
derived factor-1 (SDF-1) in platelets following activation of PAR-1 on their surface 
(Etulain, Mena, Negrotto and Schattner, 2015; Chatterjee et al., 2011). In this sense, 
the local release of alpha-granules following thrombin-dependent PAR-1 activation 
could represent one of the main mechanisms by which platelets promote angiogenesis. 
Although not expressed by platelets, PAR-2 has been shown to play a role in blood 
vessel formation. It is known that this receptor is involved in the downstream signalling 
of tissue factor (TF)-VIIa protease complex that regulates angiogenesis (Belting et al., 
2004) and that its activation increases VEGF expression in human glioblastoma cell 
lines through ERK phosphorylation (Dutra-Oliveira, Monteiro and Mariano-Oliveira, 
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2012). Also of relevance, the injection of PAR-2 activating peptide in mice stimulated 
capillary formation and enhanced recovery in a mouse model of limb ischaemia (Milia 
et al., 2002), but unfortunately no studies have followed up on these findings and 
investigated the outcome of such approach in human subjects. 
While it has been shown that PAR-1 is expressed in ECFCs (Smadja et al., 2009), 
the expression of PAR-2 has not been investigated in this cell type. If PAR-2 is 
expressed in ECFCs, the local accumulation of active proteases following stimulation of 
the coagulation cascade by tissue damage could play a relevant role in the recruitment 
and activation of these progenitors at the site of vascular injury. Additionally, since 
PAR-2 is not expressed in platelets and is activated mainly by trypsin (not directly by 
thrombin, like PAR-1), it could represent a possible selective target for manipulation of 
ECFCs and their utilisation in cell therapy and tissue engineering without interfering 
with the normal coagulation process. 
 







Figure 3.1. Mechanism of protease-mediated receptor activation. The figure depicts the 
activation of PARs by proteolytic cleavage and exposure of the tethered ligand to stimulate 
signalling   (a). Activation of PARs can also be achieved by addition of synthetic agonist 









a  Classical activation! b  Peptide activation!
Second messenger activation 
and cell responses!
Second messenger activation 
and cell responses!
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3.2. Aims & Objectives 
As described, PARs are involved in the regulation of a range of vascular 
mechanisms but their role in vasculogenesis is still not clear. Since these receptors can 
be selectively activated by small peptides, they may constitute a suitable target for 
promotion of vascularization using ECFCs if they are proven to positively influence the 
formation of blood vessels by these cells. 
The aim of the work in this chapter is therefore to investigate the role of PARs in 
ECFC-driven vasculogenesis, which encompasses the following objectives: 
• To establish the isolation of ECFCs and phenotypically characterize them. 
• To confirm the expression of PAR-1 and PAR-2 in ECFCs. 
• To test the effect of PAR stimulation on ECFC isolation. 
• To assess the role of PAR activation on proliferation and tubular network 
formation by ECFCs and characterize signalling mechanisms. 
 																								




3.3.1 Characterisation of ECFCs 
ECFCs can be isolated as cell colonies and expanded ex vivo from both umbilical 
cord blood mononuclear cells and adult peripheral blood mononuclear cells (PBMNCs) 
(Ingram et al., 2004). To establish the isolation of these cells as a routine method 
within our laboratory, hPBMNCs were harvested from healthy adults and the existing 
protocol developed by Ingram and colleagues (Ingram et al., 2004) was followed. 
Distinct colonies with cobblestone morphology could be observed among the adherent 
spindle-shaped hPBMNCs around 14-21 days after seeding (Figure 3.2). These 
colonies could be expanded for up to 8-10 passages with no obvious morphological 













Figure 3.2. Representative ECFC colony. Photomicrograph of a typical ECFC colony 
appearing between 14 and 21 days following initial plating of hPBMNCs. Freshly isolated 
hPBMNCs were cultured on collagen type I-coated plates in EGM-2 medium and emerging 
colonies could be distinguished by their cobblestone morphology characteristic of endothelial 
cells. 
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The endothelial phenotype of the isolated cells was confirmed by immunoblotting 
for endothelial markers VEGFR-2, vWF, VE-Cad and CD31 (Figure 3.3A). While CD31 
expression could be detected in both ECFCs and in the initial hPBMNC population (as 
expected due to the presence of leukocytes and platelets), specific endothelial markers 
such as VEGFR-2 and VE-Cad could only be detected in ECFCs. This phenotype was 
further confirmed by immunostaining for VE-Cad, (Figure 3.3B), denoting a typical 
localization pattern at the intercellular junctions, and for vWF, highlighting a punctate 
distribution compatible with the staining of the Weibel-Palade bodies (Figure 3.3C). 
Other hallmarks of an endothelial lineage were demonstrated, such as staining with 
FITC-conjugated Ulex europaeus lectin (FITC-UEA I) (Figure 3.3D), which binds to α-L-
fucose-containing glycocompounds on the surface of these cells, and the ability to take 
up 1,1’-dioctadecyl–3,3,3’,3’-tetramethyl-indocarbocyanine perchlorate-labelled 
acetylated low-density lipoprotein (DiI-Ac-LDL) (Figure 3.4).  
Finally, cells treated with rhVEGF were grown on a layer of Growth Factor 
Reduced-Matrigel for up to 24 h (Arnaoutova and Kleinman, 2010). ECFCs organized 
into tubular networks in under 6 h in response to rhVEGF (Figure 3.5), suggestive of 
















Figure 3.3. Phenotypical characterisation of ECFCs. (A) Immunoblotting for the endothelial 
markers VEGFR-2, vWF, VE-cadherin, the monocytic marker CD31 and actin (from top to 
bottom) in lysates of ECFCs and PBMNCs (day 0). (B and C) Immunofluorescence staining for 
VE-Cadherin and vWF. (D) Lectin staining with FITC-UEA 1. Nuclei were stained with DAPI. 
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Figure 3.5. Network formation by ECFCs. ECFCs in growth factor reduced medium were 
seeded on a Growth Factor Reduced Matrigel™ matrix and incubated for up to 24 hours, and 
treated with rhVEGF (25 ng/mL). Tubes were already formed after 4 h, maturated by 6 h and 









Figure 3.4. Uptake of DiI-Ac-LDL by ECFCs. Cells were pre-incubated with 10 μg/mL DiI-Ac-
LDL (4 hours, 37 ºC, 5% CO2). After fixation and permeabilisation, nuclei were stained with 
DAPI. Images were acquired with a Leica DMI4000B microscope. Images are representative 
of three independent experiments. 
 
50 μm 25 μm
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3.3.2. Assessment of expression of protease-activated receptor (PAR)-1 and 2 in 
ECFCs 
Both PBMNCs and ECFCs at day 0 were shown to express both PAR-1 and PAR-
2, using N-19 and SAM-11 antibodies (Figure 3.6A-B). These antibodies have been 
shown to detect endogenous expression of PAR-1 and PAR-2 in primary cell lysates 
(Adams, Pagel, Mackie and Hooper, 2012). Platelet and HUVEC protein extracts were 
used as positive controls for PAR-1 and PAR-2, respectively. Their expression at 
mRNA level was then confirmed by qPCR and compared to other cell types known to 
express these receptors (lung fibroblasts, glomerular endothelial cells, myofibroblasts 
and HK2 cells) (Ortiz-Stern et al., 2012; Kumar Vr et al., 2016; Borensztajn et al., 2010; 
Grandaliano et al., 2000). In the case of PAR-2, expression in ECFCs was markedly 
higher compared to other cell types, suggesting it may have an important physiological 
role (Figure 3.6C-D). Finally, to further confirm the expression and assess the 
localization of these proteins in ECFCs, cells were stained with antibodies raised 
against PAR-1 and 2 and images acquired by confocal microscopy. The expression of 
both receptors was confirmed, with ECFCs exhibiting both membrane and cytoplasmic 
staining, a localization pattern similar to that observed previously in primary endothelial 
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Figure 3.6. ECFCs express PAR-1 and PAR-2. The expression of (A) PAR-1 and (B) PAR-2 
was tested in platelets or HUVECs (for PAR1 and PAR2 respectively), PBMNCs at days 0 and 
14 and in ECFCs (from left to right) by immunoblotting using selective antibodies (N19 and 
SAM11, respectively). An actin-specific antibody was also utilized to detect the expression of a 
housekeeping gene in the different lysates. (C) Relative PAR-1 (D) PAR-2 expression in 
ECFCs, fibroblasts, myofibroblasts, glomerular endothelial and epithelial HK2 cells, was 
analysed by RT-qPCR using specific primers as described in Chapter 2.9. Data are normalized 

































Figure 3.7. Immunofluorescence staining of PAR-1 and PAR-2. ECFCs were grown to near 
confluence were fixed in methanol. Expression and localization of PAR-1 and PAR-2 were 
assessed by immunostaining using specific antibodies combined with Alexa Fluor 488 Rabbit 
Anti-Mouse (green) and Alexa Fluor 546 Donkey Anti-Goat IgG (red) secondary antibodies. 
DAPI (blue) was used to localize cell nuclei. Superimposition of the three channels is shown in 
the lower right corner indicating co-localization of the receptors. Images are representative of 
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3.3.3. Isolation of ECFCs under PAR-stimulation 
As PAR activators such as thrombin and metalloproteases are abundant at sites of 
tissue injury, it was hypothesised that PAR-1 and/or PAR-2 may play a role in recruiting 
circulating progenitors or promoting their differentiation towards new endothelium. 
Therefore, the rate of ECFC colony formation in vitro was compared with or without 
PAR activation. 
Selective activation of PAR-1 or PAR-2 was achieved by treating the cells with 
synthetic peptides (Table 3.1) displaying the sequence of the endogenous agonist 
peptide of the targeted receptor (Hollenberg et al., 1997). PAR-activating peptides 
were added at a concentration of 50 μM during every change of medium during the first 
2 weeks of the isolation procedure. The number of colonies observed was then used to 
compare the isolation efficiency under PAR-stimulation versus the control condition. A 
peptide with a scrambled sequence was used as negative control. The sequences of 
the activating and scrambled peptides are detailed below: 
 
Table 3.1. Sequences of synthetic agonist peptides 
 
As shown in figure 3.8, the activation of either PAR-1 or PAR-2 did not significantly 









Targeted Receptor Peptide Sequence 
PAR-1 H-Thr-Phe-Leu-Leu-Arg-NH2 
PAR-2 Ser-Leu-Ile-Gly-Lys-Val-NH2 
























Figure 3.8. Isolation of ECFCs under PAR-stimulation. hPBMNCs from each 40 mL 
donation were divided and plated into collagen-coated 96-well plates. Cells were cultured in 
EGM-2 medium supplemented with either scrambled control peptide, PAR-1- or PAR-2-
activating peptide (50 μM). Plates were inspected microscopically for the appearance of 
colonies and manually counted. No significant difference was observed using one-way 
ANOVA (n=4). 
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3.3.4. ERK activation by PAR-1 and -2 stimulation 
As endothelial proliferation can be partly responsible for the angiogenic process, 
and as ERK1 and 2 are often associated with a proliferative response, it was 
investigated whether PAR-1 and/or PAR-2 are functionally coupled to the ERK1/2 
pathway in ECFCs. For this purpose, cells were treated with synthetic agonist peptides 
and lysed after 30 min in buffer containing phosphatase inhibitors. By immunoblotting 
with specific antibodies for the total and phosphorylated forms of ERK1/2, followed by 
densitometric quantification, the level of ERK activation was assessed. In ECFCs, 
stimulation with both PAR-1 and PAR-2 activating peptides led to a significant increase 
in ERK1/2 phosphorylation (Figure 3.9).  
These kinases and subsequent cascade can be inhibited in vitro with the 
compound PD98059 (Alessi et al., 1995). In order to determine the temporal profile of 
ERK activation via PAR-1 stimulation and validate PD98059 as an inhibitor of the ERK 
pathway, relevant to the network formation assay, cells were treated with PAR-1-
activating peptide over a time course of 4 h and with PD98059. Phosphorylation was 
then assessed by immunoblotting with specific antibodies for the total and 
phosphorylated forms of ERK1/2. Stimulation of PAR-1 led to increased 
phosphorylation of ERK1/2 for up to 2 h, returning to basal levels at 4 h (Figure 3.10), 
in accordance with the timeframe of the angiogenesis assay. ERK phosphorylation was 
efficiently inhibited in the presence of 50 μM PD98059. 
Due to the recognized role of ERKs in the regulation of EPC proliferation (Guo et 
al., 2012), the effect of PAR-1 or PAR-2 stimulation on cell proliferation was tested in 
our experimental conditions. ECFCs were grown for 24 h with scrambled, PAR-1- or 
PAR-2-activating peptides and their metabolic activity assessed using a resazurin-
based assay (PrestoBlue). Despite the increased ERK1/2 activation in ECFCs, their 
metabolism did not appear to be affected by PAR-1/2 activation in either complete 
culture medium or growth factor reduced medium (i.e. complete medium diluted 1 in 5 
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A 
B 
Figure 3.9. ERK activation by PAR-1 and PAR-2 stimulation. (A) Following treatment of 
ECFCs with 50 μM PAR-1- or PAR-2-activating peptide for 30 minutes, proteins were isolated 
in RIPA buffer containing phosphate inhibitors, as described in Chapter 2.7. A peptide with a 
scrambled sequence was used at a concentration of 50 μM as a negative control. Phospho-
ERK1/2, total ERK1/2 and actin (from top to bottom) were detected by immunoblotting. (B) 
Densitometry analysis was performed using ImageJ. Graphs display the normalized intensities 
as arbitrary units for the phospho-ERK1 and phospho-ERK2. The data are mean ± SEM and 































































































Figure 3.11. No effect of PAR-1 or PAR-2 stimulation on ECFC proliferation and 
endothelial differentiation. 2x105 cells/well were seeded in 24-well plate in either complete 
culture medium or in depleted medium. Following 48 h incubation with 50 μM PAR-1- or PAR-
2-activating peptide or 50 μM scrambled peptide, metabolic activity was quantified using the 
PrestoBlue assay. The data represent the mean ± SEM. No statistically significant difference 




























Figure 3.10. Time course of ERK activation by stimulation of PAR-1. Time-dependent 
activation of ERK1/2 by PAR-1-activating peptide (1, 2 and 4 hours) and its inhibition by 50 μM 
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3.3.5. Inhibition of network formation by ECFCs through activation of PAR-1 
Next, the effect of PAR-1 and PAR-2 stimulation on the tubulogenic activity of 
ECFCs was investigated in vitro by monitoring network formation on Matrigel. This 
assay has been widely used to model the spatial reorganization of endothelial cells 
during angiogenesis and measures their ability to form tubular networks (devoid of a 
lumen, however). Thus, this assay has often been employed for the initial testing of 
potential pro- or anti-angiogenic compounds.  
ECFCs were plated on Matrigel in basal endothelial medium (supplemented with 
2% FBS to guarantee cell survival), and treated with 50 μM of PAR-activating peptide 
or scrambled control peptide. After 4 h incubation, wells were imaged under phase-
contrast microscopy and network formation was quantified by measuring both the 
number of tubes as well as the total tube length, using a dedicated ImageJ plugin 
(Angiogenesis Analyzer). Unexpectedly, the stimulation of PAR-1, but not PAR-2 or 
treatment with scrambled peptide, strongly inhibited tube formation by ECFCs in this 
assay (Figure 3.12). Interestingly, treatment with ERK-inhibitor PD98059 did not affect 
basal tube formation by ECFCs and did not interfere with PAR-1-dependent inhibition 
of network formation, suggesting that ERK activation is not primarily involved in tube 

















































Figure 3.12. The activation of PAR-1 inhibits network formation by ECFCs on Matrigel. 
(A) 1x104 ECFCs/well were plated onto Matrigel matrix in basal medium (with 2% FBS). Cells 
were cultured with 50 μM scrambled control peptide, PAR-1-activating peptide or PAR-2-
activating peptide in the absence or presence of 50 μM PD98059 (as indicated). Phase 
contrast images were acquired 4 h after seeding. (B) The number of tubes per image and the 
total tube length were quantified using the Angiogenesis Analyzer plugin for ImageJ. Means ± 
SEM from four independent experiments are shown. Statistical significance was tested by one-
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3.3.6. The effect of PAR-stimulation on gene expression in ECFCs 
In view of the inhibitory effect of PAR-1 activation on network formation by ECFCs, 
the expression of a set of genes that are known to play a role in angiogenesis was 
evaluated. Among these are included both soluble factors, such as VEGF-A (Drake, 
LaRue, Ferrara and Little, 2000) and SDF-1 (Sbaa et al., 2006), and their receptors 
VEGFR-2 and CXCR4. 
ECFCs were cultured under growth-arrested conditions for 24 h to unmask any 
effects produced by the growth factors in the complete culture medium and, in turn, 
highlight any change produced by the treatment with PAR-activating peptides. Cells 
were then treated with 50 μM of either PAR-activating peptides or scrambled control 
peptide, and total RNA was extracted at 1, 2, 4 and 8 hours. Relative gene expression 
was then analysed by RT-qPCR using specific primers. 
While the expression of most genes analysed was not significantly affected 
following stimulation of PAR-1 or PAR-2 throughout the time course of the experiment, 
a significant decrease in VEGFR-2 expression was shown after 1 hour of treatment 
with PAR-1-activating peptide (Figure 3.13). Although not statistically significant, a 
trend towards down-regulation was visible at the 2 h time point with the expression 
levels of VEGFR-2 returning to control levels from 4 hours onwards post-treatment. 
Other changes included a trend for upregulation of IL-8 expression at shorter time 
points, and a marginally significant down-regulation for the expression of CD31 after 8 
hours following PAR-1 stimulation (p=0.05). 
In order to confirm the down-regulation of VEGFR-2 by PAR-1-stimulation, ECFCs 
were incubated with PAR-1-activating peptide for up to 4 hours, and the expression of 
VEGFR-2 was analysed by SDS-PAGE and immunoblotting. At the protein level, a 
significant down-regulation of VEGFR-2 was observed after 2 and 4 hours incubation, 
but not 1 hour (Figure 3.14A). This is in line with the previous results obtained by qPCR 
and matching the timeframe of tubulogenic inhibition observed on Matrigel. The 
densitometric analyses of VEGFR-2 immunoblots, with separate quantification of each 
of the two bands typically observed by western blot (representing two isoforms), are 
shown in Figure 3.14B. 
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Figure 3.13. Effect of PAR stimulation on expression of angiogenesis-related genes. Total 
RNA was extracted at 1, 2, 4 and 8 hours after stimulation with 50 μM scrambled control 
peptide, PAR-1-activating peptide or PAR-2-activating peptide, and relative expression was 
analysed by RT-qPCR using specific primers as described in Chapter 2.9. Data are normalized 
to GAPDH and are expressed as mean ± SEM (n=3). Statistical significance was tested by one-
way ANOVA with Bonferroni’s post-test (*=p<0.05, compared to scrambled peptide treatment at 

















































































































































Figure 3.14. Downregulation of VEGFR-2 by PAR-1 stimulation. (A) Proteins were isolated 
from ECFCs as described in the Chapter 2.7 after treatment with 50 μM PAR-1-activating 
peptide for 0, 1, 2 and 4 hours. VEGFR-2 and actin were detected by SDS-PAGE and 
immunoblotting. (B) Densitometry analysis was performed with ImageJ. Graphs display the 
normalized intensities as arbitrary units for VEGFR-2’s top and bottom band. The data are 
mean ± SEM and the statistical significance of the difference was tested by one-way ANOVA 
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3.3.7. VEGF rescues the inhibitory effect of PAR-1 activation on network 
formation 
The rescue of tubular network formation was attempted in the presence of PAR-1 
stimulation through the addition of an excess of exogenous VEGF. Cells were plated 
onto Matrigel matrix and cultured with 50 μM scrambled control peptide or 50 μM PAR-
1-activating peptide in the absence or presence of recombinant VEGF. After 4 hours, 
images were acquired by phase contrast microscopy (Figure 3.15A) and tube formation 
was quantified using ImageJ by measuring the number of tubes formed and total tube 
length. 
As shown in Figure 3.15B, the addition of 50 or 100 ng/mL VEGF significantly 
reversed the inhibition of network formation induced by PAR-1-activating peptide, while 
no effect was seen in cells treated with scrambled peptide. As a control, the rescue of 
network formation with fibroblast growth factor (FGF) was also tested. As expected, 
FGF did not rescue tube formation in the presence of PAR-1-activating peptide at any 
of the tested concentrations (25, 50 and 100 ng/mL, Figure 3.16), and did not 
significantly increase tube formation in the absence of PAR-1-activating peptide.  
In summary, these data suggest that PAR-1 inhibition of tubulogenesis is most 
likely happening through modulation of VEGFR-2 signalling rather than other GF 






















Figure 3.15. Reversal of network formation inhibition due to PAR-1 activation by 
increasing concentrations of VEGF. (A) 1x104 ECFCs/well were plated onto Matrigel matrix 
in basal medium (with 2% FBS). Cells were cultured with 50 μM scrambled control peptide or 
50 μM PAR1-activating peptide in the absence or presence VEGF (50 and 100 ng/mL). Phase 
contrast images were acquired 4 h after seeding. (B) The number of tubes per image as well 
as the total tube length were quantified using the Angiogenesis Analyzer plugin for ImageJ. 
Data are mean ± SEM. Statistical significance was tested by one-way ANOVA with 












































































































































































































Figure 3.16. Inhibition of network formation due to PAR-1 activation is not reversed by 
FGF. 1x104 ECFCs/well were plated onto Matrigel matrix in basal medium (with 2% FBS). Cells 
were cultured with 50 μM scrambled control peptide or 50 μM PAR1-activating peptide in the 
absence or presence FGF (25, 50 and 100 ng/mL). Phase contrast images were acquired 4 h 
after seeding and the number of tubes per image as well as the total tube length were 
quantified the using the Angiogenesis Analyzer plugin for ImageJ. Data are expressed as mean 
± SEM. No statistically significant difference was detected between treatments using one-way 
ANOVA (n=3). 
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3.4. Summary of results 
• ECFCs can be routinely isolated, and express a typical endothelial phenotype. 
• ECFCs express both PAR-1 and PAR-2. 
• PAR stimulation does not promote endothelial colony formation. 
• Activation of PAR-1 and PAR-2 leads to ERK1/2 phosphorylation, but does not 
have an effect on proliferation in ECFCs. 
• Activation of PAR-1, but not PAR-2, inhibits network formation by ECFCs. 
• The ERK pathway is not involved in this inhibition. 
• VEGFR-2 is significantly down-regulated in response to PAR-1 stimulation. 


















ECFCs are derived from a circulating source of vasculogenic progenitors with 
significant potential for tissue engineering (Tasev, Koolwijk and Hinsbergh, 2016). 
Following a well-established method (Ingram et al., 2004), ECFCs were successfully 
and routinely isolated from human peripheral blood. These cells, obtained as colonies, 
exhibited a cobblestone morphology, which is typical of the endothelial phenotype, and 
could be expanded for several passages (up to 10), as well as cryopreserved. Their 
phenotype was confirmed by a number of techniques. The simultaneous expression of 
CD31, VEGFR-2, VE-cadherin and vWF was demonstrated by immunoblotting, 
distinguishing them from the starting population of PBMNCs (Bogoslovsky et al., 2013; 
Van Craenenbroeck et al., 2008). The expression of VE-Cadherin and vWF was also 
confirmed by immunostaining, and the endothelial lineage was further validated by 
successful staining with fluorescent UEA-1 (Holthöfer et al., 1982) and uptake of Dil-
Ac-LDL (Voyta, Via, Butterfield and Zetter, 1984). Additionally, ECFCs could form 
networks on basement membrane matrix in a shorter time then HUVECs (Arnaoutova 
and Kleinman, 2010), suggestive of their high vasculogenic potential. 
The aim of this chapter was to determine if PAR-1 and PAR-2 are expressed, 
functionally active and involved in vasculogenesis in ECFCs. Mature endothelial cells 
have been shown to express all of the known protease-activated receptors (PAR-1 to 
PAR-4) (Camerer et al., 2002), but research has been mainly focused on the role of 
PAR-1 and PAR-2. These have been implicated in junctional remodelling and 
permeability (Feistritzer, Lenta and Riewald, 2005), paracrine activity (Garcia et al., 
1993) and inflammatory response in endothelial cells in response to coagulation 
proteases, and as extensively reviewed by others (Alberelli and De Candia, 2014; 
Rezaie, 2014; Coughlin, 2005). Conversely, only the expression of PAR-1 had been 
previously reported in adult peripheral blood EPCs (Smadja et al., 2005; 2009). 
The expression of both PAR-1 and PAR-2 was confirmed in adult peripheral blood 
ECFCs, detected by immunoblotting, qPCR and immunohistochemistry. The 
expression of PAR-2 was found to be particularly high in comparison to other cell types 
by qPCR, suggestive of a relevant physiological role. The constitutive activation of 
either PAR-1 or PAR-2 was investigated to ascertain whether it could promote the 
differentiation of the circulating progenitors into ECFCs, thereby increasing the number 
of colonies obtained. It is known that high amounts of thrombin are produced at sites of 
tissue injury during the coagulation cascade (Narayanan, 1999) resulting in the 
conversion of fibrinogen into fibrin and activation of platelets. Therefore, it is plausible 
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that circulating cells with regenerative potential could also be recruited via activation of 
PAR-1 by thrombin, with a subsequent increase in vasculogenesis at these sites of 
vascular damage. In a similar fashion, during the remodelling phases of tissue repair 
where several different proteases are released (Lu, Takai, Weaver and Werb, 2011), 
PAR-2 activation by trypsin-like proteases could constitute a mechanism by which 
endothelial progenitors participate in the generation of new blood vessels. If the 
addition of PAR-activating peptides had led to an increase in colony formation, this 
could have constituted a substantial improvement in the isolation of ECFCs without 
significantly aggravating the cost of this procedure. Unfortunately, despite a minor 
trend towards higher colony formation with added PAR-1-activating peptide, the 
addition of neither of the PAR-activating peptides resulted in a significant increase in 
the number of endothelial colonies after 2 weeks of culture, when compared to the 
standard protocol. 
In isolated ECFCs, both PAR-1 and PAR-2 stimulation resulted in increased 
phosphorylation of ERK1/2. As this pathway is often linked to proliferation and 
differentiation (Mebratu and Tesfaigzi, 2009; Lian et al., 2014), the effect of PAR 
activation on ECFC proliferation was investigated. It has been previously reported that 
PAR-1 activation can lead to accelerated proliferation in ECFCs (Smadja et al., 2005; 
2009). In contrast, no significant increase in ECFC proliferation was observed in our 
experiments. This discrepancy can be explained by several methodological differences 
between this study and those by Smadja et al. First, a different isolation protocol was 
adopted, which is likely to result in a significantly different phenotype in comparison 
with the cells used in the literature studies. Following the protocol established by 
Ingram et al., ECFCs were isolated from adult PBMNCs without pre-enrichment by 
magnetic-activated or fluorescence-activated cell sorting, while in the reports by 
Smadja et al, the authors isolated cells mostly from CD34+-enriched cord blood 
populations. Albeit similar in most basic aspects, it is known that ECFCs isolated from 
cord blood have a genetic profile which is 20% different from those isolated from adult 
blood, with an overall lower expression of pro-thrombotic and pro-inflammatory genes 
(Nuzzolo et al., 2014), which could partly account for the differences observed between 
our study and those previously published. Other less relevant experimental differences 
include: 1) ECM coating of culture substrate (collagen type I in this study versus gelatin 
in (Smadja et al., 2005)) and 2) a different concentration of FBS in the culture medium 
(12% versus 2-5% in (Smadja et al., 2005)). Additionally, due to the extremely high 
proliferation rate of cells obtained with the protocol adopted in this thesis (Ingram et al., 
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2004; Yoder et al., 2007; Hur et al., 2004), any further growth increase may be hard to 
assess. This growth profile supports previous suggestions for using ECFCs in tissue 
engineering (Fadini, Avogaro and Agostini, 2007). As with PAR-1, stimulation of PAR-2 
did not have an effect on ECFC proliferation. Therefore, phosphorylation of ERK1/2 via 
PAR-stimulation in ECFCs appears to lead mainly to cellular events other than 
proliferation, such as transcription changes or cytoskeletal reorganization (Roskoski, 
2012). 
The role of PARs in vasculogenesis was then assessed. Converse to the initial 
hypothesis, network formation on Matrigel was strongly inhibited following PAR-1 
activation and unaffected by PAR-2 activation. Again, this is in disagreement with the 
work by Smadja and colleagues (Smadja et al., 2005) in which PAR-1 activation was 
reported to have a pro-angiogenic effect using the same type of assay. The authors 
correlated this finding with the increased expression of pro-angiogenic chemokines IL-8 
(Smadja et al., 2009), SDF-1 and its receptor CXCR4 (Smadja et al., 2005). Although a 
non-significant trend towards increased IL-8 was observed following PAR-1 activation 
(Figure 3.13), no relevant changes were detected in the expression of SDF-1 or 
CXCR4 following stimulation of either PAR-1 or PAR-2. As with the proliferation 
experiments, this discrepancy may again be due to the different starting population 
utilized for the isolation of ECFCs (i.e. non-selected PBMNCs in our study vs. cord 
blood CD34+ cells in the study by Smadja et al), a hypothesis that is reinforced by the 
strikingly different timing of network formation between the two studies (4 hours vs. 18 
hours of culture on Matrigel) (Smadja et al., 2005), possibly indicating a stronger 
vasculogenic response by the ECFCs used in this work. A similar inhibition of 
tubulogenesis on Matrigel in the presence of PAR-1-activating peptide or high 
concentrations of thrombin was previously shown using HUVECs (Chan, Merchan, 
Kale and Sukhatme, 2003) and with human microvessel endothelial cells (Blackburn 
and Brinckerhoff, 2008), respectively. This is in agreement with the results presented 
here with ECFCs. In addition, a swift down-regulation in VEGFR-2 by PAR-1 activation 
in ECFCs was observed by both qPCR and immunoblotting, corresponding to the 
timeframe of the inhibition seen on tube formation. Accordingly, network formation 
could be rescued by high concentrations of exogenous VEGF in the presence of PAR-
1-activating peptide. This receptor is known to be crucial for proper vasculogenic 
responses by EPCs (Smadja et al., 2007), which suggests that PAR-1 stimulation could 
impair VEGF signalling by reducing VEGFR-2 density on the ECFC surface.  
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The inhibition of tube formation by PAR-1 activation was independent of activation 
of the ERK pathway, as the inhibitor PD98059 failed to affect tube formation, and PAR-
2 stimulation activated ERKs without affecting tube formation. Of interest, recombinant 
VEGF failed to increase tube formation above basal levels, suggesting that the 
concentration of endogenously produced VEGF and, or that present in Matrigel, is 
sufficient to achieve a full response in the absence of PAR-1 stimulation (possibly 
because VEGFR-2 is expressed at a relatively high level). In contrast with the 
hypothesis presented here, i.e. that PAR-2 activation could promote vasculogenesis by 
ECFCs and despite similarities of the signal transduction of PAR-2 and PAR-1 (i.e. the 
MEK-ERK pathway) (Camerer et al., 2002; Syeda et al., 2006), no effect was seen on 
network formation or gene expression following treatment with a PAR-2-activating 
peptide. This hypothesis was based on previously published reports of angiogenic 
effects seen in mouse hindlimb ischaemia, where enhanced limb salvage was 
achieved through PAR-2-dependent reparative angiogenesis (Milia et al., 2002). 
Additionally, PAR-2 signalling appears to be essential for hypoxia-induced retinal 
angiogenesis (Uusitalo-Jarvinen et al., 2007) as well as in cancer-associated 
angiogenesis (Ruf, Yokota and Schaffner, 2010; Belting, Ahamed and Ruf, 2005). 
Although it cannot be excluded that basal levels of tube formation on Matrigel masked 
any effect of PAR-2, it is likely that the effects observed in the studies above are the 
consequence of secretion of paracrine growth factors or direct cell-to-cell interactions 
with other cell types. For example, it has been reported that PAR-2 increases the 
production of VEGF in both human adipose stem cells (hASCs) (Rasmussen et al., 
2012) and in glioblastoma cell lines (Dutra-Oliveira, Monteiro and Mariano-Oliveira, 
2012). Hence, it is plausible that the angiogenic outcome of PAR-2 activation seen in 
vivo is actually a result of an indirect action on endothelial cells. 
As discussed by others	 (Staton, Reed and Brown, 2009; Auerbach et al., 2003), 
the assay that was adopted for this study, despite being one of the most widely used 
assays to study angiogenesis in vitro (Arnaoutova, George, Kleinman and Benton, 
2009), does not accurately represent all of the different stages of blood vessel 
formation, including vascular lumen formation (Bikfalvi, Cramer, Tenza and Tobelem, 
1991). In addition, the Matrigel assay has been suggested to be a poor approximation 
of the physiological extracellular environment and the three-dimensional environment 
of the extravascular space (Zimrin, Villeponteau and Maciag, 1995; Guo et al., 2014; 
Segura et al., 2002). It is commonly agreed that this assay is more representative of 
later stages of angiogenesis, such as differentiation and network reorganization rather 
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than sprouting (Staton, Reed and Brown, 2009). The data obtained with this assay are 
therefore informative of the formation of tight junctions between endothelial cells rather 
than a true representation of the angiogenic response (Auerbach et al., 2003). In 
accordance with this theory, a marginally significant down-regulation in expression of 
CD31 was observed after PAR-1 stimulation (p=0.05), which could contribute to the 
disruption of cell-cell junctions and consequent lack of interconnectivity. In a similar 
manner, it has been shown by others that PAR-1 activation by thrombin drastically 
reduces the expression of CD31 in ECFC monolayers, disturbing the intercellular 

























In conclusion, it was shown that PAR-1 and PAR-2 are both expressed in ECFCs 
and are functionally coupled to the ERK1/2 pathway. The anti-tubulogenic effect of 
PAR-1 in ECFCs was proposed to be a consequence of the down-regulation of 
VEGFR-2, which diminishes the responsiveness of these cells to VEGF. In spite of a 
previous report showing a beneficial effect on angiogenesis of PAR-2 activation in vivo, 
no evidence was found of a direct effect on ECFC-dependent tubulogenesis in vitro. 
Future studies that can expand the range of experimental techniques, including the use 
of more complete angiogenesis assays, would have the potential to shed light on the 
exact mechanism of reparative angiogenesis driven by PAR-2. Such findings could be 
of great interest for the modulation of the vasculogenic activity of ECFCs for cell 
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Insufficient vascularization is not only the main cause of chronic ischaemic 
diseases but also the main bottleneck towards the clinical implementation of tissue-
engineered grafts (Novosel, Kleinhans and Kluger, 2011). In both situations, a shortage 
of an adequate extracellular matrix that can support blood vessel formation leads to a 
deficient regeneration of the host tissue (Lu et al., 2011), as cells that are further than 
200 μm from a source of oxygen will become necrotic (Loffredo and Lee, 2008). 
Therefore, it is imperative to develop new ways of inducing tissue revascularization. 
The combined delivery of angiogenic growth factors (GFs) and endothelial progenitor 
cells (EPCs) within a supporting scaffold has been suggested as an approach capable 
of solving this challenge (Herrmann, Verrier and Alini, 2015). This approach aims at 
promoting the ingrowth of host vasculature into injectable scaffolds as well as through 
the generation of a vascular network from within the implanted construct (i.e. 
vasculogenesis). 
For the formation of functional and stable new blood vessels, it is crucial that 
different cooperating cell types are recruited and prompted by a series of angiogenic 
signals to form new tubular structures (Stratman and Davis, 2012). Therapeutic 
approaches based on the delivery of a single GF, such as VEGF, usually fail to 
promote the formation of a healthy and lasting vasculature (Martino et al., 2015), one of 
the reasons being the failure to recruit perivascular cells that are capable of supporting 
endothelial cells (ECs) in the newly formed blood vessels (Stratman and Davis, 2012). 
However, the production of a set of GFs is extremely expensive and its clinical 
application is hardly feasible from an economical point of view. Furthermore, cells 
respond more efficiently to matrix-bound growth factors compared to soluble growth 
factors (Kang et al., 2011; Cybulsky, McTavish and Cyr, 1994; Swindle et al., 2001). 
This is due to the establishment of a spatial GF gradient which cells can sense and 
migrate towards, and also as a result of the essential crosstalk between integrins and 
GF receptors (Martino et al., 2015). While synthetic polymers have been extensively 
investigated for the delivery of GFs due to their off-the-shelf nature, these need to be 
modified in order to efficiently bind other molecules, such as GFs (Reed and Wu, 
2014). Moreover, despite a few very recent examples (Lang et al., 2014), most 
synthetic polymers do not adhere efficiently to the target tissue and sometimes lack the 
ideal degradation profile. On the other hand, animal-derived biomaterials can naturally 
overcome these issues but their approval for clinical application is harder due to the 
risk of animal-borne disease transmission to the recipients and other adverse reactions 
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to animal products (Petter-Puchner et al., 2008; Doerr, Cinatl, Stürmer and Rabenau, 
2003). 
Platelets are a natural reservoir of angiogenic GFs and cytokines and are activated 
at sites of tissue injury, where they promote tissue repair, including revascularization, 
by releasing these GFs (Anitua et al., 2004; Kisucka et al., 2006). Therefore, through 
lysis of platelets, these GFs can be extracted, providing a less expensive and laborious 
alternative to recombinant production (Schallmoser and Strunk, 2009). Because 
platelet-enriched plasma (PRP) is already used systematically to treat patients with 
thrombocytopenia, it is widely available and can be easily approved for additional 
therapies. Furthermore, as these platelet concentrates are suspended in plasma, they 
also provide a source of ECM precursors, like fibrinogen, which can be quickly 
polymerized into fibrin at body temperature through the coagulation cascade. This can, 
in turn, bind to other scaffolding proteins present in plasma, such as fibronectin, or 
those originating from the disruption of platelets, like vitronectin (Seiffert and Schleef, 
1996) (Figure 4.1A). These proteins are adhesive to collagen (Erat, Sladek, Campbell 
and Vakonakis, 2013) and other ECM components in injury sites and contain integrin-
binding sites (e.g. RGD motifs), allowing for cell attachment. Importantly, the backbone 
of this natural polymer network, can be gradually degraded by the action of proteases 
produced by cells, such as plasmin and matrix metalloproteinases (MMPs), thus 
achieving full biodegradability and host integration (Ahmed, Ringuette, Wallace and 
Griffith, 2014). A further advantage of such approach compared to synthetic polymers 
is that these ECM proteins have a natural affinity for growth factors forgoing the need 
to be modified beforehand (Zhu and Clark, 2014). 
The decision was taken to investigate the use of human platelets as the sole 
source of GFs and structural proteins for the generation of a complete animal product-
free 3D cell culture support (Figure 4.1B). Previous studies on human stem cells 
demonstrated the possibility of fabricating scaffolds using human platelet lysates in 
conjugation with animal proteins (Walenda et al., 2012). Nonetheless, this approach 
has never been chosen for the culture of EPCs and, most importantly, no studies yet 
have focused on the ability of platelet lysate to support the formation of vascular 
capillaries by endothelial progenitors on their own. 
 		















Figure 4.1. Proposed mechanism of hPL polymerization and application rationale. (A) 
hPLG is formed through a chain reaction, in which thrombin cleaves fibrinogen monomers to 
form fibrin protofibrils. Factor XIII then crosslinks these into a fibrin mesh, to which fibronectin 
and vitronectin bind at multiple sites. (B) By using hPLG as both a scaffold and a growth factor 
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4.2. Aims & Objectives 
In spite of the interesting findings in the previous chapter regarding PAR-1 
modulation of tubologenesis by ECFCs, there was no conclusive indication of a 
vasculogenic role played by PAR-2 in these cells, which could be exploited for tissue 
engineering purposes. Considering the need for developing alternative ways of 
promoting sustained blood vessel formation, the next chapter focused on the 
development of an animal-free multi-component system that can support ECFCs in this 
process. 
The aim of the work in this chapter is therefore to create an angiogenic material 
derived from platelets as a fully human therapeutic approach for tissue 
revascularization by ECFCs. The objectives were defined as follows: 
• To investigate if hPL could be gelled, and examine its structure and GF 
constitution. 
• To test gelled hPL as a human substrate for in vitro expansion of ECFCs, 
characterizing their phenotype, gene expression profile and proliferation rate. 
• To encapsulate ECFCs in the hPL matrix and evaluate their vasculogenic 
response. 
• To evaluate the potential of gelled hPL to stimulate angiogenesis from existing 



















4.3.1. hPLG is dense fibrous scaffold containing plasma proteins and multiple 
angiogenic growth factors 
The majority of ECM protein precursors in hPL, that allow it to be gelled, originate 
from its plasma component. Plasma is rich in soluble fibrinogen that can be quickly 
converted into an insoluble fibrin network, in a reaction catalysed by thrombin. 
Additionally, this mesh is also composed of fibronectin and vitronectin, which bind to 
the fibrin backbone. This conjugation of ECM proteins imports a number of advantages 
in using hPLG for cell delivery compared to the commercially available pure fibrin, such 
as improved structural stability, ability to bind growth factors and the number of cell 
binding sites. In order to evaluate the structure of hPLG and compare it against pure 
fibrin gels, samples of both were analysed by SEM. PRP was lyzed by ultrasonication 
to obtain hPL, as described in chapter 2.2, and gelled with and without encapsulated 
ECFCs.  
hPLG was revealed to be composed of a fibrous matrix very similar to pure fibrin 
gels. However, fibrin gels were characterized as having a more unorganized structure 
and smooth texture, while hPLG was shown to have an abundant protein coating and 
more consistently organized fibres. This protein layer appears to be mostly released or 
digested over the period of 3 days, though a remainder of it still visible on the surface 




























hPLG (3 days) 5 μm
Figure 4.2. Microscopic structure of fibrin and hPLG. Scanning electron microscopy 
images of fresh fibrin (top), fresh hPLG (middle) and hPLG after 3 days incubation (bottom) at 
5,000x (left) and 20,000x (right) magnification. 
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Additionally, hPL produced by freeze-thaw methods has been shown to contain a 
variety of GFs with angiogenic profiles	 (Fekete et al., 2012; Burnouf et al., 2016). To 
confirm that ultra sonication could be equally efficient in disruption of platelets, the 
identity and concentrations of some of these GFs was determined in hPL produced by 
this method. Data obtained by ELISA showed that hPLG contains significant amounts 
of VEGF (77±50 pg/mL), EGF (545±49 pg/mL), PDGF-BB (2,293±20 pg/mL) and FGF-
2 (318±10 pg/mL) (Figure 4.3A), which are in line with the previously reported values in 
the literature for platelet lysates produced by the more conventional freeze-thaw 
method. The release of these GFs from hPLG was then analysed in culture medium. 
Gels were incubated at 37 ºC in basal medium and samples of medium were collected 
at 1, 3 and 5 days from different replicates (i.e. data are non-cumulative). Only VEGF-
A, EGF and PDGF-BB appeared to be efficiently released, with the latter being the GF 










Figure 4.3. Initial concentration and release of GFs by hPLG. (A) Growth factor 
concentrations in fresh hPL (20% v/v) and (B) released from hPLG after 1, 3 and 5 days of 
incubation at 37 ºC were determined by ELISA. Data are expressed as mean ± SEM (n=3). 
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4.3.2. Culture of ECFCs on hPLG stimulates cell proliferation in a GF-dependent 
manner 
The suitability of hPLG as a substitute to rat collagen I coating (i.e. traditional 
surface coating) in the continuous culture of ECFCs was assessed by 
immunofluorescence for endothelial markers CD31 and vWF (Figure 4.4). Cells were 
seeded on both substrates and cultured for 2 days until being fixed and stained. The 
endothelial phenotype of ECFCs was retained when cultured on hPLG, exhibiting 
typical cobblestone morphology with CD31 localized to intracellular junctions and 
identical punctate cytoplasmic distribution of vWF protein, denoting the existence of 
Weibel-Palade bodies.  
Additionally, the phenotype of ECFCs cultured on hPLG was also confirmed by 
gene expression analysis of a broader series of endothelial markers. In this case, cells 
were cultured on each of the substrates for 24 h, at which point total RNA was 
extracted and analyzed by RT-qPCR. The relative expression of CD31, eNOS, FGFR-
1, VE-cadherin and vWF remained unchanged in comparison to that of ECFCs grown 
on collagen (Figure 4.5). Interestingly, the expression of a series pro-angiogenic 
molecules and receptors such as angiogenin, PDGFR-β, SDF-1 and VEGFR-2 were 
significantly upregulated in ECFCs grown on hPLG compared to collagen I coating 
(Figure 4.5). 
Figure 4.4. ECFC morphology and phenotype on collagen I vs hPLG. ECFCs grown on 
collagen-coated plastic and hPLG were stained with antibodies for specific endothelial markers 
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Figure 4.5. Gene expression of endothelial markers and pro-angiogenic genes by 
ECFCs on hPLG. Total RNA was extracted from ECFCs cultured on collagen-coated plastic 
and hPLG for 24 h. Relative expression of selected genes was analysed by RT-qPCR using 
specific primers as described in Methods chapter 2.9. Data are normalized to GAPDH and are 
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Considering the observations on GF concentrations in hPLG and overexpression 
of some of their receptors by ECFCs when cultured on this substrate, the proliferation 
rate of these cells was assessed over a 24 h period on hPLG in comparison to the 
traditional coating, while maintaining all the other normal culture conditions (i.e. culture 
in full medium). Additionally, the role of GF signalling as well as the activation of 
ERK1/2 and CXCR4 on proliferation was determined through the addition of specific 
inhibitors. Because this gel was found to interfere with most commonly used metabolic 
activity assays, such as MTS or resazurin-based assays, as well as with dsDNA 
quantification assays due to residual amounts of DNA originating from contaminating 
leukocytes in PRP, a different method had to be employed. Cells were fixed and their 
nuclei stained with Hoechst 33342, followed by epifluorescence imaging. Nuclei were 
then manually counted and expressed as the relative increase versus the number of 
cells seeded. The proliferation of ECFCs on hPLG was significantly higher than on 
collagen-coated plastic (Figure 4.6A) and this difference was associated with the 
activity of several GFs. A decrease in proliferation on hPLG was seen with the non-
specific growth factor receptor blocker pazopanib, without significantly affecting growth 
on collagen. In the presence of VEGF receptor specific inhibitors Ki8751 and tivozanib 
or PDGFRβ/VEGFR inhibitor brivanib, ECFC proliferation was nearly halted on both 
surfaces. Additionally, in agreement with the gene expression data, the increased 
proliferation on hPLG was partially related to SDF-1/CXCR4 signalling as the CXCR4 
antagonist AMD3100 significantly reduced proliferation, while no significant effect was 
observed on collagen I (Figure 4.6B). As expected due to its role in GF signalling and 
cell proliferation, ERK1/2 inhibition with PD98058 suppressed proliferation on hPLG but 
not the traditional collagen coating (Figure 4.6B). 
In order to determine whether the GFs contained in hPL were responsible on their 
own for the higher proliferation observed on hPLG, experiments were performed with 
hPL as a liquid supplement to the culture medium. In addition to collagen coating and 
hPLG, pure fibrin was also tested as a substrate for ECFCs. Data showed that the 
addition of the same quantity of liquid hPL per well as that used for the generation of 
hPLG did not lead to the same improvement in proliferation in as observed for ECFCs 
growing on hPLG (Figure 4.6C and D). 
 
 









Figure 4.6. Stimulation of ECFC proliferation on hPLG. (A) 12,000 ECFCs/well were 
seeded on collagen-coated plastic and hPLG and cultured for 24 h in complete culture medium 
before being fixed and nuclear-stained with Hoechst 33342 (in blue). (B) ECFCs were 
incubated with PD98059 (50 μM), AMD3100 (10 μg/mL), Brivanib (10 μM), Ki8751 (100 nM), 
Tivozanib (1 μM), Pazopanib (20 μg/mL) on both collagen-coated plastic and hPLG. The 
number of cells per mm2 was quantified by microscopy and expressed as fold increase, as 
described in chapter 2.11.1. Data show mean ± SEM. Statistical significance was tested by 
one-way ANOVA with Bonferroni’s post-test test to compare different inhibitors against the 
control conditions (Δ and * indicate statistical differences against the collagen I and hPLG 
controls respectively) (*=p<0.05) (n=6). ECFC proliferation was also tested in 2D cultures on 
collagen-coated plastic and fibrin gels with soluble hPL provided as a source of extra GFs. 
Representative pictures are shown in (C) and quantitative analysis is shown in (D). Data are 
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In view of the demonstrated role of ERK1/2 in the promotion of ECFC proliferation, 
it was decided to investigate the time frame of ERK activation elicited by hPLG. ECFCs 
were seeded on both hPLG or control collagen-coated plastic, and phosphorylation 
was assessed after 1 h and 6 h by immunoblotting using specific antibodies for total 
ERK1/2 and the respective phosphorylated forms. At both time points, these kinases 
were found to be robustly activated on hPLG (Figure 4.7). Because hPLG contains 
considerable amounts of platelet cytoplasmic proteins, actin could not be used as an 
additional loading control and for proper intensity quantification it was necessary to 
take in account the contribution of ERK1/2 from hPLG devoid of ECFCs, which is not 
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Figure 4.7. Culture of ECFCs on hPLG continually activates ERK1/2. (A) Activation of 
ERK1/2 by contact with hPLG versus rat collagen I-coating (1 and 6 hours incubation) and its 
inhibition by 50 μM PD98059. ERK1/2 phosphorylation was assessed using phospho-specific 
ERK1/2 antibodies and immunoblotting. Last lane demonstrates expression but no 
phosphorylation of ERK1/2 from platelets in hPLG (in the absence of ECFCs). (B) Densitometry 
analysis was performed using ImageStudio (LICOR). Graphs display the normalized intensities 
as arbitrary units for the phospho-ERK1 and phospho-ERK2. Data show mean ± SEM. 
Statistical significance was tested using one-way ANOVA with Tukey’s post-test (*=p<0.05). Δ 
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The contribution of VEGF signalling to this elevated ERK1/2 activation was then 
assessed by inhibition of VEGFR-2 with the specific inhibitor Ki8751. At both time 
points, no decrease in ERK activation was observed when VEGFR-2 was inhibited, 
suggesting that either VEGF is not connected to the increased ERK phosphorylation or 
that this pathway is redundantly activated by the different growth factors in hPLG 
(Figure 4.8). 
 





























































































Figure 4.8. Activation of ERK pathway by culture on hPLG is not VEGF dependent. (A) 
Effect of inhibition of VEGFR-2 on ERK activation in ECFCs cultured on hPLG was tested by 
incubating cells with 100 nM Ki8751 or 50 μM PD98059 (1 and 6 hours incubation). ERK1/2 
phosphorylation was assessed using phospho-specific ERK1/2 antibodies and immunoblotting. 
Last lane demonstrates expression but no phosphorylation of ERK1/2 from platelets in hPLG 
(in the absence of ECFCs). (B) Densitometry analysis was performed using ImageStudio 
(LICOR). Graphs display the normalized intensities as arbitrary units for the combined 
phospho-ERK1/2. Data show mean ± SEM. Statistical significance was tested using one-way 
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4.3.3. 3D culture of ECFCs in hPLG promotes capillary vascular network 
formation 
Due to the possibility of gelling hPLG in situ by the simple addition of thrombin, it 
has great potential to become an off-the-shelf means of delivering cells for tissue 
regeneration, especially for the promotion of vascularization. Therefore, the potential of 
hPLG as a supportive scaffold for the formation of fully human endothelial networks 
was investigated. For that purpose, ECFCs were encapsulated in hPLG and their 
response compared with ECFCs in collagen I and fibrin gels, the two gold standards for 
3D angiogenic assays (di Blasio, Bussolino and Primo, 2015). Cells in hPLG were 
cultured in serum-free basal medium, while complete medium (i.e. 10% FBS plus 
recombinant GFs) was used for cells in collagen or fibrin gels in order to ensure cell 
viability and angiogenic response. To visualize and measure the degree of network 
formation, cells were either fixed and stained with fluorescent lectin or live imaged 
following loading with calcein AM. 
Over a 3 day period, ECFCs within hPLG rapidly established a de novo endothelial 
network as evidenced by dual staining with FITC-UEA I and Hoechst 33342 (Figure 
4.9A). Conversely, in collagen I or fibrin gels there was negligible formation of an 
interconnected capillary network, as shown by quantitative image analysis (Figure 
4.9B). Again, as for ERK phosphorylation in 2D cultures, the activation of VEGFR-2 
was not essential for network formation in 3D, as no significant effect was observed 
using the specific inhibitor Ki8751 (Figure 4.10). The cell-permeant dye calcein AM was 
then used to clearly distinguish lumens lined by endothelial cells as part of the capillary 
structures in hPLG. Both epifluorescence (Figure 4.11A) and confocal microscopy were 
used (Figure 4.11B). Confocal images are shown with orthogonal views obtained by z-
stacking, which clearly show the presence of a lumen in the capillaries. The formation 
of capillaries with lumens by ECFCs cultured in hPLG was also confirmed by TEM 
(Figure 4.12A). Through this technique it was possible to detect the different stages by 
which a capillary lumen is typically formed, including the emergence of small vacuoles 
inside individual cells and their gradual fusion to give origin to continuous multicellular 
hollow tubes. Although the lumens of the capillaries reached a considerable size, due 
to limitations in TEM technique (i.e. grid size and data acquisition), only capillaries with 
lumens smaller than 30 μm can be frequently captured in one scan. Larger capillaries 
can be detected and displayed by building a composite picture made of several scans, 
as in Figure 4.12B.  
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Figure 4.9. Network formation by ECFCs in different matrices. (A) ECFCs were 
encapsulated in collagen I, fibrin or hPLG and cultured for 3 days at 37 ºC. Constructs were 
fixed and stained with FITC-conjugated Ulex europaeus lectin (FITC-UEA I) which binds to α-
L-fucose-containing glycocompounds on the surface of endothelial cells and with Hoechst 
33342 to localize cell nuclei. Images were captured with an EVOS FL microscope at 4x (top 
row) and 10x magnifications (bottom row). (B) Total length of capillary network was manually 
measured using ImageJ. Data are mean ± SEM. Statistical significance was tested using one-
way ANOVA with Tukey’s post-test (*=p<0.05) (n=3). 
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Figure 4.10. hPLG supports network formation in a VEGFR-2 independent manner. (A) 
ECFCs were embedded in hPLG and treated daily with Ki8751 solution (100 nM) or vehicle 
solution. Cells were live stained after 3 days of the start of the experiment. Fluorescent calcein 
AM was used to stain the cytoplasm of viable cells. Confocal images were acquired using a 
Zeiss LSM 510 META microscope (10x objective). (B) Total length of the capillary network in 
the different conditions was manually measured using ImageJ. Data are mean ± SEM. 
























Figure 4.11. Detection of lumenized capillary networks by ECFCs encapsulated in hPLG 
using fluorescence microscopy. hPLG-encapsulated ECFCs were live stained 3 days after 
the start of the experiment. Fluorescent calcein AM was used to stain the cytoplasm of viable 
cells, while Hoechst 33342 was used to localize cell nuclei. (A) Images show multiple ECFCs 
organized into primitive vascular structures with a lumen (white arrows). Epifluorescence 
images were obtained using an EVOS FL microscope (10x and 20x objectives). (B) Z-stack 




















   
   














Figure 4.12. Detection of lumenized capillary networks formed by ECFCs encapsulated 
in hPLG using transmission electron microscopy (TEM). (A) TEM was used to confirm the 
existence of a lumen in tubular structures by ECFCs in hPLG. Different stages of lumen 
formation can be observed: from the initial vacuolization within individual cells, to the fusion of 
vacuoles from neighbouring cells forming continuous multicellular tubes (, left to right). Tight 
junctions formed between connecting cells at sites of overlap can be seen in I and II (right side 
panel) while a larger lumen delimited by multiple cells is shown in (B) (stitched composition of 
several electron micrographs). 
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4.3.4. hPLG stimulation of pre-existing vessels in an ex vivo model  
As a proof of concept for the application of hPLG as an injectable scaffold and cell 
carrier, a previously developed ex vivo animal assay was adapted to demonstrate the 
ability of this biomaterial to promote angiogenesis through sprouting of existing blood 
vessels, while allowing for anastomosis between these and the network newly formed 
by injected ECFCs. 
Rat aortic ring sections were encapsulated in hPLG and compared with collagen I 
and fibrin gels. While for hPLG, culture was performed in basal medium, for collagen 
and fibrin matrices 2% FBS was added to guarantee cell survival. In spite of the 
unfavourable conditions, a swift and robust response was seen in hPLG, with sprouts 
reaching close to 600 μm on average into the gel matrix, while negligible sprouting was 
observed in collagen and fibrin gels during the 3 day period (Figure 4.13). Then, to 
simulate in vitro the delivery of ECFCs in hPLG into an ischaemic site as closely as 
possible, these cells were co-encapsulated with rat aortic rings and cultured for 3 days. 
Rat capillaries sprouting from the aortic tissue were stained with TRITC-conjugated 
Isolectin B4 (IB4), which binds terminal α-galactosyl residues expressed on non-
primate ECs, and human ECFCs were stained with FITC-UEA I as previously. Again, 
on a short time scale, extensive sprouting from the aortic rings was observed, closely 
surrounded by a capillary network of ECFCs (Figure 4.14A). Additionally, despite the 
xenogeneic nature of this assay, points of interaction between human and rat 
vasculature were identified already at this early time point (white arrows in Figure 
4.14B), which suggests the ability of ECFC capillaries to anastomose with the “host's” 























Figure 4.13. hPLG induces robust aortic ring sprouting. (A) Cross sections of rat aorta 
were encapsulated in collagen I, fibrin or hPLG for 3 days at 37 ºC. Aortic rings were fixed and 
images captured with an EVOS FL microscope (4x objective, stitched images). (B) 
Angiogenesis was quantified as total sprouting area and average length of sprouts, measured 
using ImageJ. Data show mean ± SEM. Statistical significance was tested by one-way ANOVA 
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Figure 4.14. Interaction between ECFC capillary network with rat aortic sprouts in hPLG. 
(A) Cross sections of rat aorta were co-encapsulated with ECFCs in hPLG and cultured in 
serum-free basal medium, leading to robust sprout formation. After 3 days of incubation, gels 
were fixed and stained with FITC-conjugated Ulex europaeus lectin (FITC-UEA I) to specifically 
label human endothelial cells (ECs) and with TRITC-conjugated Isolectin B4 (IB4) which binds 
terminal α-galactosyl residues expressed on non-primate ECs, in addition to Hoechst 33342 for 
nuclear staining. (B) White arrows indicate sites of close interaction between rat ECs and 
network formed by human ECFCs. Images were obtained with an EVOS FL microscope (4x, 
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4.4. Summary of results 
• hPLG consists of a fibrin-based matrix containing several angiogenic GFs. 
• Significant upregulation of the angiogenic markers angiogenin, PDGFR-β, 
VEGFR-2 and SDF-1 on hPLG. 
• hPLG stimulates ECFCs proliferation, while maintaining the endothelial 
phenotype. 
• ECFC proliferation is mainly dependent on VEGFR-2. 
• Prolonged ERK activation on hPLG vs collagen I. 
• Encapsulation of ECFCs in hPLG promotes the formation of morphologically 
complete capillaries in 3D cultures. 























The delivery of EPCs and angiogenic growth factors (GFs) has been proposed as 
a viable approach for vascularization of tissue-engineered grafts as well as for the 
treatment of ischaemic conditions through therapeutic vasculogenesis (Herrmann, 
Verrier and Alini, 2015; Martino et al., 2015; Kuroda et al., 2014; Levengood et al., 
2011; Lesman et al., 2011). In light of this, there is a need to develop a multi-
component system comprising a source of autologous endothelial cells, a cocktail of 
human growth factors that can induce cell survival and blood vessel formation, and a 
biodegradable scaffold that can be used to deliver and help retain both at the target 
site. Human Platelet Lysate Gel (hPLG) was investigated as a potential injectable 
scaffold that is enriched in several angiogenic GFs to expand and deliver human 
ECFCs. 
To obtain a plasma-derived gel-based scaffold enriched in platelet-derived growth 
factors, we have opted for lysing platelet-rich plasma by ultrasonication. This method 
disrupts platelets and their alpha-granules through cavitation, diminishing the possible 
impact of repeated freeze-thaw methods (Arakawa, Prestrelski, Kenney and Carpenter, 
2001), often used by others (Schallmoser and Strunk, 2012; Doucet et al., 2005), on 
the bioactivity of GFs. It was shown that significant amounts of VEGF-A, EGF, PDGF-
BB and FGF-2 can be obtained in this manner (Figure 4.3A). This panel is further 
complemented by ANGPT-1, IGF-1, PDGF-AB and TGFβ-1, as previously 
demonstrated (Leotot et al., 2013; Fekete et al., 2012; Doucet et al., 2005). These 
growth factors have been shown to play a role in tissue repair through promotion of 
angiogenesis, due to their chemotactic, mitogenic and anti-apoptotic effects on both 
endothelial cells and perivascular cells (pericytes and smooth muscle cells) (Mazzucco, 
Borzini and Gope, 2010; Rozman and Bolta, 2007). Most of these GFs have a natural 
affinity for ECM proteins found in hPLG, such as fibrin (Sahni and Francis, 2000; 
Martino et al., 2013), fibronectin (Rahman et al., 2005; Wijelath et al., 2002; Lin et al., 
2011; Martino and Hubbell, 2010) and vitronectin (Rahman et al., 2005; Upton et al., 
2008), and are slowly released due to the action of proteases that cleave the ECM or 
the ECM-binding domains of GFs (Ferrara, 2010). In our experiments, the 
quantification of growth factor release from hPLG into the medium was performed in 
the absence of cells and only PDGF-BB reached concentrations above 1 ng/mL over 5 
days (Figure 4.3B). It is likely that the majority of the growth factor content remains 
bound to the hPLG matrix and it’s only released in higher amounts due to cell activity. 
The ultrastructure of this matrix appeared more organized than that of pure fibrin gels 
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(Figure 4.2). This difference can be mainly attributed to presence of plasma fibronectin, 
which is known to bind to fibrin (Makogonenko, Tsurupa, Ingham and Medved, 2002). 
Such binding has been reported to lead to the formation of thicker and denser fibres 
(Procyk and King, 1990; Carr, Gabriel and McDonagh, 1987), as well as in the 
stiffening of the protofibril bundles by additional linkage of the α chains, with a 
subsequent increase of its elastic modulus (Kamykowski, Mosher, Lorand and Ferry, 
1981). In addition to higher elasticity, hPLG should also benefit from the incorporation 
of vitronectin from a structural point of view. Although not investigated in our study, 
vitronectin has been found to inhibit fibrinolysis by modulating the action of Type 1 
plasminogen activator inhibitor (PAI-1) (Podor et al., 2000), while its deficiency has 
been associated with increased wound fibrinolysis and decreased microvascular 
angiogenesis in animal models (Jang, Tsou, Gibran and Isik, 2000). Fibrin gels used in 
surgical settings (i.e. fibrin glue) require the addition of aprotinin to slow down its 
degradation (Thompson, Letassy and Thompson, 1988). This bovine protein has been 
associated with serious allergic reactions, especially in the case of repeated exposure 
(Scheule et al., 1998; Beierlein et al., 2000). Therefore, the use of hPLG as an 
alternative to fibrin glue in certain clinical procedures has the potential to dispense with 
the use of aprotinin, as vitronectin should produce the same effect without any adverse 
effects. 
We focused on the use of hPLG for culture and vascular network formation by 
ECFCs. The standard isolation protocol for ECFCs initially developed by Ingram et al. 
(2004) requires the coating of wells with collagen I from rat-tail to increase the 
adhesion and proliferation of these cells. The use of rat collagen or other animal 
products raises safety issues and hinders clinical applications of these cells. As 
mentioned above, in addition to the high GF content, hPLG contains high amounts of 
ECM proteins, which facilitate integrin interactions and result in higher cell adhesion 
and proliferation, while avoiding the use of animal proteins. Culture of ECFCs on hPLG 
did not lead to significant changes in morphology or expression of endothelial markers 
when compared to the traditional collagen I coating. On both substrates, ECFCs 
organized into a monolayer with cobblestone morphology with CD31 localized at the 
tight intercellular junctions, as well as vWF pinpointing Weibel–Palade bodies, typical of 
functional endothelial cells (Figure 4.4). The preservation of their structure and function 
was further confirmed by the unchanged gene expression of VE-cad, which plays an 
essential role in the maintenance of a restrictive endothelial barrier, and eNOS, which 
is involved in the regulation of vascular tone and platelet aggregation (Figure 4.5). 
Chapter 4: hPLG for expansion of ECFCs and microvascular network formation 
_______________________________________________________________________________________________ 
	 101 
Despite this, hPLG greatly increased the proliferation rate of ECFCs when compared to 
the standard collagen I (Figure 4.6). This effect appeared to be correlated with the 
simultaneous activation of EGFR, FGFR, VEGFR-2 and PDGFR-β, since the multiple 
inhibition of these receptors decreased cell growth to the same extent as single 
VEGFR-2 inhibition. As reviewed by Mazzucco et al., it is known that the two main 
downstream targets shared by all of these receptors are ERK and PI3K (Mazzucco, 
Borzini and Gope, 2010). Accordingly, the prolonged activation of ERK1/2 pathway 
was observed in ECFCs cultured on hPLG (Figure 4.7), yet the inhibition of VEGF 
signalling did not decrease ERK phosphorylation on its own (Figure 4.8). This is 
probably due to the synergistic effect of the different GFs on ERK activation and the 
enhanced integrin binding on hPLG’s ECM, which further stimulates this mechanism 
(Wang and Milner, 2006). As observed in our study, the phosphorylation of ERK1/2 
proteins is often linked to cell proliferation but, in fact, its end result cannot be 
dissociated from the effect of the simultaneously activated PI3K pathway on cell 
migration (Graupera et al., 2008; Huang and Sheibani, 2008; Lai et al., 2011), protein 
synthesis (Viñals, Chambard and Pouysségur, 1999) and inhibition of apoptosis 
(Gerber et al., 1998; Dai, Zheng and Fu, 2008). Therefore, it is plausible that although 
VEGFR-2 is not solely responsible for increased ERK phosphorylation, by acting as a 
biological checkpoint for endothelial cell survival via PI3K (Zhuang et al., 2013; Fujio 
and Walsh, 1999), its complete inhibition can have such a dramatic effect on 
proliferation. In agreement, even on collagen, the inhibition of VEGFR-2 completely 
halted any degree of proliferation. On the other hand, inhibition of ERK1/2 decreased 
cell proliferation only partially when compared to blocking of VEGFR-2, further 
demonstrating the multiple pathways through which this receptor can have an effect on 
cell growth. Likewise, inhibition of the SDF-1/CXCR4 axis, which is known for playing a 
role in migration and cell survival (Zheng et al., 2008; Pi et al., 2009; Mirshahi et al., 
2000; Yun and Jo, 2003), resulted in a partial decrease in proliferation. Additionally, the 
superior proliferation observed on hPLG vs collagen I is not simply due to its content in 
GFs but can also be explained by the interplay between these and ECM, integrins and 
respective GF receptors. The presentation of an ECM-bound GF generates a 
protracted signalling on the target cell, when compared to a liquid-phase GF, by 
delaying GF receptor internalization (Kang et al., 2011; Swindle et al., 2001; Cybulsky, 
McTavish and Cyr, 1994). Also, the proximity of GF-binding domains and integrin-
binding sites in ECM proteins facilitates the formation of focal adhesion complexes and 
regulates the activity of associated GF receptors (Zhu and Clark, 2014; Kim, Turnbull 
and Guimond, 2011). For example, VEGF signalling in endothelial cells is impaired 
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when the binding of αvβ3 integrin to RGD motifs in vitronectin is blocked (Montenegro 
et al., 2012) and angiogenesis regulated by FGF-2 is dependent on binding of integrin 
α5β1 to fibronectin (Kim, Bell, Mousa and Varner, 2000). 
Interestingly, for the first time a coordinated upregulation of a set of genes involved 
in angiogenesis by endothelial cells was reported in response to a platelet-derived 
biomaterial (Figure 4.5). The expression of both VEGFR-2 and PDGFR-β by ECFCs 
was in fact significantly upregulated on hPLG after 24 h, which suggests increased 
sensitivity to VEGF and PDGF by ECFCs in these culture conditions. One plausible 
hypothesis is that the binding of a set of integrins to fibrin and other ECM proteins in 
hPLG may initiate a cascade of events that lead to an increase in the transcription 
levels of these receptors. Indeed, it is known, for example, that the attachment to RGD 
motifs via αvβ3 and α5β1 integrins is required for endothelial cell morphogenesis in 
fibrin matrices (Bayless, Salazar and Davis, 2000). In addition, the expression of the 
secretable molecules SDF-1 and angiogenin was also significantly upregulated at the 
same time point. The first is known to stimulate the recruitment of pro-angiogenic 
hematopoietic cells (Ascione et al., 2015) as well as the migration of endothelial cells 
(Zheng, Fu, Dai and Huang, 2007; Mai et al., 2014; Pi et al., 2009) which might explain 
the decrease in ECFC proliferation when its receptor CXCR4 is inhibited. Although 
SDF-1 is already present in hPLG (Rafii et al., 2015), it appears to be further produced 
by ECFCs, likely also promoting proliferation in an autocrine manner. Finally, 
angiogenin is a ribonuclease essential for focal adhesion formation (Wei et al., 2011) 
and plasmin generation (Hu and Riordan, 1993), but perhaps more important in this 
context is its role in inhibition of apoptosis (Li, Yu and Hu, 2012; Li, Yu, Kishikawa and 
Hu, 2010) and cell proliferation induced by other growth factors, namely VEGF, EGF 
and FGF (Kishimoto et al., 2005). Additionally, it has been reported that angiogenin 
can lead to ERK1/2 phosphorylation in endothelial cells on its own (Liu et al., 2001), 
contributing to the prolonged activation of this kinase observed in our study. Taken 
together, the combined effect of direct receptor activation by synergistic matrix-bound 
GFs, enhanced integrin binding and crosstalk between these GF receptors in addition 
to the consequential upregulation of pro-angiogenic genes is likely responsible for the 
superior proliferation of ECFCs on hPLG. 
It was also demonstrated that hPLG can support the formation of a profuse 
microvascular network by human ECFCs. The 3D network formed in vitro was not only 
far superior to those formed in collagen I and fibrin gels (Figure 4.9), but also exhibited 
a well-defined lumen generated in a period of just 3 days (Figures 4.11 and 4.12), with 
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diameter similar to that of native human capillaries (Hansen et al., 2013). As a point of 
comparison, other groups have reported the formation of networks by HUVECs in 
collagen/fibrin gels requiring between 7 and 14 days (Peterson et al., 2014). The short 
time frame of our approach is believed to be optimal for the regeneration of tissues by 
scaffold implantation, where it is vital to avoid tissue necrosis due to an initial lack of 
blood supply. Therefore, hPLG is ideally suited for the in vivo delivery of ECFCs and 
possibly of other pro-angiogenic cells. Such a combinatorial approach has the 
advantage of not requiring the production and delivery of any recombinant GFs, like in 
other proposed methods (Chu and Wang, 2012; Bai et al., 2013). While the delivery of 
high amounts of rhVEGF has been extensively attempted to promote in situ 
angiogenesis, it is now known that this leads to aberrant blood vessel formation 
(Ozawa et al., 2004) and the combined delivery of VEGF and PDGF-BB is necessary 
to induce normal angiogenesis (Banfi et al., 2012). By using this platelet-derived gel 
both these GFs, plus others, can be delivered, and more efficiently induce the 
formation of healthy blood vessels. Interestingly, the inhibition of VEGF receptors did 
not diminish network formation in our 3D model (Figure 4.10), in contrast to what was 
seen for 2D proliferation, suggesting that morphogenesis into lumenized structures is 
not as dependent on VEGF signalling and can still happen due to the variety of GFs in 
hPLG. Also, due to its properties, the initial cell density needed for the development of 
a network is on average 10 times less than that previously reported in other 
vasculogenic approaches (Koh et al., 2008; Allen, Melero-Martin and Bischoff, 2011; 
Sieminski, Hebbel and Gooch, 2012). In a clinical setting, these aspects greatly 
improve the feasibility of delivering ex vivo expanded ECFCs for regenerative 
purposes, as less time and resources would be needed to obtain the necessary cells 
and produce a bioactive scaffold.  
Furthermore, the prompt formation of a capillary network by administered cells 
must be able to anastomose with the host’s vasculature at the earliest possible. For 
this purpose, a scaffold should simultaneously promote the sprouting of existing blood 
vessels into it, including perivascular cells to stabilize the newly formed network 
(Aguilera and Brekken, 2014; Stratman and Davis, 2012; Evensen et al., 2009). As 
PDGF-BB is considered the main driver of pericyte migration and proliferation 
(Campagnolo et al., 2010; Stratman, Schwindt, Malotte and Davis, 2010; Hellberg, 
Ostman and Heldin, 2010), hPLG should be particularly efficient at recruiting these 
cells. In our ex vivo model system, hPLG exhibited an unsurpassed angiogenic activity, 
using the rat aortic ring assay (Figure 4.13). While an angiogenic response only starts 
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around day 3 in fibrin and collagen I matrices, at the same time point an extensive 
sprouting network can already be observed in hPLG. While the addition of recombinant 
GFs is known to improve this response (Aplin and Nicosia, 2015), no equivalent 
outcome has been reported before in such a short period. In addition, by combining 
this ex vivo assay with the encapsulation of ECFCs, it is believed that the in vivo 
conditions of delivering ECFCs into a tissue using hPLG can be mimicked. Although 
this assay lacks some of the more dynamic and physiological components (e.g. blood 
flow), it can accurately depict the timing of formation of the human endothelial network 
and the concurrent sprouting from vascular tissue sections, as well as the interactions 
between the two. In this regard, due to the swiftness of sprout formation and despite 
the xenogeneic nature of the assay, an initial association between both can already be 
observed after 3 days (Figure 4.14). Considering the gelling properties of this 
biomaterial, these preliminary findings demonstrate its potential for a wide range of 
applications, such as cell-sheet technologies for skin regeneration or as an injectable 





















In conclusion, it was shown that hPLG can support the formation of in vitro 
endothelial networks by ECFCs and strongly promotes the proliferation of these cells 
by upregulating several angiogenic genes. Vitally, it was also shown that hPLG has the 
ability to promote sprouting of existing vessels and the subsequent formation of cellular 
bridges with the ECFC-generated vascular network. Current tissue engineering and 
regenerative medicine strategies are severely hampered by poor integration of 
implanted scaffolds and tissues with the host vasculature (Novosel, Kleinhans and 
Kluger, 2011). The use of hPLG as a combined scaffold and cell delivery vehicle has 
the potential to overcome this barrier. Thus, we propose the use of hPLG as a human-
derived method for the expansion and delivery of endothelial progenitors to promote 
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The swift and effective endothelisation of grafts has been suggested as a possible 
method of preventing the thrombogenic and fibrotic response seen in earlier synthetic 
scaffolds for vascular replacement (Sato, Abdel-Wahab and Richardt, 2015; Sreerekha 
and Krishnan, 2006). Endothelial cells are known for their role inhibiting platelet 
aggregation and activation of immune cells, thus facilitating the continuous flow of 
blood. Being easily obtained, ECFCs constitute a suitable source of autologous cells 
for this purpose (Fioretta et al., 2012). As demonstrated in the previous chapter or 
shown by others, platelet lysate in its gel form (i.e. hPLG) or as culture supplement 
(Reinisch et al., 2009) strongly promotes ECFC proliferation while avoiding the use of 
animal proteins. To impart these properties onto artificial scaffolds for vascular tissue 
engineering, the decision was taken to develop a method of adsorbing the different 
components of hPL onto electrospun scaffolds. 
Electrospinning was first developed as a way of generating relatively flat 3D 
matrices of synthetic fibres with diameters that could not be manufactured by other 
methods (Tucker et al., 2012). Briefly, a polymer is dissolved in a volatile solvent 
(usually an organic solvent or an acid) and is then slowly extruded from a syringe at the 
same time as a high voltage current is applied. Instead of giving rise to droplets, 
extremely fine fibres are continuously produced and collected on a conductive metallic 
surface with a desired shape. The architecture of these fibres mimics the fibrillar nature 
of the extracellular matrix, allowing for its use as a scaffold for cell growth (Kai, Liow 
and Loh, 2014; Braghirolli, Steffens and Pranke, 2014). In recent years, this technique 
has been also adopted for the development of scaffolds with a tubular shape, with 
different approaches being pursued, such as the use of synthetic and natural polymers, 
the engraftment of different moieties to promote vascularization or the incorporation of 
antithrombotic drugs (Ercolani, Del Gaudio and Bianco, 2013). 
The polymers chosen for this study, polylactic-co-glycolic acid (PLGA) and 
polycaprolactone (PCL), are two synthetic, FDA-approved, biodegradable polymers of 
relatively low-cost that have been extensively used in the biomedical field for both 
tissue engineering and drug delivery (Martina and Hutmacher, 2006). Their 
biocompatibility is mainly due to their degradation mechanisms, which confers them 
low cytotoxicity. PLGA is degraded relatively quickly (a few days to months) by 
hydrolysis into its original monomers, lactic acid and glycolic acid, which are common 
by-products of various metabolic pathways, hence can be easily dealt by the body 
(Makadia and Siegel, 2011). On the other hand, PCL takes considerably longer to be 
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degraded (up to a few years), being slowly broken into smaller MW fragments followed 
by hydrolysis. During this process it is completely secreted via the kidneys and is not 
accumulated in any tissues (Sun et al., 2006). 
Nevertheless, these two polymers share a common drawback with many of the 
synthetic polymers used in tissue engineering – an inherently very hydrophobic profile 
(Martina and Hutmacher, 2006). This feature hinders cell adhesion and proliferation on 
their surface, as cells usually respond better to hydrophilic surfaces (van Wachem et 
al., 1985). Additionally, synthetic polymers lack integrin-binding sites, such as RGD 
repeats, hence cell adhesion to these materials relies mostly on an interfacial protein 
layer being established (Wilson, Clegg, Leavesley and Pearcy, 2005; Duque Sánchez 
et al., 2016). However, in line with their poor wettability, a number of these synthetic 
polymers are also characterized by a weak ability to adsorb proteins. With the aim of 
improving both of these traits, many research groups have turned to chemical plasma 
treatment in order to modify the surface of these polymers without compromising their 
inner structure and physical properties (Jokinen, Suvanto and Franssila, 2012). This 
treatment is based on the ionisation of a low-pressure gas by an oscillating electric 
field, creating radicals that interact with the surface of the polymer (Aziz, De Geyter and 
Morent, 2015). While the most common surface modification is the introduction of 
functional groups, it can also be used to alter its roughness, induce crosslinking or 
deposit polymer coatings (Poncin-Epaillard and Legeay, 2003). As a result of the 
increased wettability and surface polarity (Duque Sánchez et al., 2016), several cases 
of increased cell adhesion, proliferation and differentiation into a number of target 
phenotypes have been reported (Sankar et al., 2014; Uppanan et al., 2015), including 
endothelial (Ramires et al., 2000; De et al., 2005). 
Many of these studies have employed rather expensive or dangerous gases, such 
as oxygen, hydrogen or acetylene (Yan et al., 2013; Girard-Lauriault et al., 2009), 
which grant less control over the simultaneous etching of the material’s surface than 
less reactive gases (Huang and Weigand, 2008). However, in this work the use of safer 
nitrogen gas plasma is proposed for the improvement of surface properties of 
PLGA/PCL blended scaffolds. By improving the ability of the electrospun fibres to be 
coated with hPL proteins, their biocompatibility towards ECFCs should be greatly 
improved due to the interfacial bridge that is created. 
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5.2. Aims & Objectives 
An important endeavour of investigation in vascular tissue engineering is the 
development of artificial vascular grafts. Considering that electrospinning of synthetic 
polymers is one of the preferred methods of scaffold fabrication for this purpose, new 
methods that can increase the adhesion and proliferation of endothelial progenitors 
onto these substrates are obviously of great interest to the field. In the previous 
chapter, the potent effect of hPLG on ECFC proliferation was demonstrated. Therefore, 
the decision was taken to explore a method to improve hPL absorption to electrospun 
fibre-based scaffolds. This approach could potentially become usable for the 
manufacture of polymers with improved ability to stimulate endothelial cell adhesion 
and growth and the generation of artificial vascular grafts with superior patency.   
The work is this section of the project was therefore divided into the following 
objectives: 
• Design and test a new method for the fabrication of tubular scaffolds by 
electrospinning. 
• Investigate the structure and morphology of electrospun scaffolds produced 
from different PLGA/PCL blends. 
• Analyse the effect of N2 gas plasma treatment on the surface properties of 
these scaffolds, including topography, chemical nature, wettability and 
adsorption of hPL proteins. 
• Assess the effect on ECFC proliferation onto these scaffolds as a result of the 
plasma treatment and incubation in hPL. 









5.3.1. Characterisation of electrospun scaffolds  
Tubular scaffolds were produced using a novel method, as described in chapter 
2.4. Briefly, PLGA and PCL were blended together in three different ratios in an organic 
solvent mixture and electrospun into an ethanol (non-solvent) bath. Individual fibres 
coalesced soon after wetting in ethanol, giving rise to bundles of polymer fibres, which 
were collected by winding onto a rotating tubular Teflon mould. The ethanol was then 
eluted from the scaffolds allowing the maintenance of the cylindrical shape, which is 
necessary for the generation of bioengineered vascular grafts (Figure 5.1A). 
Considering the scope of this study, scaffolds with a rather wide diameter (1 cm) were 
produced in order that relatively flat samples of the tube walls could be obtained for 
subsequent experiments (e.g. cell staining). 
For the assessment of fibre morphology, samples of each scaffold were examined 
by SEM and analysed regarding fibre diameter using ImageJ software (Figure 5.1B). At 
lower magnification, it is sometimes possible to observe the juxtaposition or overlap of 
the fibres bundles (top row) with little degree of alignment of individual fibres (bottom 
row). Fibre diameter increased with increasing concentration of PCL relative to PLGA, 
with an average size of 0.87±0.03 μm for PLGA 75:25 PCL, 1.25±0.02 μm for PLGA 
50:50 PCL and 2.80±0.05 μm for PLGA 25:75 PCL (Figure 5.2). This last mixture ratio 
was also characterized for having the larger spread in this parameter, with a standard 
deviation approximately double of the other blends (Figure 5.2). 
 
 














Figure 5.1. Macro- and microscopic imaging of electrospun scaffolds. (A) Tubular 
scaffolds were produced by electrospinning from PLGA 75:25 PCL, PLGA 50:50 PCL and 
PLGA 25:75 PCL polymer blends (left to right). (B) Fibre morphology was evaluated by SEM at 
100x (top) and 1,500x (bottom) magnification. 
 


















































Figure 5.2. Fibre size distribution. Diameter of individual fibres from the three different 
PLGA/PCL blends was manually measured using ImageJ from SEM images at 1,500x and 
3,000x magnification (100 fibres per sample). 
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5.3.2. Effect of plasma treatment on surface properties of electrospun scaffolds 
PLGA and PCL are naturally hydrophobic polymers and characterized by a limited 
ability to adsorb proteins on their surface, which consequently hinders cell adhesion 
and growth (van Wachem et al., 1985). In an attempt to increase both the hydrophilicity 
and protein adsorption of the scaffolds in this study, they were treated with N2 gas 
plasma. In theory, this procedure should render the surface of each fibre rich in 
nitrogen-based groups (e.g. amines), without affecting the bulk of the polymer so that 
inherent physicochemical and mechanical properties are preserved (Sanchis et al., 
2008).  
SEM was used to compare the morphology and texture between untreated and 
plasma-treated (60 s) scaffolds. As expected, no obvious differences were observed 
between the two conditions within the resolution permitted by the SEM equipment and 
defined by the grain size of the conductive gold layer (Figure 5.3A). Most importantly, 
plasma treatment with N2 gas did not result in any evident surface etching, as is often 
common when other gases are employed (Hirotsu, Nakayama and Tsujisaka, 2002; 
Tsujisaka, Masuda and Nakayama, 2000). 
Subsequently, scaffold samples were plasma-treated for increasingly longer 
periods (up to 120 s) and analysed by Fourier transform infrared spectroscopy (FTIR). 
This technique is based on the interaction of an oscillating electromagnetic field with 
molecules in the sample. A particular structural group reveals infrared absorption 
bands within characteristic regions on the spectrum. Therefore, it provides information 
on the nature of functional groups with a depth penetration of up to several microns 
(Kazarian and Chan, 2006). Although the formation of groups such as primary amines 
(usually detected above 3,000 cm-1) was expected, we could not observe any traces of 
this even at the longest treatment times (120 s, Figure 5.3B). This suggests that the 
plasma treatment may have only marginal effects polymer chemistry or that the 
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Figure 5.3. Coarse surface examination of plasma-treated scaffolds by SEM and FTIR. 
Electrospun scaffolds were surface treated with N2 gas plasma for up to 120 s. Changes to the 
surface texture of polymer fibres due to the plasma treatment were evaluated by SEM at 
10,000x magnification (A). Surface chemical group functionalization was analysed by FTIR 
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In order to analyse the surface chemistry of the scaffolds, samples of scaffolds 
treated for the maximum duration (120 s) were analysed by X-Ray Photoelectron 
Spectroscopy (XPS). When using this technique, samples are irradiated with a beam of 
X-rays, while the kinetic energy and electrons that are emitted from the superficial 
layers of the sample (i.e. 1-10 nm) is measured, producing a photoelectron spectrum. 
Figure 5.4 shows that the incorporation of nitrogen atoms is dependent on the amount 
of PLGA in the scaffolds. Survey spectra are characterized by two pronounced peaks 
at 531 eV and 285 eV, corresponding to the oxygen and carbon elements of PLGA and 
PCL chains (Figure 5.4A). Following plasma treatment, a nitrogen peak at 400 eV can 
be detected in the spectrum of PLGA 75:25 PCL and, to a smaller degree, in that of 
PLGA 50:50 PCL. For PLGA 75:25 PCL scaffolds, a high-resolution spectrum of N1s 
more clearly demonstrates the characteristic peak arising from the incorporation of 
nitrogen (Figure 5.4B). Deconvolution of this peak further reveals two narrower peaks 
at 399.9 eV and 401.6 eV, which are likely due to the formation of N-H and C-N bonds, 
respectively (Figure 5.4C). Quantification of the constituent elements shows a relevant 
increase in the percentage of nitrogen as a result of plasma treatment, especially in the 
case of PLGA 75:25 PCL scaffolds, while none could be detected in PLGA 25:75 PCL 
(Table 5.1). Interestingly, the carbon content was reduced in all plasma-treated 
scaffolds compared to the untreated ones, accompanied by an increase in the oxygen 
content. This indicates that treated scaffolds reacted with oxygen in the atmosphere, 
becoming oxidized. Furthermore, O1s spectra suggest that the oxygen moieties were 
likely to be incorporated through the formation of C=O bonds, as seen by the 


























































Figure 5.4. XPS analysis of untreated and N2 plasma-treated scaffolds. (A) XPS survey spectra of untreated (blue) and N2 gas plasma-treated (red) 
scaffolds. (B) N1s scan of PLGA 75:25 PCL scaffolds and (C) deconvoluted spectrum of plasma-treated PLGA 75:25 PCL.	
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Figure 5.5. High-resolution XPS analysis of oxygen spectra of untreated and N2 plasma-
treated scaffolds. O1s deconvoluted spectra of the different untreated (left) and plasma-
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Wettability of the scaffolds was then characterized as a function of the duration of 
plasma treatment. Samples of the different PLGA/PCL blend scaffolds were left 
untreated or treated for either 30 s, 60 s or 120 s and water contact angle analysis was 
performed using a semi-automated system (see chapter 2.15). A drop of distilled water 
was dispensed onto each sample and recorded over a period of 60 s (Figure 5.6). The 
contact angle was then measured using the proprietary software. If the contact angle 
was smaller than 90º, the surface was considered hydrophilic, and hydrophobic if larger 
than 90º (Sanchis et al., 2008). All untreated scaffolds were found to be very 
hydrophobic, with initial contact angles above 120º and no droplets were absorbed by 
the matrices within the recorded period (Tables 5.2-5.4). Plasma treatment reduced 
contact angles more strongly with increasing PLGA content in the scaffolds, with PLGA 
72:25 PCL being the only scaffold type that became hydrophilic at all treatment 
durations tested. This suggests that PLGA is more sensitive to plasma treatment than 
PCL. Of relevance, treatment for 60 s was enough to efficiently reverse the 
hydrophobicity of all scaffolds and led to droplet absorption within 1 min. 
 
  C O N 
PLGA 75:25 PCL 
Untreated 71.47 27.23 0.24 
Plasma 64.22 32.37 2.24 
PLGA 50:50 PCL 
Untreated 66.30 33.28 * 
Plasma 64.02 35.50 0.19 
PLGA 25:75 PCL 
Untreated 72.12 27.88 * 
Plasma 68.08 31.84 * 
Untreated Plasma-treated 60 s
0’’ 5’’ 60’’0 è 60’’
Figure 5.6. Water contact angles of untreated and plasma-treated scaffolds as a function 
of time. Wetting of electrospun scaffolds over the period of 1 min was assessed using a semi-
automated contact angle analysis system as described in chapter 2.15. Plasma treatment 
reduces scaffold hydrophobicity as shown for PLGA 50:50 PCL (60 s treatment) and water 
droplet is no longer repelled.  
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Table 5.4. Water contact angles of untreated and plasma-treated PLGA 25:75 PCL 
scaffolds. 
PLGA 75:25 PCL
Untreated Plasma 30 s Plasma 60 s Plasma 120 s
0’’ 128.9 ± 2.0 110.0 ± 2.3 104.2 ± 4.5 84.9 ± 24.9
5’’ 128.5 ± 1.7 99.2 ± 6.5 35.0 ± 0.8 *
10’’ 128.4 ± 1.7 59.1 ± 23.6 * *
20’’ 128.4 ± 1.7 * * *
40’’ 128.2 ± 1.7 * * *
60’’ 128.2 ± 1.7 * * *
* Absorbed
PLGA 50:50 PCL
Untreated Plasma 30 s Plasma 60 s Plasma 120 s
0’’ 123.0 ± 1.4 101.7 ± 3.9 118.2 ± 1.6 97.9 ± 2.0
5’’ 121.6 ± 0.8 102.1 ± 3.5 98.1 ± 3.0 *
10’’ 120.9 ± 1.5 102.1 ± 3.5 * *
20’’ 120.8 ± 1.5 101.9 ± 3.5 * *
40’’ 121.5 ± 0.9 101.7 ± 3.5 * *
60’’ 120.6 ± 1.6 101.4 ± 3.6 * *
* Absorbed
PLGA 25:75 PCL
Untreated Plasma 30 s Plasma 60 s Plasma 120 s
0’’ 125.8 ± 4.2 128.2 ± 0.9 117.1 ± 1.1 *
5’’ 125.0 ± 4.6 128.3 ± 0.8 111.6 ± 2.8 *
10’’ 124.9 ± 4.5 128.2 ± 0.8 106.8 ± 3.1 *
20’’ 124.8 ± 4.5 127.9 ± 0.9 53.8 ± 28.0 *
40’’ 124.7 ± 4.6 127.8 ± 0.9 * *
60’’ 124.6 ± 4.6 127.7 ± 0.9 * *
* Absorbed
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Next, the effect of plasma treatment on the adsorption of proteins from hPL onto 
the scaffolds was investigated by protein quantification and spectroscopy. Scaffold 
samples were treated with N2 gas plasma for 30 s, 60 s or 120 s and incubated in hPL 
(diluted 1:1 in PBS) for 1 h at room temperature, then washed to remove any unbound 
protein as described in chapter 2.17. For quantification of protein adsorbed to 
scaffolds, binding proteins were eluted with RIPA buffer, and total protein was 
measured using the micro BCA assay. Interestingly, and contrary to the trend observed 
by contact angle analysis, baseline adsorption was dependent on the ratio of PCL in 
scaffolds, with untreated PLGA 25:75 PCL adsorbing approximately double the amount 
of protein of the other untreated polymer blends (Figure 5.7). Plasma treatment for all 
the tested durations significantly improved protein adsorption onto all scaffolds except 









Figure 5.7. Quantification of hPL protein adsorption by scaffolds. Scaffolds of the different 
PLGA/PCL blends were plasma-treated for 30 s, 60 s or 120 s, or left untreated, and incubated 
with hPL. Protein was eluted from scaffolds and quantified by micro BCA assay. Data are mean 
± SEM. Statistical significance was tested by one-way ANOVA with Bonferroni’s post-test (* 
indicates statistical difference against “Untreated”) (*=p<0.05) (n=3). 
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Scaffolds treated similarly to the BCA analysis described above (i.e. plasma 
treatment for 30, 60 and 120 s, followed by hPL incubation) were then freeze-dried 
after the washing step and examined by FTIR. Additionally, hPL was analysed to 
provide a reference spectrum. Plasma treatment increased hPL protein adsorption onto 
all polymer blends proportionally with increasing treatment duration (Figure 5.8). The 
main absorbance peaks seen in the hPL spectrum (dashed lines) could also be 
detected in the spectra of all scaffold types incubated with hPL, except for untreated 
PLGA 75:25 PCL. Such peaks are characteristic of amide groups in proteins and are 
due to the different stretches in these groups. Wide peaks between 3100 and 3500 cm-
1 correspond to N-H bonds, while peaks around 2900 cm-1 and 1600 cm-1 indicate the 
presence of C-H and C=O bonds, respectively. Amongst the three polymer blends, 
PLGA 25:75 PCL adsorbed the highest amount of protein prior to plasma treatment but 
also benefited the most from the plasma treatment. 	
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Figure 5.8. Characterisation of protein adsorption by FTIR. Scaffolds of the different 
PLGA/PCL blends were plasma-treated for 30 s, 60 s or 120 s, or left untreated, and incubated 
with hPL. Spectra were obtained by FTIR on freeze-dried scaffold samples and on liquid hPL. 
Dashed lines indicate the wavenumber of the main peaks detected in hPL spectrum. Such 
peaks are characteristic of amide groups in proteins and are due to the different stretches in 
these groups (between 3100 and 3500 cm-1 for N-H, around 2900 cm-1 for C-H and around 
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5.3.3. Adhesion and growth of ECFCs on electrospun PLGA/PCL scaffolds 
The increased hydrophilicity and ability to adsorb proteins from hPL conferred by 
N2 gas plasma treatment was expected to promote the adhesion and proliferation of 
seeded cells on to electrospun PLGA/PCL scaffolds. To test this hypothesis, scaffold 
samples of equal sizes were left untreated or plasma-treated and incubated with FBS 
(acting as a control) or with hPL. Treatment was performed for 60 s as this was shown 
to be sufficient time to improve the surface properties in an efficient manner and 
considering that longer treatment periods might impart an excess of surface energy, 
which might hinder cell proliferation (Kennedy, Washburn, Simon and Amis, 2006). 
Proliferation was measured using the metabolic assay of resazurin conversion (i.e. 
PrestoBlue) at days 1, 3 and 5, returning samples to culture after each time point. 
Across all polymer blends, plasma treatment led to significantly increased metabolic 
rates after 1 and 3 days for both FBS- and hPL-incubated scaffolds versus untreated 
control samples (Figure 5.9A). Although overall metabolic levels had decreased by day 
5, in the case of PLGA 25:75 PCL proliferation was still significantly higher in samples 
treated with N2 gas plasma plus hPL. Additionally, this synergistic combination proved 
to be more effective than FBS incubation of treated scaffolds at day 3 for the same 
polymer blend (bottom graph).  
At the end of the time course, samples were lyzed and dsDNA was quantified 
using the PicoGreen assay, as a measure of absolute cell density. The amount of 
retrieved dsDNA was repeatedly higher for plasma treatment samples with either of the 
protein solutions, except in the case of PLGA 25:75 PCL (bottom graph), where only 














Figure 5.9. Proliferation of ECFCs on electrospun scaffolds. Untreated and plasma-treated  
(60 s) samples of PLGA/PCL scaffolds were incubated with either FBS or hPL for 1 h at room 
temperature. 7,000 ECFCs were seeded per scaffold and (A) metabolic rate was assessed by 
PrestoBlue assay at 1, 3 and 5 days, (B) followed by lysis for quantification of dsDNA amount 
on each sample using PicoGreen assay. Data are mean ± SEM. Statistical significance was 
tested using two-way ANOVA with Tukey’s post-test. (* indicates statistical difference against 
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To qualitatively assess the viability and coverage of cells on the different scaffolds, 
constructs were live/dead stained after 5 days of seeding with calcein AM and EthD-III 
to label healthy cells and necrotic cells, respectively. This demonstrated that scaffolds 
exposed to hPL or FBS without prior N2 plasma treatment supported a highly viable cell 
population, but cells were much sparser and less well spread in comparison to plasma-
treated scaffolds (Figure 5.10). The latter supported a confluent layer of viable cells, 
with hPL and FBS being very comparable to one another.  
Taken together, these data suggest that treatment of PLGA/PCL electrospun 
scaffolds with N2 plasma followed by incubation with hPL constitutes a facile method of 
improving the biocompatibility of these scaffolds for endothelial cell seeding, without 
the use of animal protein coatings.  																										
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Figure 5.10. Viability of ECFCs grown on electrospun scaffolds. Live/Dead assay was 
used to assess viability and coverage of ECFCs on different scaffolds. Untreated and plasma-
treated (60 s) samples of PLGA/PCL scaffolds were incubated with either FBS or hPL for 1 h at 
room temperature. 7,000 ECFCs were seeded onto each scaffold and after 5 days incubated 
with Calcein AM/EthD-III to fluorescently label viable and necrotic cells respectively, and with 
Hoechst 33342 to localize cell nuclei. Images were acquired with a Leica DMI4000B 
microscope (n=3). Scale bars represent 100 μm. 
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5.3.4. ECFC morphology on plasma-treated scaffolds  
In order to mimic the endothelial lining of a blood vessel, a vascular graft should 
allow the formation of monolayer of tightly packed endothelial cells (i.e. cobblestone 
morphology) to provide a smooth barrier surface for the flowing blood. The specific 
fibre size and associated porosity of scaffolds produced using the different PLGA/PCL 
blends may give origin to distinct three-dimensional cellular arrangements. To 
determine the morphology and cytoskeletal organization of ECFCs on the different 
scaffold types, scaffolds were seeded and cultured for 5 days after N2 gas plasma 
treatment and hPL adsorption. Following fixation, samples were either prepared for 
SEM analysis or stained with DAPI and phalloidin to respectively label nuclei and the 
actin cytoskeleton. By SEM, it was possible to observe the formation of a thin ECFC 
monolayer on both PLGA 75:25 PCL and PLGA 50:50 PCL scaffolds, while on 
PLGA 25:75 PCL cells were found mostly wrapped around fibres and did not form a 
continuous endothelial layer (Figure 5.11). During the preparation of samples for SEM, 
constructs were dried which led to shrinking of the cellular content, revealing where 
some of the intercellular junctions were located and exposing the fibres underneath 
(Figure 5.11, top and middle rows). The same pattern was also observed by imaging of 
fluorescently stained cells (Figure 5.12). On PLGA 75:25 PCL and PLGA 50:50 PCL 
scaffolds, ECFCs existed in a monolayer with typical endothelial morphology, exhibiting 
a cytoskeleton mostly organized in close association with intercellular junctions. On 
PLGA 25:75 PCL (Figure 5.12, bottom row), cells failed to form a continuous barrier 
and were found deeper inside the scaffolds. Their cytoskeletons displayed a mixed 
profile, with filamentous actin fibres aligned along the polymer fibres as well as 
perpendicular to these. These data indicate that PLGA 25:75 PCL scaffolds do not 
provide enough anchoring points for ECFCs to grow into a monolayer, as they are 
unable to come in contact with each other to the same extent as in the other polymer 
blends. 	









100 μm 25 μm
25 μm
25 μm
Figure 5.11. Assessment of ECFC morphology grown on electrospun scaffolds by SEM. 
Electrospun scaffolds treated by N2 plasma for 60 s and incubated with hPL were seeded with 
7,000 ECFCs and cultured for 5 days. Constructs were fixed and imaged by SEM at 100x (left) 
and 500x magnification (right). 
 








   
   
   













   
   
   









   
   
   














Figure 5.12. Assessment of morphology and cytoskeleton arrangement by confocal 
microscopy. Electrospun scaffolds treated by N2 plasma for 60 s and incubated with hPL 
were seeded with 7,000 ECFCs and cultured for 5 days. After fixation, TRITC-conjugated 
phalloidin was used to stain F-actin cytoskeleton and DAPI to localize nuclei. Z-stack images 
were acquired using a Zeiss LSM 510 META confocal microscope (20x objective). Maximum 
intensity Z-projections were obtained with ImageJ (left). Zoomed in images (right) show the 
cytoskeleton arrangement of ECFCs on different size fibre scaffolds. White arrow pinpoints an 
example of actin fibres organized perpendicularly to the polymer fibres. 
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5.4. Summary of results 
• Scaffolds were successfully produced by wet-electrospinning using different 
blends of PLGA and PCL. 
• Fibre diameter increased with increasing PCL content. 
• N2 gas plasma treatment led to incorporation of nitrogen-based groups in PLGA 
75:25 PCL and PLGA 50:50 PCL matrices, as well as oxidation of all scaffold 
types. 
• Plasma treatment efficiently reduced hydrophobicity of scaffolds and increased 
adsorption of proteins from hPL. 
• Plasma-treated scaffolds promoted higher proliferation of ECFCs, especially 
when coated with hPL proteins. 
• ECFC growth into a confluent monolayer was dependent on fibre size, only 
occurring on N2 plasma-treated PLGA 75:25 PCL and PLGA 50:50 PCL 
scaffolds. 																								




While electrospinning has been previously adapted to produce tubular scaffolds 
(Vaz, van Tuijl, Bouten and Baaijens, 2005), the most commonly used method for 
doing so suffers from a number of drawbacks. The method consists of electrospinning 
the chosen polymer(s) directly onto an earthed rotating metallic mandrel instead of a 
flat collector. Efficient capture of the fibres requires a continuously conductive surface 
but, after some time, the collector becomes gradually insulated by the polymer fibres 
themselves, hindering the process and limiting the thickness of scaffolds that can be 
generated by this method (Migliaresi, Ruffo, Volpato and Zeni, 2012). Additionally, at 
least one more technical issue is usually reported when following this approach. 
Because fibres are tightly held onto the collector, removal of the whole scaffold without 
damaging it has proven to be very difficult (Errico et al., 2011). Some groups have 
overcome this issue by spinning an initial sacrificial layer of a polymer with a different 
solubility onto the collector followed by the polymer intended for use as a scaffold 
(Inoguchi et al., 2006). The inner layer is then dissolved in a solvent that does not 
affect the outer layer, allowing for its subsequent removal. While this might be a valid 
solution in some instances, due to the solubility requirements, the combinations of 
polymers that can be employed are very limited. Moreover, it has the potential of 
considerably aggravating the previously mentioned issue of collector insulation. To 
circumvent these issues, a new method that does not require the direct collection of the 
fibres onto a conductive mandrel was developed in this work for the fabrication of 
tubular scaffolds by combining wet-electrospinning (Yang et al., 2013) with yarn 
spinning (Teo et al., 2007; Smit, Buttner and Sanderson, 2005). As, in this approach, 
fibres were instead indirectly collected onto a Teflon tube, there is no practical limit to 
the desired wall thickness, and the scaffold can be removed from the mould with ease. 
In this study, tubular scaffolds were successfully produced from PLGA/PCL blends 
(ranging between 25% and 75% of each polymer) using this method (Figure 5.1A).  
Each different polymer can only be properly electrospun into a very narrow range 
of fibre sizes, determined mainly by the flow-rate, the voltage applied, the solvent used 
and the solution’s viscosity and conductivity (Li and Wang, 2013). Hence, for the same 
solvent and electrospinning conditions, the two polymers can give rise to differently 
sized fibres. Moreover, PLGA is known for its brittleness and relatively fast degradation 
rates, while PCL is more elastic and can take up to a few years to be degraded once 
implanted (Sa and Kim, 2013). By mixing these two polymers in different ratios, it is 
possible to tailor the fibre size, degradation rate and mechanical properties to 
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conveniently create a scaffold with the optimal characteristics for a vascular graft. This 
study focused on the initial adhesion and proliferation of endothelial cells under static 
conditions, thus emphasis was placed only on investigating the effect of fibre diameter 
on cell behaviour rather than looking at the degradation rates or mechanical properties 
of the different scaffolds. As expected, the fibre size varied with the ratio of PLGA and 
PCL in the initial solution (Figure 5.2), providing a range of fibre topographies for the 
study of endothelial growth patterns.  
N2 gas plasma treatment was used to modify the surface of the electrospun 
scaffolds, with the aim of simultaneously reducing their hydrophobicity and increasing 
their ability to adsorb proteins. As hoped, the treatment with this gas plasma did not 
damage or chemically modify the bulk of the fibres (Figure 5.3A), as observed by SEM 
and FTIR, but was efficient at improving their surface properties (Figures 5.6-5.7). 
Conversely, plasma generated using other gases, such as oxygen, has been reported 
to etch the surface of PLGA fibres and structurally degrade them (Park et al., 2007). 
Other groups have used atomic force microscopy (AFM) to examine the surface of 
films and found an increase in roughness at the lower nanometre scale following N2 
plasma treatment of polymers, such as polypropylene (Mortazavi, Ghoranneviss and 
Sari, 2011; Morent et al., 2008) or polyethylene terephthalate (Junkar et al., 2009) for 
example. It is possible that the same texture modification is imparted to the PLGA/PCL 
scaffolds however, technical issues arise when this method is used with fibre scaffolds 
as the AFM tip becomes jammed in the nanofibres instead of passing over them 
(Verdonck, Calíope, Hernandez and da Silva, 2006). Next, it was demonstrated that N2 
plasma treatment results in increased nitrogen content at the surface of scaffolds when 
the PLGA ratio was at least 50% (Figure 5.4A) and was especially clear in the case of 
PLGA 75:25 PCL samples (Figure 5.4A-C). This increase in nitrogen incorporation with 
increasing PLGA concentration, suggests that PLGA is more amenable to this process 
than PCL. It can also be speculated that, the increased surface area conferred by the 
smaller fibre diameter in these scaffolds allows for more polymer chains to be exposed 
to chemical modification by the plasma and attachment of nitrogen-based groups. 
Although, the specific nature of these groups cannot be precisely determined without 
further empirical evidence, these would be most likely amine groups (-NH2) as 
pinpointed by the predicted N-H and C-N peaks detected in the deconvoluted N1s 
spectrum (Figure 5.4C). In a similar manner, other researchers have detected the 
formation of amine groups on the surface of polymers following treatment with 
ammonia gas plasma (Marasescu and Wertheimer, 2008). Interestingly, all scaffolds 
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were shown to become oxidized, independently of the polymer blend, as indicated by 
the increased relative amount of oxygen at their surface (Table 5.1). As suggested by 
others, this increase is probably due to the scission of C-H bonds from the polymer 
chains, which then induces the formation of free radicals (Correia, Ribeiro, Botelho and 
Borges, 2016). After the treatment and upon exposure to atmospheric oxygen, these 
radicals give rise to C=O groups (Figure 5.5), via an intermediate step where highly 
unstable hydroperoxides are formed. Polar groups such as –NH2 and C=O groups are 
known to increase the surface energy and, as a consequence, also the hydrophilicity of 
polymer surfaces (Ferreira et al., 2009). Accordingly, the wettability of all electrospun 
scaffolds was greatly increased as a result of the plasma treatment, proportional to the 
duration of the treatment (Figure 5.6). Again, the increased surface area of 
PLGA 75:25 PCL scaffolds might explain why shorter treatments were more effective 
on these substrates than on PLGA 25:75 PCL. However, the amine groups detected on 
the former may also contribute significantly to this outcome. Another advantage of 
grafting amine groups onto the surface of the scaffolds is that these are usually 
positively charged at physiological pH. Since most proteins carry a net negative 
charge, this chemical modification should favour the interaction between these and the 
polymer surface.  
Plasma treatment, produced with a variety of gases, has been widely shown to 
enhance protein adsorption on different polymers (Alves et al., 2008; Yang, Bei and 
Wang, 2002; Nandakumar et al., 2013). These reports usually focus on the adsorption 
of animal or recombinant proteins, while improving the adsorption of a complex mixture 
of human proteins, such as platelet lysates, has never been described before. In line 
with the findings regarding contact angle, it was demonstrated that the adsorption of 
proteins from hPL was significantly increased after plasma treatment (Figure 5.7). 
Surprisingly, of all the blends PLGA 25:75 PCL was the most efficient at this process in 
its native state and this difference was also seen with the treated scaffolds. Of 
relevance, the FTIR profile of the adsorbed proteins on treated scaffolds was similar 
across all blends, although all the peaks were once again detected more strongly with 
increasing PCL content (Figure 5.8). Therefore, it can be presumed that plasma 
treatment improves this phenomenon even when amine groups were not apparently 
formed at the surface of the polymers. Additionally, this adsorption profile was shown to 
be identical to that of pure PCL scaffolds incubated with platelet-rich plasma (PRP), as 
previously reported by (Diaz-Gomez et al., 2014), suggesting a similar protein 
constitution and adsorption specificity. For the coating of scaffolds with protein mixtures 
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rich in GFs, as in the case hPL (Fortunato et al., 2016), it is vital that this adsorption 
process can happen as quickly as possible so that the integrity and bioactivity of GFs is 
preserved. While several other tissue engineering studies have been published with 
incubation of scaffolds in protein solutions being performed for long periods of time, 
including overnight (Oliveira et al., 2014; Woo, Chen and Ma, 2003) and often at 37 ºC 
(Salvay et al., 2008), N2 plasma treatment, as described in this study, permits the swift 
adsorption of proteins at room temperature. As a result, the shorter incubation period 
required for the coating of scaffolds when this treatment is employed should help 
preserving the integrity of the hPL proteins. 
The increase of hydrophilicity and protein adsorption by treating the scaffolds with 
N2 gas plasma was shown to significantly promote the initial adhesion and proliferation 
of ECFCs onto these scaffolds (Figure 5.9). Although across all polymer blends, the 
incubation with either FBS or hPL led to comparable metabolic rates 1 day after 
seeding, on PLGA 25:75 PCL scaffolds hPL coating further stimulated ECFC 
proliferation above FBS levels at day 3, as assessed by the PrestoBlue assay (Figure 
5.9A). A similar effect was seen at the end of the time course using the PicoGreen 
assay (Figure 5.9B), which is considered a more accurate method of determining the 
differences in cell numbers (Ng, Leong and Hutmacher, 2005; Sittampalam et al., 
2004). The fact that only on plasma-treated PLGA 25:75 PCL a significant difference is 
seen between FBS and hPL coating may be due to the greater ability of PCL to adsorb 
hPL proteins, compared to the other blends. As shown in the previous chapter, this 
protein mix is rich ECM proteins and angiogenic growth-factors (Fortunato et al., 2016), 
which once adsorbed to scaffolds should greatly increase the ECFC adhesion via 
integrins and subsequent proliferation. Worth noting, an overall decrease in the 
metabolic rate was seen by the last day of the time course, especially for 
PLGA 75:25 PCL and PLGA 50:50 PCL. Although, the measurement of the metabolism 
of cells is often used as an indicator of their proliferative rate, it is likely that the 
repeated exposure to resazurin for long incubation periods led to a toxic effect on the 
cells. Indeed, changes of cell morphology after only a few hours of incubation have 
been reported before, which suggest that this compound interferes with normal cell 
function by reducing the amount of ATP measured as a marker of cell viability 
(Sittampalam et al., 2004). Additionally, the accuracy of this assay as a method of 
determining the actual cell number has been debated, as metabolism can obviously be 
affected by cellular processes other than mitosis, leading to a lack of correlation 
between the values obtained by this assay and those of more absolute methods (i.e. 
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cell counting or dsDNA quantification) (Quent et al., 2010). This issue is even more 
prominent in the case of the measurement of cell proliferation in three-dimensional 
substrates over time, with inconsistent or even inverse results to those obtained by 
PicoGreen assay being reported (Ng, Leong and Hutmacher, 2005). It is also possible 
that ECFCs have a lower basal metabolism as they are cultured under static rather 
than dynamic conditions, unlike endothelial cells in a living blood vessel, and because 
these have already reached confluence and stopped dividing by day 5. Corroborating 
this hypothesis, the reduction in metabolism was not as pronounced on PLGA 
25:75 PCL scaffolds, which may be due to their wider fibre diameter. This results in a 
higher porosity, allowing cells to infiltrate the scaffolds and grow for longer periods of 
time. In agreement, ECFCs were shown to grow into a confluent monolayer on the 
surface of both PLGA 75:25 PCL and PLGA 50:50 PCL in just 5 days, but appeared to 
be spread deeper inside PLGA 25:75 PCL scaffolds (Figures 5.10 and 5.11). This 
morphology was confirmed by staining the actin cytoskeleton and confocal imaging. On 
the smaller and intermediate size fibres, the ECFCs arranged into monolayers and 
exhibited cytoskeletons organized at the periphery of cells (Figure 5.12), in similarity to 
what was reported in another study regarding the morphology of HUVECs seeded on 
sub-micron fibres (Whited and Rylander, 2014). Likewise, Fioretta and colleagues have 
observed a monolayer type of growth by ECFCs seeded on electrospun fibres with a 
diameter less than 2 μm and a penetrating growth pattern on larger diameter fibres 
(Fioretta et al., 2014). Interestingly, on these latter fibres, the same authors described a 
cytoskeleton organization that was strictly in alignment with the polymer fibres, which is 
not in agreement with our observations characterised by a mixed type of arrangement, 















In this chapter, a novel method for the generation of tubular electrospun scaffolds 
of PLGA and PCL polymers was described, and their modification via plasma treatment 
was investigated with the final purpose of improving the adhesion and proliferation of 
ECFCs. It was shown that gas plasma treatment using N2 gas modified the surface of 
the polymer fibres by addition of different oxygen and nitrogen functionalities in a 
controlled manner. This surface treatment was responsible for a decrease in the 
hydrophobicity of the scaffolds and an improvement in their ability to adsorb proteins 
from hPL. As a consequence, these effects synergistically enhanced ECFC 
proliferation on these scaffolds. Future work should investigate the ratio of formation of 
specific chemical groups and determine the specificity of the protein adsorption 
mechanism. 
It was also demonstrated that ECFCs exhibited a different morphology and 
intercellular organization depending on the average diameter of the substrate fibres, 
pinpointing a fibre size threshold between 1.3 μm and 2.7 μm, and respective porosity, 
for the transition between an endothelial-like cobblestone monolayer type of growth 
and a more invasive one. Considering the need to establish a single layer of 
endothelial cells on the luminal side of a bioengineered graft, these findings provide 
useful information regarding the ideal polymer blend to be used in the different layers 
of a vascular scaffold. Future work should assess the marker expression by ECFCS on 
these scaffolds to appraise their phenotype. In addition, it would be of interest to 
expand the cell types being tested on these scaffolds (e.g. smooth muscle cells) to 
include cells that can give origin to the remaining layers of the blood vessels. 
Taken together, the combination of N2 plasma treatment and hPL incubation 
described here provides a novel approach for the improvement of ECFC adhesion and 
proliferation onto synthetic electrospun scaffolds. The off-the-shelf nature of the 
polymers as well as the human origin of the proteins used, coupled with the simplicity 
of the scaffold’s fabrication process and surface treatment constitutes a promising first 
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ECFCs are a promising cell population for vascular tissue engineering, from 
minute capillary networks up to arterial-sized vessels. Several approaches based on 
the application of ECFCs were explored in this project. 
The first aim of the work in this thesis was to assess the role of PAR-1 and PAR-2 
in ECFCs from a vasculogenesis perspective. The stimulation of PAR-1 in ECFCs was 
shown to lead to inhibition of in vitro tubulogenesis, as a likely consequence of 
VEGFR-2 down-regulation. On the contrary, exogenous activation of PAR-2 did not 
alter the vasculogenic response of these cells, despite being both functionally couple to 
the ERK1/2 pathway. In view of these results, PARs did not prove to be a suitable 
target in the promotion of vascularization by ECFCs and was not pursued any further. 
In a second line of investigation, human platelets were utilized to develop an ECM-
based hydrogel rich in angiogenic growth factors. Culturing of ECFCs on hPLG 
induced the proliferation and maturation of ECFCs through the upregulation of several 
angiogenic genes. It was also shown for the first time that this material can support the 
formation of microvascular networks in vitro solely by ECFCs and simultaneously 
promote the sprouting of existing vessels from arterial explants. Therefore, hPLG 
exhibits a considerable potential as a both a substrate for the expansion of ECFCs, as 
well as for the delivery of endothelial progenitors to promote tissue revascularization 
via existing vessel angiogenesis, ECFC-driven vasculogenesis and anastomosis of 
these two vascular networks. An additional advantage of hPLG is the elimination of 
animal products from ECFC culture and delivery methods. 
Finally, in chapter 5, a series of novel PLGA and PCL tubular scaffolds with a wide 
range of fibre diameters were developed using a variant of the electrospinning 
technique. The chemical modification of these scaffolds using N2 plasma treatment was 
shown to introduce new oxygen and nitrogen moieties, which drastically altered the 
physical properties of these conduits. Most importantly, the adsorption of proteins from 
platelet lysate was greatly improved as a result, revealing a facile method of 
accelerating the coating of biomaterials with human proteins. In this case, the 
combination of plasma treatment and coating with platelet proteins greatly increased 
the adhesion and proliferation of ECFCs on these scaffolds. Furthermore, cells 
exhibited a markedly different infiltration and morphology depending on the fibre size in 
each scaffold. These findings provide useful information regarding the ideal scaffold 
properties necessary to regulate endothelial growth and organization. In addition, it 
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was demonstrated that the bioactive properties of platelet-derived factors can be 
successfully imparted onto synthetic scaffolds and constitutes a reliable method of 
promoting the endothelisation of scaffolds for tissue engineering.  	
6.2. Future directions 
The initial aims of this work were to investigate and develop novel biomaterial-
based approaches for the promotion of vasculogenesis and endothelisation of vascular 
grafts by ECFCs. Although successful approaches were created for these two tissue 
engineering avenues, a deeper understanding of the mechanisms that govern 
endothelial cell behaviour on these materials would be necessary in order to bring a 
significant contribution to the field. 
 
6.2.1. Short-term targets 
While tubular scaffolds have been fabricated before via electrospinning (Ercolani, 
Del Gaudio and Bianco, 2013), the novel method described in this thesis can give 
origin to scaffolds with new microscopic structures that may also lead to different 
mechanical and biological properties. More specifically, the organization of the polymer 
fibres into circumferentially aligned bundles may mimic the orientation of smooth 
muscle cells (SMCs) and collagen fibrils in the media layer of the blood vessels 
providing the added mechanical strength needed to withstand the circulatory 
pressures. In the short term, it would be of relevance to compare the mechanical 
properties of tubular scaffolds produce by previous methods versus those fabricated 
using this new technique. As discussed before, PLGA and PCL are degraded at 
considerably different speeds and vascular scaffolds should degrade in tune with the 
simultaneous growth of new tissue to prevent graft failure. Thus, it would be important 
to characterize the degradation profiles of scaffolds produced from each of the different 
polymer blends. Additionally, aspects of scaffold micro-architecture, such as fibre 
diameter or anisotropy, are known to play a major role on cell differentiation and ECM 
deposition. Specifically, the effect of fibre size and alignment on the maintenance of an 
anti-thrombotic phenotype by the endothelial cells would be further investigated. 
Finally, although the coating of electrospun scaffolds with proteins from hPL was 
shown to promote ECFC growth, the exact reason for this effect is still unknown. For 
this purpose, it would be crucial to determine the nature of the adsorbed proteins that 
are responsible for this effect. 
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6.2.2. Medium to long-term targets 
Considering the robust pro-vasculogenic response of ECFCs in hPLG in vitro and 
its potential as an injectable cell-delivery method, it would be of the utmost relevance to 
assess the ability of ECFCs to form functional blood vessels in vivo as a proof of 
concept towards its future application in humans. Among the different therapeutic 
targets that could benefit from such approach, chronic wound healing and bone 
fracture repair are likely the most relevant. For the first, this would be initially 
investigated using animal models of chronic skin wounds using an immunodeficient 
diabetic mouse strain to assess the ability of human ECFCs and hPLG in reversing the 
impairment in revascularization and reepithelization that is common in diabetic patients. 
The potential increase in capillary formation, coupled with the recognized anti-
inflammatory and anti-bacterial effect of platelet preparations (Bendinelli et al., 2010)	
(Drago et al., 2013), could synergistically lead to a measurable improvement in wound 
rate closure. Nevertheless, mouse skin is considerably thinner than the human skin 
and exhibits a predominantly contractile wound-healing phenotype due to significant 
structural differences, resulting in limited resemblance to the human response following 
injury (Dunn et al., 2013). Therefore, it would be also imperative to perform a similar 
study using large animal models, such as the porcine, since the skin’s stratification, 
ECM, turnover time and content in immune cells in these animals is more similar to that 
of the human skin (Seaton, Hocking and Gibran, 2015). Additionally, hPLG could also 
be investigated as a delivery method for other cell types that, unlike ECFCS, can be 
quickly obtained and contribute as well to enhanced angiogenesis (e.g. circulating 
CD34+ cells or MSCs). While the utilization of ECFCs can only be envisaged for the 
treatment of less urgent medical conditions (due to the time required for ECFC isolation 
and expansion), such studies could also demonstrate the ability of hPLG to promote 
revascularization on its own by sprouting of existing vessels and recruitment of tissue 
progenitors, as hinted by the results presented in Chapter 4. Due to the negligible 
immunogenic risk, this more simplistic approach could expand the range of suitable 
applications of hPLG to include those of a more acute character, such as skin burns, 
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When it comes to regenerating tissues, time is of the essence and promiscuity is a must - networking is all that 
matters. The recent emergence of lab-grown tissues and organs has posed a new challenge; their survival after 
implantation into the human body. It is vital to establish a swift connection between the host blood vessels and the 
implant.    
In our lab, we are studying ways of promoting this “speed dating” of vascular networks by harnessing our own 
bodies’ tools. We have developed an injectable hydrogel derived from human blood platelets to stimulate and 
support this biological tête-à-tête, creating an off-the-shelf and animal-free approach. 
Here, lab-engineered human capillaries (in green) derived from stem cells are caught in the act of “making contact” 
with the sprouts protruding from a rat aorta (in red) in a bed of platelet hydrogel, documenting the, not so shy, first 
stages of recognition and interaction.
